0001012477-19-000005.txt : 20190508 0001012477-19-000005.hdr.sgml : 20190508 20190508165926 ACCESSION NUMBER: 0001012477-19-000005 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190508 DATE AS OF CHANGE: 20190508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 19807451 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 10-Q 1 avdl2019q1.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
———————
FORM 10-Q
———————
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended: March 31, 2019
 
———————
AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
———————
 
Ireland
000-28508
98-1341933
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
Block 10-1, Blanchardstown Corporate Park
Ballycoolin
Dublin 15, Ireland
(Address of Principal Executive Office and Zip Code)
 
+353-1-485-1200
(Registrant’s telephone number, including area code)
 
N/A
(Former name, former address and former fiscal year, if changed since last report) 
———————
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
þ
Non-accelerated
¨
Smaller reporting company
¨
(Do not check if a smaller reporting company)
 
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ
 
At May 6, 2019, 37,355,511 ordinary shares, nominal value $0.01 each, of the Company were outstanding.






TABLE OF CONTENTS
 



- 2 -



Cautionary Note Regarding Forward-Looking Statements
 
This quarterly report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements as to our future expectations, beliefs, plans, strategies, objectives, events, conditions, financial performance, prospects, or other events. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof.

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks and as a result there can be no assurance that actual results of our research, development and commercialization activities and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements.  Factors that could cause actual results to differ from expectations in our forward-looking statements include: 

(a) risks relating to our 2018 net loss and recent restructuring plan, including risks relating to the following:
our ability to fully pursue our business strategy is limited due to a decrease in our available liquid assets;
our recent restructuring plan may not be as effective as we anticipated and may have unintended negative impacts;
further restructuring actions, if needed, may require third-party consents that may not be granted;
the Chapter 11 bankruptcy filing by our subsidiary Avadel Specialty Pharmaceuticals LLC (“Specialty Pharma”) may have unexpected adverse results; and
a management-directed audit of the development program for our FT218 sodium oxybate product could result in changes that increase the cost of the program and further delay its completion;

(b) The other risks specified in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 15, 2019, including the following:
our three products Bloxiverz®, Vazculep® and Akovaz®, which are not patent protected and have a small number of customers, produce a majority of our revenues, and such products could face further competition resulting in a loss of market share and/or forcing us to further reduce our prices for those products;
we could fail to develop our current “unapproved marketed drug” (UMD) product candidate or future potential UMD product candidates, or competitors could develop such products and apply for FDA approval of such products before us;
we could experience failure or delay in completing the Phase 3 clinical trial for our FT218 product, and if the FDA ultimately approves such product, the approval may not include any period of market exclusivity;
We may not have sufficient cash or the ability to raise sufficient cash to service our $143.75 million Exchangeable Senior Notes due 2023 (“2023 Notes”), including the amounts necessary to repay the 2023 Notes at maturity, to settle exchanges of the 2023 Notes in cash, or to repurchase the 2023 Notes as required following a “fundamental change” event described in the indenture governing the 2023 Notes.
our products may not reach the commercial market or gain market acceptance;
we must invest substantial sums in research and development in order to remain competitive;
we depend on one or a limited number of providers to develop certain of our products and drug delivery technologies, to manufacture certain of our products and to provide certain raw materials used in our products;
our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do;
we face challenges in protecting intellectual property underlying our products and drug delivery technologies; and
we depend on key personnel to execute our business plan.

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise the forward-looking statements contained in this Quarterly Report.



- 3 -



PART I – FINANCIAL INFORMATION 
ITEM 1.  FINANCIAL STATEMENTS 
AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS
(In thousands, except per share data)
(Unaudited)
 
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
Revenues:
 
 

 
 

Product sales
 
$
16,437

 
$
33,161

License revenue
 

 
132

Total revenues
 
16,437

 
33,293

Operating expenses:
 
 

 
 

Cost of products
 
3,266

 
6,592

Research and development expenses
 
7,329

 
9,951

Selling, general and administrative expenses
 
10,446

 
24,487

Intangible asset amortization
 
201


1,767

Changes in fair value of related party contingent consideration
 
2,134

 
2,968

Restructuring costs
 
1,228

 
153

Total operating expenses
 
24,604

 
45,918

Operating loss
 
(8,167
)
 
(12,625
)
Investment and other income, net
 
817

 
54

Interest expense
 
(3,062
)
 
(1,597
)
Loss on deconsolidation of subsidiary
 
(2,673
)
 

Other income - changes in fair value of related party payable
 
(307
)
 
(395
)
Loss before income taxes
 
(13,392
)
 
(14,563
)
Income tax benefit
 
(374
)
 
(2,327
)
Net loss
 
$
(13,018
)
 
$
(12,236
)
 
 
 
 
 
Net loss per share - basic
 
$
(0.35
)
 
$
(0.32
)
Net loss per share - diluted
 
(0.35
)
 
(0.32
)
 
 
 
 
 
Weighted average number of shares outstanding - basic
 
37,354

 
38,559

Weighted average number of shares outstanding - diluted
 
37,354

 
38,559

 
See accompanying notes to unaudited condensed consolidated financial statements.

- 4 -



AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
(Unaudited)
 
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
Net loss
 
$
(13,018
)
 
$
(12,236
)
Other comprehensive (loss) income, net of tax:
 
 

 
 

Foreign currency translation (loss) gain
 
(161
)
 
249

Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively
 
374

 
(238
)
Total other comprehensive income, net of tax
 
213

 
11

Total comprehensive loss
 
$
(12,805
)
 
$
(12,225
)
 
See accompanying notes to unaudited condensed consolidated financial statements.

- 5 -



AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
 
 
March 31, 2019
 
December 31, 2018
 
 
(unaudited)
 
 
ASSETS
 
 

 
 

Current assets:
 
 

 
 

Cash and cash equivalents
 
$
9,630

 
$
9,325

Marketable securities
 
70,221

 
90,590

Accounts receivable
 
11,772

 
11,330

Inventories
 
4,258

 
4,770

Prepaid expenses and other current assets
 
6,556

 
8,836

Total current assets
 
102,437

 
124,851

Property and equipment, net
 
1,749

 
1,911

Operating lease right-of-use assets
 
5,802

 

Goodwill
 
18,491

 
18,491

Intangible assets, net
 
1,428

 
1,629

Research and development tax credit receivable
 
7,591

 
7,272

Other non-current assets
 
36,124

 
36,146

Total assets
 
$
173,622

 
$
190,300

 
 
 
 
 
LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
 
 

 
 

Current liabilities:
 
 

 
 

Current portion of long-term debt
 
$
104

 
$
106

Current portion of long-term related party payable
 
9,391

 
9,439

Current portion of operating lease liability
 
982

 

Accounts payable
 
4,150

 
3,503

Deferred revenue
 
115

 
114

Accrued expenses
 
14,689

 
21,695

  Other current liabilities
 
1,927

 
3,526

Total current liabilities
 
31,358

 
38,383

Long-term debt, less current portion
 
117,178

 
115,734

Long-term related party payable, less current portion
 
18,202

 
19,401

Long-term operating lease liability
 
3,889

 

Other non-current liabilities
 
12,577

 
14,002

Total liabilities
 
183,204

 
187,520

 
 
 
 
 
Shareholders’ (deficit) equity:
 
 

 
 

Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at March 31, 2019 and December 31, 2018, respectively
 

 

Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,762 issued and 37,355 outstanding at March 31, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018
 
427

 
427

Treasury shares, at cost, 5,407 shares held at March 31, 2019 and December 31, 2018, respectively
 
(49,998
)
 
(49,998
)
Additional paid-in capital
 
434,199

 
433,756

Accumulated deficit
 
(371,007
)
 
(357,989
)
Accumulated other comprehensive loss
 
(23,203
)
 
(23,416
)
Total shareholders’ (deficit) equity
 
(9,582
)
 
2,780

Total liabilities and shareholders’ (deficit) equity
 
$
173,622

 
$
190,300

 See accompanying notes to unaudited condensed consolidated financial statements.

- 6 -



AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY
(In thousands) 
(Unaudited)

Three Months Ended March 31, 2019

 
 
Ordinary shares
 
Additional
 
Accumulated
 
Accumulated
other
comprehensive
 
Treasury Shares
 
Total
shareholders’
 
 
Shares
 
Amount
 
paid-in capital
 
deficit
 
(loss) income
 
Shares
 
Amount
 
(deficit) equity
Balance, December 31, 2018
 
42,720

 
$
427

 
$
433,756

 
$
(357,989
)
 
$
(23,416
)
 
5,407

 
$
(49,998
)
 
$
2,780

Net loss
 

 

 

 
(13,018
)
 

 

 

 
(13,018
)
Other comprehensive income
 

 

 

 

 
213

 

 

 
213

Vesting of restricted shares
 
1

 

 

 

 

 

 

 

Employee share purchase plan share issuance
 
42

 

 
92

 

 

 

 

 
92

Stock-based compensation expense
 

 

 
351

 

 

 

 

 
351

Balance, March 31, 2019
 
42,763

 
$
427

 
$
434,199

 
$
(371,007
)
 
$
(23,203
)
 
5,407

 
$
(49,998
)
 
$
(9,582
)

Three Months Ended March 31, 2018

 
 
Ordinary shares
 
Additional
 
Accumulated
 
Accumulated
other
comprehensive
 
Treasury Shares
 
Total
shareholders’
 
 
Shares
 
Amount
 
paid-in capital
 
deficit
 
(loss) income
 
Shares
 
Amount
 
equity
Balance, December 31, 2017
 
41,463

 
$
414

 
$
393,478

 
$
(262,685
)
 
$
(23,266
)
 
2,117

 
$
(22,361
)
 
$
85,580

Net loss
 

 

 

 
(12,236
)
 

 

 

 
(12,236
)
Other comprehensive income
 

 

 

 

 
11

 

 

 
11

Exercise of warrants
 
603

 
6

 
2,905

 

 

 

 

 
2,911

Expiration of warrants
 

 

 
2,167

 

 

 

 

 
2,167

Stock-based compensation expense
 

 

 
2,134

 

 

 

 

 
2,134

Equity component of 2023 Notes
 

 

 
26,699

 

 

 

 

 
26,699

Share repurchases
 

 

 

 

 

 
2,307

 
(20,212
)
 
(20,212
)
Balance, March 31, 2018
 
42,066

 
$
420

 
$
427,383

 
$
(274,921
)
 
$
(23,255
)
 
4,424

 
$
(42,573
)
 
$
87,054







- 7 -



AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) 
(Unaudited)
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
Cash flows from operating activities:
 
 

 
 

Net loss
 
$
(13,018
)
 
$
(12,236
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 

 
 

Depreciation and amortization
 
369

 
1,985

Amortization of premiums on marketable securities
 
9

 
518

Remeasurement of related party acquisition-related contingent consideration
 
2,134

 
2,968

Remeasurement of related party financing-related contingent consideration
 
307

 
395

Amortization of debt discount and debt issuance costs
 
1,445

 
657

Change in deferred tax and income tax deferred charge
 
(222
)
 
(2,851
)
Stock-based compensation expense
 
351

 
2,134

Loss on deconsolidation of subsidiary
 
1,750

 

Other adjustments
 
(550
)
 
139

Net changes in assets and liabilities
 
 

 
 

Accounts receivable
 
(1,021
)
 
(1,891
)
Inventories
 
467

 
(466
)
Prepaid expenses and other current assets
 
(3,228
)
 
(2,285
)
Research and development tax credit receivable
 
(449
)
 
(494
)
Accounts payable & other current liabilities
 
752

 
6,374

Accrued expenses
 
(4,750
)
 
(5,854
)
Accrued income taxes
 
(46
)
 
32

Earn-out payments for related party contingent consideration in excess of acquisition-date fair value
 
(3,181
)
 
(5,790
)
Royalty payments for related party payable in excess of original fair value
 
(507
)
 
(825
)
Other assets and liabilities
 
(1,818
)
 
(518
)
Net cash used in operating activities
 
(21,206
)
 
(18,008
)
 
 
 
 
 
Cash flows from investing activities:
 
 

 
 

Purchases of property and equipment
 
(30
)
 
(41
)
Proceeds from sales of marketable securities
 
34,864

 
194,400

Purchases of marketable securities
 
(13,444
)
 
(275,098
)
Net cash provided by (used in) investing activities
 
21,390

 
(80,739
)
 
 
 
 
 
Cash flows from financing activities:
 
 

 
 

Earn-out payments for related party contingent consideration
 

 
(402
)
Proceeds from debt issuance
 

 
143,750

Payments for debt issuance costs
 

 
(5,391
)
Share repurchases
 

 
(18,000
)
Proceeds from exercise of warrants
 

 
2,911

Other financing activities, net
 
92

 
47

Net cash provided by financing activities
 
92

 
122,915

 
 
 
 
 
Effect of foreign currency exchange rate changes on cash and cash equivalents
 
29

 
179

 
 
 
 
 
Net change in cash and cash equivalents
 
305

 
24,347

Cash and cash equivalents at January 1,
 
9,325

 
16,564

Cash and cash equivalents at March 31,
 
$
9,630

 
$
40,911

 
 
 
 
 
Supplemental disclosures of cash flow information:
 
 
 
 
     Interest paid
 
$
3,234

 
$
263

     Income taxes paid
 
$
72

 
$
90

 
See accompanying notes to unaudited condensed consolidated financial statements.

- 8 -



AVADEL PHARMACEUTICALS PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except per share data) 

NOTE 1: Summary of Significant Accounting Policies
Nature of Operations.  Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company.  Our primary focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.   The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020.

Our current marketed products include:
Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “ - The Reincorporation Merger.” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under

- 9 -



the trade name Avadel Ireland) is an Irish corporation which, Since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities. A complete list of the Company’s subsidiaries can be found in Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

Basis of Presentation. The unaudited condensed consolidated balance sheet as of March 31, 2019, which is primarily derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.
The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. 
On February 6, 2019, the Company’s indirect wholly owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See Note 3: Subsidiary Bankruptcy and Deconsolidation.
Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC Therapeutics and FSC Laboratories, Inc., (collectively “FSC”), prior to its February 16, 2018 disposition date. See Note 14: Divestiture of the Pediatric Assets, for additional information. All intercompany accounts and transactions have been eliminated.
Revenue. Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements. 
Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Sales and Services 

The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis.


- 10 -



License Revenue 

The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.

For a complete discussion of the accounting for net product revenue and license revenues, see Note 4: Revenue Recognition.

NOTE 2: Newly Issued Accounting Standards
Recently Adopted Accounting Guidance

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. In July 2018, the FASB issued ASU 2018-11 “Targeted Improvements”, amending certain aspects of the new leasing standard. The amendment allows an additional optional transition method whereby an entity records a cumulative effect adjustment to opening retained earnings in the year of adoption without restating prior periods, which the Company has elected. The impact of this new guidance is further discussed in Note 9: Leases.

Recent Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.

NOTE 3: Subsidiary Bankruptcy and Deconsolidation

Bankruptcy Filing and Deconsolidation

As a result of Specialty Pharma’s bankruptcy filing on February 6, 2019, Avadel has ceded authority for managing the business to the Bankruptcy Court, and Avadel management cannot carry on Specialty Pharma’s activities in the ordinary course of business without Bankruptcy Court approval. Avadel manages the day-to-day operations of Specialty Pharma, but does not have discretion to make significant capital or operating budgetary changes or decisions and purchase or sell significant assets, as Specialty Pharma’s material decisions are subject to review by the Bankruptcy Court. For these reasons, we have concluded that Avadel has lost control of Specialty Pharma, and no longer has significant influence over Specialty Pharma during the pendency of the bankruptcy. Therefore, we deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy in February 2019.

In order to deconsolidate Specialty Pharma, the carrying values of the assets and certain liabilities of Specialty Pharma were removed from our unaudited condensed consolidated balance sheet as of February 5, 2019, and we recorded our investment in Specialty Pharma at its estimated fair value of $0. As the estimated fair value of our investment in Specialty Pharma was lower than its net book value immediately prior to the deconsolidation, we recorded a non-cash charge of approximately $2,673 associated with the deconsolidation of Specialty Pharma. Subsequent to the deconsolidation of Specialty Pharma, we are accounting for our investment in Specialty Pharma using the cost method of accounting because Avadel does not exercise significant influence over the operations of Specialty Pharma due to the Chapter 11 filing.

On April 26, 2019, Specialty Pharma sold its intangible assets and remaining inventory to an unaffiliated third party in exchange for aggregate cash proceeds of approximately $250, pursuant to an order approving such sale which was issued by the Bankruptcy

- 11 -



Court on April 15, 2019. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business.

DIP Financing – Related Party Relationship

In connection with the bankruptcy filing, Specialty Pharma entered into a Debtor in Possession Credit and Security Agreement with Avadel US Holdings (“DIP Credit Agreement”) dated as of February 8, 2019, in an aggregate amount of up to $2,700, of which the funds are to be used by Specialty Pharma solely to fund operations through February 6, 2020. As of March 31, 2019, the Company had funded $407 under the DIP Credit Agreement. As the Company has assessed that it is unlikely that Specialty Pharma will pay back the loan to Avadel, the $407 has been recorded as part of the loss on deconsolidation of subsidiary within the unaudited condensed consolidated statements of loss. At March 31, 2019 the fair value of the remaining commitment under the DIP Credit Agreement is not material.

NOTE 4: Revenue Recognition

The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.

Product Sales and Services

Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Reserves to reduce Gross Revenues to Net Revenues

Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Product Returns

Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products.


- 12 -



Chargebacks, Discounts and Rebates

Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.

Revenue from licensing arrangements

The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Disaggregation of revenue

The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product.

Contract Balances

The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.

A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional. See the unaudited condensed consolidated balance sheets for the balance of accounts receivable at March 31, 2019.

See below for contract liability discussion and balance related to a license agreement.

There were no material deferred contract costs at March 31, 2019.

Transaction Price Allocated to the Remaining Performance Obligation

For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.

For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product.

The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.
 


- 13 -



NOTE 5: Fair Value Measurement
The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:  

ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:  

Income approach, which is based on the present value of a future stream of net cash flows.
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:  
Level 1 - Quoted prices for identical assets or liabilities in active markets.
Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.
Level 3 - Unobservable inputs that reflect estimates and assumptions.
The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:
 
 
As of March 31, 2019
 
As of December 31, 2018
Fair Value Measurements:
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities (see Note 6)
 
 
 
 
 
 
 
 
 
 
 
 
Equity securities
 
$
9,825

 
$

 
$

 
$
9,145

 
$

 
$

Money market funds
 
48,947

 

 

 
52,996

 

 

Corporate bonds
 

 
3,463

 

 

 
6,339

 

Government securities - U.S.
 

 
4,285

 

 

 
12,701

 

Other fixed-income securities
 

 
3,701

 

 

 
9,409

 

Total assets
 
$
58,772

 
$
11,449

 
$

 
$
62,141

 
$
28,449

 
$

 
 
 
 
 
 
 
 
 
 
 
 
 
Related party payable (see Note 10)
 

 

 
27,593

 

 

 
28,840

Total liabilities
 
$

 
$

 
$
27,593

 
$

 
$

 
$
28,840

A review of fair value hierarchy classifications is conducted on a quarterly basis.  Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended March 31, 2019 and December 31, 2018, respectively, there were no transfers in and out of Level 1, 2, or 3. During the three month periods ended March 31, 2019 and 2018, respectively, we did not recognize any other-than-temporary impairment loss.
Some of the Company’s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.

Debt

We estimate the fair value of our $143,750 aggregate principal amount of 4.50% exchangeable senior notes due 2023 (the “2023 Notes”), a Level 2 input, based on interest rates that would be currently available to the Company for issuance of similar types of

- 14 -



debt instruments with similar terms and remaining maturities or recent trading prices obtained from brokers. The estimated fair value of the 2023 Notes at March 31, 2019 is $58,568 compared to a book value of $117,136.

Additionally, the Company’s other debt is reflected in the balance sheet at carrying value. The fair value of these loans impracticable to estimate as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.

See Note 11: Long-Term Debt for additional information regarding our debt obligations.

NOTE 6: Marketable Securities 
The Company has investments in available-for-sale marketable securities which are recorded at fair market value. The change in the fair value of available-for-sale equity investments is recognized in our unaudited condensed consolidated statements of loss and the change in the fair value of all other available-for-sale investments is recorded as other comprehensive income (loss) in shareholders’ (deficit) equity, net of income tax effects.
The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of March 31, 2019 and December 31, 2018, respectively:
 
 
March 31, 2019
Marketable Securities:
 
Adjusted Cost
 
Unrealized Gains
 
Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Equity securities
 
$
10,133

 
$
23

 
$
(331
)
 
$
9,825

Money market funds
 
48,438

 
509

 

 
48,947

Corporate bonds
 
3,442

 
30

 
(9
)
 
3,463

Government securities - U.S.
 
4,249

 
43

 
(7
)
 
4,285

Other fixed-income securities
 
3,673

 
30

 
(2
)
 
3,701

Total
 
$
69,935

 
$
635

 
$
(349
)
 
$
70,221

 
 
December 31, 2018
Marketable Securities:
 
Adjusted Cost
 
Unrealized Gains
 
Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Equity securities
 
$
10,101

 
$

 
$
(956
)
 
$
9,145

Money market funds
 
52,733

 
316

 
(53
)
 
52,996

Corporate bonds
 
6,411

 
7

 
(79
)
 
6,339

Government securities - U.S.
 
12,714

 
66

 
(79
)
 
12,701

Other fixed-income securities
 
9,400

 
22

 
(13
)
 
9,409

Total
 
$
91,359


$
411


$
(1,180
)

$
90,590

 
We determine realized gains or losses on the sale of marketable securities on a specific identification method. We reflect these gains and losses as a component of investment income in the accompanying unaudited condensed consolidated statements of loss.
We recognized gross realized gains of $94 and $213 for the three months ended March 31, 2019, and 2018, respectively. These realized gains were offset by realized losses of $147 and $134 for the three months ended March 31, 2019, and 2018, respectively.

- 15 -



The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of March 31, 2019:
 
 
Maturities
Marketable Debt Securities:
 
Less than 1 Year
 
1-5 Years
 
5-10 Years
 
Greater than 10 Years
 
Total
 
 
 
 
 
 
 
 
 
 
 
Corporate bonds
 
$
688

 
$
2,775

 
$

 
$

 
$
3,463

Government securities - U.S.
 

 
3,841

 

 
444

 
4,285

Other fixed-income securities
 
50

 
3,651

 

 

 
3,701

Total
 
$
738

 
$
10,267

 
$

 
$
444

 
$
11,449

The Company has classified our investment in available-for-sale marketable securities as current assets in the unaudited condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.

NOTE 7: Inventories 
The principal categories of inventories, net reserves of $1,085 and $4,757 at March 31, 2019 and December 31, 2018, respectively, are comprised of the following:
Inventory:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Finished goods
 
$
3,720

 
$
4,270

Raw materials
 
538

 
500

Total  
 
$
4,258

 
$
4,770


Total net reserves decreased by $3,672 during the three months ended March 31, 2019 driven largely by the deconsolidation of Specialty Pharma.

NOTE 8: Goodwill and Intangible Assets 
The Company’s amortizable and unamortizable intangible assets at March 31, 2019 and December 31, 2018 are as follows: 
 
 
March 31, 2019
 
December 31, 2018
Goodwill and Intangible Assets:
 
Gross
Value
 
Accumulated
Amortization
 
Net Carrying
Amount
 
Gross
Value
 
Accumulated
Amortization
 
Impairment
 
Net Carrying
Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amortizable intangible assets:
 
 

 
 

 
 

 
 

 
 

 
 
 
 

Acquired developed technology - Noctiva
 
$

 
$

 
$

 
$
73,111

 
$
(7,024
)
 
$
(66,087
)
 
$

Acquired developed technology - Vazculep
 
12,061

 
(10,633
)
 
1,428

 
12,061

 
(10,432
)
 

 
1,629

Total amortizable intangible assets
 
$
12,061

 
$
(10,633
)
 
$
1,428

 
$
85,172

 
$
(17,456
)
 
$
(66,087
)
 
$
1,629

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unamortizable intangible assets:
 
 

 
 

 
 

 
 

 
 

 
 
 
 

Goodwill
 
$
18,491

 
$

 
$
18,491

 
$
18,491

 
$

 
$

 
$
18,491

Total unamortizable intangible assets
 
$
18,491


$


$
18,491


$
18,491


$


$

 
$
18,491

 
The Company recorded amortization expense related to amortizable intangible assets of $201 and $1,767 for the three months ended March 31, 2019 and 2018, respectively.
During the fourth quarter 2018, certain conditions came to light, largely the lack of a meaningful increase in Noctiva prescriptions despite the substantial investment of resources, which indicated that the carrying value of the asset, may not be fully recoverable.

- 16 -



As such, the Company performed an impairment test based on a comparison of the pretax discounted cash flows expected to be generated by the asset, which is a Level 3 fair value estimate, to the recorded value of the asset and concluded that the associated cash flows did not support any of the carrying value of the intangible asset and the Company recorded a full impairment charge of $66,087 at December 31, 2018 related to the acquired developed technology associated with Noctiva. The February 6, 2019 Chapter 11 bankruptcy filing of Specialty Pharma, the subsidiary which markets, sells and distributes Noctiva, confirmed management’s conclusion on the impairment.
Amortizable intangible assets are amortized over their estimated useful lives, which generally range from three to fifteen years. Estimated amortization of intangible assets for the next five years is as follows: 
Estimated Amortization Expense:
 
Amount
 
 
 
2019
 
$
815

2020
 
814

2021
 

2022
 

2023
 


NOTE 9: Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. On January 1, 2019, the Company adopted the ASU using the modified retrospective transition approach and elected the transition option to recognize the adjustment in the period of adoption rather than in the earliest period presented. As January 1, 2019, adoption of the new guidance resulted in the initial recognition of operating lease right-of-use assets of $5,046 and operating lease liabilities of $5,131. At March 31, 2019, the balances of the operating lease right-of-use asset and total operating lease liability are $5,802 and $4,871, respectively, of which $982 of the operating lease liability is current.

The Company leases certain facilities for office and manufacturing purposes, comprising approximately 99% of the total lease population. All leased facilities are classified as operating leases with remaining lease terms between one and seven years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. For all of the Company’s leases, lease and non-lease components are accounted for as a single lease component, as all non-lease components are immaterial to break out separately.

The components of lease costs, which is included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the period ended March 31 were as follows ($ in thousands):
Lease cost:
 
2019
 
 
 
Operating lease costs (1)
 
$
345

Sublease income (2)
 
44

Total lease cost
 
$
301


(1) Variable lease costs were immaterial for the three months ended March 31, 2019.
(2) Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020.

During the three months ended March 31, 2019, the Company reduced its operating lease liabilities by $310 for cash paid. In addition, new operating leases commenced resulting in the recognition of operating lease right-of-use assets and liabilities of $1,000 and $0, respectively, as the entire lease payment was paid on March 31, 2019. As of March 31, 2019, the Company is aware of one additional embedded lease that has not yet commenced and will not commence until the time of FDA approval of the product (if approved). Once FDA approval is given and the start date is determined, annual production suite fees of approximately $3,000 to $4,000 would commence and at that time, and an operating lease right-of-use asset and corresponding operating lease liability will be recorded.


- 17 -



As of March 31, 2019, our operating leases have a weighted-average remaining lease term of 5.2 years and a weighted-average discount rate of 5.3%. Nearly all of Avadel’s lease contracts do not provide a readily determinable implicit rate. For these contracts, Avadel’s estimated incremental borrowing rate is based on information available at the inception of the lease.

Maturities of the Company’s operating lease liabilities were as follows ($ in thousands):
Maturities:
 
Operating Leases
 
 
 
Remaining nine months of 2019
 
$
920

2020
 
1,225

2021
 
1,004

2022
 
764

2023
 
693

Thereafter
 
942

Total lease payments
 
5,548

Less: interest
 
677

Present value of lease liabilities
 
$
4,871


Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were ($ in thousands):
Lease Commitment:
 
Operating Leases
 
 
 
2019
 
$
1,191

2020
 
1,208

2021
 
1,008

2022
 
767

2023
 
695

Thereafter
 
967

Total minimum lease payments
 
$
5,836


NOTE 10: Long-Term Related Party Payable 
Long-term related party payable and related activity are reported at fair value and consist of the following at March 31, 2019 and December 31, 2018:
 
 
 
Activity during the Three Months Ended
March 31, 2019
 
 
 
 
 
 
 
Changes in Fair Value of Related Party Payable
 
 
Long-Term Related Party Payable:
Balance,
December 31, 2018
 
Payments to
Related Parties
 
Operating Expense
 
Other
Expense
 
Balance, March 31, 2019
 
 
 
 
 
 
 
 
 
 
Acquisition-related contingent consideration:
 

 
 

 
 

 
 

 
 

Earn-out payments - Éclat Pharmaceuticals (a)
$
25,615

 
$
(3,180
)
 
$
2,134

 
$

 
$
24,569

Financing-related:
 

 
 

 
 

 
 

 

Royalty agreement - Deerfield (b)
2,184

 
(344
)
 

 
208

 
2,048

Royalty agreement - Broadfin (c)
1,041

 
(164
)
 

 
99

 
976

Total related party payable
28,840

 
$
(3,688
)
 
$
2,134

 
$
307

 
27,593

Less: Current portion
(9,439
)
 
 

 
 

 
 

 
(9,391
)
Total long-term related party payable
$
19,401

 
 

 
 

 
 

 
$
18,202

(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat

- 18 -



products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.
(b)
As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.
(c)
As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.
At March 31, 2019, the fair value of each related party payable listed in (a), (b) and (c) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat products using an appropriate risk-adjusted discount rate of 15%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the unaudited condensed consolidated statements of loss in the line items entitled “Changes in fair value of related party contingent consideration” for items noted in (b) above and in “Other expense - changes in fair value of related party payable” for items (b) and (c) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities. 
The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (b) and (c) above. These financing-related liabilities are recorded at fair market value on the unaudited condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the unaudited condensed consolidated statements of loss.
The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the three-month periods ended March 31, 2019 and 2018, respectively:
Related Party Payable Rollforward:
 
Balance
 
 
 
Balance, December 31, 2017
 
$
98,925

Payments of related party payable
 
(7,017
)
Fair value adjustments (1)
 
3,363

Expiration of warrants
 
(2,167
)
Disposition of the pediatric assets
 
(20,337
)
Balance, March 31, 2018
 
$
72,767

 
 
 
Balance, December 31, 2018
 
$
28,840

Payments of related party payable
 
(3,688
)
Fair value adjustments (1)
 
2,441

Balance, March 31, 2019
 
$
27,593

(1) Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.  


- 19 -



NOTE 11: Long-Term Debt
Long-Term debt is summarized as follows:
 
 
March 31, 2019
 
December 31, 2018
Principal amount of 4.50% exchangeable senior notes due 2023
 
$
143,750

 
$
143,750

Less: debt discount and issuance costs, net
 
(26,614
)
 
(28,059
)
Net carrying amount of liability component
 
117,136

 
115,691

Other debt
 
146

 
149

     Subtotal
 
117,282

 
115,840

Less: current maturities
 
(104
)
 
(106
)
     Long-term debt
 
$
117,178

 
$
115,734

 
 
 
 
 
Equity component:
 
 
 
 
Equity component of exchangeable notes, net of issuance costs
 
$
(26,699
)
 
$
(26,699
)

NOTE 12: Income Taxes
The components of loss before income taxes are as follows: 
 
 
Three Months Ended March 31,
Loss Before Income Taxes:
 
2019
 
2018
 
 
 
 
 
Ireland
 
$
(10,234
)
 
$
(4,927
)
United States
 
(3,443
)
 
(9,835
)
France
 
285

 
199

Total loss before income taxes
 
$
(13,392
)
 
$
(14,563
)
 

- 20 -



The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:
 
 
Three Months Ended March 31,
Income Tax Rate Reconciliation:
 
2019
 
2018
 
 
 
 
 
Statutory tax rate  
 
12.5
 %

12.5
 %
International tax rates differential
 
5.0
 %

8.9
 %
Change in valuation allowance
 
(11.4
)%

(4.7
)%
Change in fair value of nondeductible contingent consideration
 
(3.1
)%

(3.8
)%
Nondeductible stock-based compensation
 
(0.4
)%

(1.1
)%
Unrecognized tax benefits
 
(0.9
)%

(1.5
)%
State and local income taxes, net of federal
 
 %

0.1
 %
Nondeductible interest expense
 
(1.2
)%
 
 %
Other
 
2.2
 %

5.6
 %
Effective income tax rate
 
2.7
 %

16.0
 %
 
 
 
 
 
Income tax benefit - at statutory tax rate
 
$
(1,673
)
 
$
(1,820
)
International tax rates differential
 
(668
)
 
(1,298
)
Change in valuation allowance
 
1,520

 
690

Change in fair value of nondeductible contingent consideration
 
413

 
551

Nondeductible stock-based compensation
 
51

 
160

Unrecognized tax benefits
 
124

 
220

State and local income taxes, net of federal
 
2

 
(19
)
Nondeductible interest expense
 
157

 

Other
 
(300
)
 
(811
)
Income tax benefit - at effective income tax rate
 
$
(374
)
 
$
(2,327
)
 
The income tax benefit for the three months ended March 31, 2019 was $374 compared to an income tax benefit of $2,327 for the three months ended March 31, 2018. The decrease in the income tax benefit for the three months ended March 31, 2019 is primarily the result of a decrease in the amount of loss generated in the United States, when compared to the same prior year period.

NOTE 13: Other Assets and Liabilities 
Various other assets and liabilities are summarized as follows:
Prepaid Expenses and Other Current Assets:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Valued-added tax recoverable
 
$
1,100

 
$
1,378

Prepaid and other expenses
 
2,607

 
2,145

Guarantee from Armistice (see Note 14)
 
543

 
534

Income tax receivable
 
996

 
921

Research and development tax credit receivable
 
270

 
283

Short-term deposit
 

 
3,350

Other
 
1,040

 
225

Total  
 
$
6,556

 
$
8,836

 

- 21 -



Other Non-Current Assets:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Deferred tax assets, net
 
$
23,216

 
$
23,029

Long-term deposits
 
1,477

 
1,477

Guarantee from Armistice (see Note 14)
 
5,555

 
5,697

Right of use assets at contract manufacturing organizations
 
5,827

 
5,894

Other
 
49

 
49

Total  
 
$
36,124

 
$
36,146

 
Accrued Expenses
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Accrued compensation
 
$
1,726

 
$
3,971

Accrued social charges
 
1,018

 
1,009

Accrued restructuring (see Note 15)
 
419

 
879

Customer allowances
 
6,616

 
6,541

Accrued contract research organization charges
 
1,383

 
1,000

Accrued contract manufacturing organization costs
 
1,030

 
2,028

Accrued contract sales organization and marketing costs
 

 
3,469

Other
 
2,497

 
2,798

Total  
 
$
14,689

 
$
21,695

 
Other Non-Current Liabilities:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Provision for retirement indemnity
 
$
1,003

 
$
1,024

Customer allowances
 
619

 
1,352

Unrecognized tax benefits
 
5,315

 
5,315

Guarantee to Deerfield (see Note 14)
 
5,574

 
5,717

Other
 
66

 
594

Total  
 
$
12,577

 
$
14,002


14: Divestiture of the Pediatric Assets

On February 12, 2018, the Company, together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” entered into an asset purchase agreement (the “Purchase Agreement”) with Cerecor, Inc. (“Cerecor”). The transaction closed on February 16, 2018 wherein Cerecor purchased from the Sellers four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets – which were held by FSC.  The Company acquired FSC in February 2016 from Deerfield and certain of its affiliates. Pursuant to the Purchase Agreement, Cerecor assumed the Company’s  remaining payment obligations to Deerfield under the Membership Interest Purchase Agreement, dated as of February 5, 2016, between Holdings, Flamel Technologies SA (the predecessor of the Company) and Deerfield and certain of its affiliates, which payment obligations consist of the following (collectively, the “Assumed Obligations”): (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 5, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300.  Cerecor also assumed certain contracts and other obligations related to the acquired assets, and in that connection Holdings agreed to pay Cerecor certain make-whole payments associated with obligations Cerecor is assuming related to a certain supply contract related to Karbinal™ ER.


- 22 -



In conjunction with the divestiture, the Company also entered into the following arrangements:

License and Development Agreement

Also, in connection with the closing under the Purchase Agreement, Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (“Avadel Ireland”) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the “License and Development Agreement”) pursuant to which, among other things:

Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland’s LiquiTime™ technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;

Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime™ products in excess of $1,000 in the aggregate;

Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees; and
Upon regulatory approval and commercial launch of any LiquiTime™ products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digit range. 

Deerfield Guarantee

In connection with the closing under the Purchase Agreement, the Company and Holdings provided their guarantee (the “Deerfield Guarantee”) in favor of Deerfield. Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the Assumed Obligations under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 6, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the “Minimum Royalties”). Given the Company’s explicit guarantee to Deerfield, the Company recorded the guarantee in accordance with ASC 460. A valuation was performed, which was based largely on an analysis of the potential timing of each possible cash outflow described above and the likelihood of Cerecor’s default on such payments assuming an S&P credit rating of CCC+. The result of this valuation identified a guarantee liability of $6,643. This liability is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield. At March 31, 2019, the carrying value of this liability was $6,119.

Armistice Guarantee

In connection with the closing under the Purchase Agreement, Armistice Capital Master Fund, Ltd., the majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties. A valuation of the guarantee asset was performed in accordance with ASC 460 and a guarantee asset of $6,620 was recorded. This asset is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield noted above. At March 31, 2019, the carrying value of this asset was $6,097.

The fair values of the Avadel guarantee to Deerfield and the guarantee received by Avadel from Armistice largely offset and when combined are not material.

Based on management’s review of ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, the disposition of our pediatric assets and related liabilities did not qualify for discontinued operations reporting. Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC, prior to its February 16, 2018 disposition date.

The net impact of this transaction was not material to the unaudited condensed consolidated statements of loss.


- 23 -



NOTE 15: Restructuring Costs
2019 Corporate Restructuring
During the first quarter of 2019, the Company announced a plan to reduce our Corporate workforce by more than 50% (“2019 Corporate Restructuring”). The reduction in workforce is primarily a result of the exit of Noctiva during the first quarter of 2019 (see Note 3: Subsidiary Bankruptcy and Deconsoldiation), as well as an effort to better align the Company’s remaining cost structure at our U.S. and Ireland locations with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of the fiscal year 2019, and to result in employee severance, benefits and other costs of up to approximately $3,000, which are likely to be recognized through December 31, 2019. 2019 Corporate Restructuring charges of $1,398 were recognized during the three months ended March 31, 2019.
The following table sets forth activities for the Company’s cost reduction plan obligations for the three months ended March 31, 2019:
2019 Corporate Restructuring Obligations:
 
2019
 
 
 
Balance of restructuring accrual at January 1,
 
$

Charges for employee severance, benefits and other costs
 
1,398

Payments
 
(754
)
Balance of restructuring accrual at March 31,
 
$
644

Restructuring liabilities of $356 and $288 are included in the unaudited condensed consolidated balance sheet in accrued expenses and accounts payable, respectively, at March 31, 2019.
2017 French Restructuring
During the first quarter of 2017, the Company announced a plan to reduce our workforce at our Venniseux, France site by approximately 50% (“2017 French Restructuring”).  This reduction was an effort to align the Company’s cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council for our French operations and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction was substantially complete at March 31, 2019. The 2017 French Restructuring income of $170 and restructuring charges of $153 were recognized during the three months ended March 31, 2019 and 2018, respectively. The following table sets forth activities for the Company’s cost reduction plan obligations for the three months ended March 31, 2019 and 2018:
2017 French Restructuring Obligation:
 
2019
 
2018
 
 
 
 
 
Balance of restructuring accrual at January 1,
 
$
879

 
$
1,000

Charges for employee severance, benefits and other
 
(170
)
 
153

Payments
 
(638
)
 
(359
)
Foreign currency impact
 
(8
)
 
30

Balance of restructuring accrual at March 31,
 
$
63

 
$
824

The 2017 French Restructuring accrual is included in the unaudited condensed consolidated balance sheet in accrued expenses at March 31, 2019 and 2018.

NOTE 16: Net Loss Per Share 
Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the diluted number of shares outstanding during each period. Except where the result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the exercise of outstanding equity compensation awards, ordinary shares expected to be issued under our employee stock purchase plan (“ESPP”) and the exercise of contingent consideration warrants, all which have been exercised or have expired during the first quarter of 2018.

We have a choice to settle the conversion obligation under the 2023 Notes in cash, shares or any combination of the two. We utilize the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result is anti-dilutive. This

- 24 -



method assumes the conversion of the 2023 Notes into shares of our ordinary shares and reflects the elimination of the interest expense related to the 2023 Notes.

The dilutive effect of the warrants, stock options, RSU’s and ordinary shares expected to be issued under or ESPP has been calculated using the treasury stock method.
A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows: 
 
 
Three Months Ended March 31,
Net Loss Per Share:
 
2019
 
2018
 
 
 
 
 
Net loss
 
$
(13,018
)
 
$
(12,236
)
 
 
 
 
 
Weighted average shares:
 
 

 
 

Basic shares
 
37,354

 
38,559

Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes
 

 

Diluted shares
 
37,354

 
38,559

 
 
 
 
 
Net loss per share - basic
 
$
(0.35
)

$
(0.32
)
Net loss per share - diluted  
 
$
(0.35
)

$
(0.32
)
 
Potential common shares of 19,762 and 19,374 were excluded from the calculation of weighted average shares for the three months ended March 31, 2019 and 2018, respectively, because their effect was considered to be anti-dilutive. For the three months ended March 31, 2019 and 2018, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in this period. 

NOTE 17: Comprehensive Loss 
The following table shows the components of accumulated other comprehensive loss for the three months ended March 31, 2019 and 2018, respectively, net of tax effects: 
 
 
Three Months Ended March 31,
Accumulated Other Comprehensive Loss:
 
2019
 
2018
 
 
 
 
 
Foreign currency translation adjustment:
 
 

 
 

Beginning balance
 
$
(23,621
)
 
$
(23,202
)
Net other comprehensive (loss) income
 
(161
)
 
249

Balance at March 31,
 
$
(23,782
)
 
$
(22,953
)
 
 
 
 
 
Unrealized gain (loss) on marketable securities, net
 
 

 
 

Beginning balance
 
$
205

 
$
(64
)
Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively
 
374

 
(238
)
Balance at March 31,
 
$
579

 
$
(302
)
Accumulated other comprehensive loss at March 31,
 
$
(23,203
)
 
$
(23,255
)
 
The effect on the Company’s unaudited condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.


- 25 -



NOTE 18: Company Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the interim CEO. The interim CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended March 31,
Revenues by Product:
 
2019
 
2018
 
 
 
 
 
Bloxiverz
 
$
2,568

 
$
7,491

Vazculep
 
9,473

 
12,961

Akovaz
 
3,792

 
10,217

Other
 
604

 
2,492

Total product sales
 
16,437

 
33,161

License revenue
 

 
132

Total revenues
 
$
16,437

 
$
33,293


NOTE 19: Commitments and Contingencies 
Litigation  
The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At March 31, 2019 and December 31, 2018, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s unaudited condensed consolidated financial position, results of operations, cash flows or liquidity.   

Litigation Related to Noctiva

Note 3: Subsidiary Bankruptcy and Deconsolidation briefly describes the Chapter 11 bankruptcy case which our subsidiary Specialty Pharma commenced on February 6, 2019, and which on April 26, 2019 resulted in the bankruptcy court-approved sale of all of Specialty Pharma’s intangible assets and inventory to an unaffiliated third party. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. During the pendency of the bankruptcy case, all pending litigation against Specialty Pharma is automatically stayed and any new litigation against Specialty Pharma is precluded unless the bankruptcy court orders otherwise. Below are descriptions of a litigation to which Specialty Pharma is a party and a contract dispute involving Specialty Pharma, both of which matters are subject to the automatic stay during the bankruptcy case.

Ferring Litigation. Some of the patents covering the NoctivaTM product (the “Noctiva Patents”) are the subject of litigation initiated by Ferring Pharmaceuticals Inc. and two of its foreign affiliates, who manufacture a competing product known as Nocdurna.  Nocdurna was approved by the FDA in June 2018 and commercially launched in the U.S. in November 2018.  In this litigation, Ferring seeks to invalidate and disputes the inventorship of the Noctiva Patents, seeks damages for various alleged breaches of contractual and common law duties, and seeks damages for alleged infringement by NoctivaTM of Ferring’s “Nocdurna” trademark.  Specialty Pharma and certain other parties including Serenity Pharmaceuticals, LLC (“Serenity”) (the licensor of the Noctiva Patents) have defended this litigation, and have made counterclaims against Ferring, including for infringement of the Noctiva Patents and a declaratory judgment of noninfringement with respect to Ferring’s “Nocdurna” trademark. The court dismissed Ferring’s inventorship claim and its claims for alleged breaches of contractual and common law duties, although these dismissals may be appealed by Ferring.  On February 15, 2019, Specialty Pharma and its co-defendants moved to stay the litigation pending completion of the bankruptcy proceeding of Specialty Pharma.

Contract Dispute. On January 21, 2019, Serenity gave notice to Specialty Pharma of an alleged breach of the parties’ Noctiva license agreement. Serenity alleges that Specialty Pharma breached its contractual obligation to devote commercially reasonable

- 26 -



efforts to the commercialization of Noctiva and seeks unspecified damages. On January 27, 2019, Specialty Pharma notified Serenity of a claim for $1.7 million in damages as a result of Serenity’s breach of its contractual obligation to pay the costs of the Ferring Litigation. Serenity’s notice to Specialty Pharma invoked the dispute resolution provisions of the Noctiva license agreement, which culminate in arbitration, but neither party has yet initiated an arbitration proceeding or filed suit.

Material Commitments
Due to the Chapter 11 bankruptcy case of Specialty Pharma, discussed in Note 3: Subsidiary Bankruptcy and Deconsolidation, the Company’s various commitments to purchase finished product from customers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of March 31, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:

Purchase Commitments:
 
Balance
 
 
 
2019
 
$
7,194

2020
 
1,320

2021
 
1,320

2022
 
1,320

2023
 
220

Thereafter
 

Total
 
$
11,374


Other than commitments disclosed in Note 15: Contingent Liabilities and Commitments to the Company’s audited consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in Note 10: Long-Term Debt and Note 13: Post-Retirement Benefit Plans, respectively, to the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 10: Long-Term Related Party Payable, to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this report.

- 27 -



ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 
Management’s Discussion and Analysis 
(In thousands, except per share data)
(Unaudited)
 
You should read the discussion and analysis of our financial condition and results of operations set forth in this Item 2 together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this quarterly report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties, and reference is made to the “Cautionary Note Regarding Forward-Looking Statements” set forth immediately following the Table of Contents of this Quarterly Report on Form 10-Q for further information on the forward looking statements herein. In addition, you should read the “Risk Factors” section in Part I, Item 1A of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 15, 2019 and Part II, Item 1A in this quarterly report on Form 10-Q for a discussion of additional important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this quarterly report.
Overview 
General Overview
Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company.  Our primary focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.   The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.
Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020.
Our current marketed products include:

Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.
Business Strategies
Our primary business strategy is to focus on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from EDS and cataplexy. In addition, we will continue to maximize our current approved hospital products portfolio, including obtaining FDA approval for and the commercialization of our fourth UMD product. Additionally, we will continue to evaluate opportunities to expand our product portfolio. These strategies are described below in greater detail.
FT218 (Micropump® sodium oxybate): FT218 (Micropump® sodium oxybate): Avadel is developing a product that uses our Micropump® drug-delivery technology for the treatment of EDS and cataplexy in patients suffering from narcolepsy. Avadel currently refers to this product as FT218. FT218 is a Micropump®-based formulation of sodium oxybate. Sodium oxybate is the sodium salt of gamma hydroxybutyrate, an endogenous compound and metabolite of the neurotransmitter gamma-aminobutyric

- 28 -



acid. Sodium oxybate has been described as a therapeutic agent with high medical value. Sodium oxybate is approved in Europe and the United States as a twice nightly formulation indicated for the treatment of EDS and cataplexy in patients with narcolepsy.

In preparation for a clinical trial of FT218, Avadel reached an agreement with the FDA for the design and planned analysis of our pivotal Phase 3 study, Rest-On through a Special Protocol Assessment (“SPA”). A SPA is an acknowledgment by the FDA that the design and planned analysis of a pivotal clinical trial adequately addresses the objectives necessary to support a regulatory submission. Pursuant to the SPA, in December 2016, Avadel initiated patient enrollment and dosing for the Rest-On clinical trial to assess the safety and efficacy of a once-nightly formulation of FT218 for the treatment of EDS and cataplexy in patients suffering from narcolepsy. The study is a randomized, double-blind, placebo-controlled study of 264 patients being conducted in 45 to 55 clinical sites in the U.S., Canada, Western Europe and Australia. Avadel believes that, if successful, this study could demonstrate improved efficacy, safety and patient satisfaction over the current primary product serving this market, which is a twice nightly sodium oxybate formulation, which the marketer generated revenues of approximately $1.4 billion in 2018.

To date, due in part to narcolepsy being a rare disease with a small patient population with no significant geographic concentration, we have not completed patient enrollment for the FT218 clinical trial, nor have we announced a projected completion date for this clinical trial. Recently, we have engaged a third-party pharmaceutical consulting firm to assist us in evaluating our clinical development program for FT218 with the goal of ensuring an approvable and commercially viable FDA submission. This evaluation is currently under way, and while the results are not known at this time, they could cause us to modify our development plan with respect to FT218 in ways that materially increase the ultimate cost of development, further delay its completion or identify presently unknown risks with the product.

In January 2018, the FDA granted FT218 Orphan Drug Designation, which makes the drug eligible for certain development and commercial incentives, including a potential U.S. market exclusivity for up to seven years as the only once-nightly formulation. However, please see the information set forth under the caption “- Risks Related to Regulatory and Legal Matters - If FT218 is approved by the FDA, we may not obtain orphan drug marketing exclusivity” in the “Risk Factors” included in Part I, Item 1A of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

Development of Micropump®-Based Products
Avadel’s versatile Micropump® drug delivery technology presents product development opportunities, representing either “life cycle” opportunities, whereby additional intellectual property can be added to a pharmaceutical product to extend the commercial viability of a currently marketed product, or innovative formulation opportunities for new chemical entities (“NCEs”). FT218 is formulated using this technology. If approved by the FDA, this product will be commercialized either by Avadel and/or by partners via licensing/distribution agreements.
Unapproved Marketed Drug (“UMD”) Products
In 2006, the U.S. Food and Drug Administration (FDA) issued its Marketed Unapproved Drugs - Compliance Policy Guide with the intention to incentivize pharmaceutical companies to pursue approvals for pharmaceutical products, many of which pre-date the establishment of the FDA. Although these products are not protected by patents or similar intellectual property, the FDA’s Compliance Policy Guide dictates that should FDA approve a new drug application (NDA) for any such products via a 505(b)(2) process, the FDA will remove competing unapproved manufacturers until a generic application is approved. Avadel believes that over a thousand unapproved drugs are marketed in the United States today and, while many of these products are outdated therapies, we strategically evaluate those UMD products that are more commonly used as candidates for possible future FDA approval and marketing under our UMD program.
To date, Avadel has received FDA approvals for three UMD products which we currently market under the brand names Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection).

Additional UMD Products. Avadel is developing and intends to seek FDA approval of a NDA for UMD #4, a sterile injectable product used in the hospital setting. The Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020. In addition, Avadel continues to monitor and evaluate other UMDs with large existing markets and limited competition for feasibility of possible future NDAs. Avadel believes its strategy to create opportunities to commercialize UMD products in markets with a limited number of competitors may have a limited number of opportunities given the lack of patent protection from competition. Avadel believes this shorter-term strategy may provide us with near term revenue growth and provide cash flows that can be used to fund R&D and inorganic initiatives for other products.


- 29 -



Corporate Information

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov.
The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “ - The Reincorporation Merger.” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.
The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, Since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities. A complete list of the Company’s subsidiaries can be found in Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.
References in these unaudited condensed consolidated financial statements and the notes thereto to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires.
Key Business Trends and Highlights 
In operating our business and monitoring our performance, we consider a number of performance measures, as well as trends affecting our industry as a whole, which include the following: 
Healthcare and Regulatory Reform: Various health care reform laws in the U.S. may impact our ability to successfully commercialize our products and technologies. The success of our commercialization efforts may depend on the extent to which the government health administration authorities, the health insurance funds in the E.U. Member States, private health insurers and other third-party payers in the U.S. will reimburse consumers for the cost of healthcare products and services.
Competition and Technological Change: Competition in the pharmaceutical and biotechnology industry continues to be intense and is expected to increase. We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing niche branded or generic specialty pharmaceutical products or drug delivery platforms. Furthermore, major technological changes can happen quickly in the pharmaceutical and biotechnology industries. Such rapid technological change, or the development by our competitors of technologically improved or differentiated products, could render our drug delivery platforms obsolete or noncompetitive.
Pricing Environment for Pharmaceuticals: The pricing environment continues to be in the political spotlight in the U.S. As a result, the need to obtain and maintain appropriate pricing for our products may become more challenging due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the U.S. and worldwide.

- 30 -



Generics Playing a Larger Role in Healthcare: Generic pharmaceutical products will continue to play a large role in the U.S. healthcare system. Specifically, we have seen, or likely will see, additional generic competition to our current and future products and we continue to expect generic competition in the future.
Access to and Cost of Capital: The process of raising capital and associated cost of such capital for a company of our financial profile can be difficult and potentially expensive. If the need were to arise to raise additional capital, access to that capital may be difficult and/or expensive and, as a result, could create liquidity challenges for the Company.
Possible Net Loss from Operations in 2019: In part because we expect sales of our hospital products to significantly decline from 2018’s levels and we will incur substantial expenses to further the clinical development of FT218, we likely will incur a net loss in 2019, the amount of which is not known to us at this time.

Financial Highlights

Highlights of our consolidated results for the three months ended March 31, 2019 are as follows: 
Revenue was $16,437 for the three months ended March 31, 2019, compared to $33,293 in the same period last year. This year over year decrease was primarily the result of increased competition driving lower prices as noted above in our discussion of Key Business Trends and Highlights. We experienced price and unit volume declines across all our hospital products due to additional competition.
Operating loss was $8,167 for the three months ended March 31, 2019, compared to operating loss of $12,625 and for the same period last year. The decrease in operating loss for the three months ended March 31, 2019 was largely driven by lower selling, general and administrative (SG&A) expenses of $14,041 driven by the exit of the Noctiva business in 2019 of approximately $10,100, the disposition of FSC in the first quarter 2018 of approximately $2,700 and lower intangible amortization of $1,566 due to the impairment of the Noctiva intangible at December 31, 2018, partially offset by lower gross margin (sales minus cost of goods sold) of $13,530.
Net loss was $13,018 for the three months ended March 31, 2019, compared to net loss of $12,236 and in the same period last year. Included in the net loss in the first quarter of 2019 was a loss on the deconsolidation of Avadel Specialty Pharmaceuticals, LLC of $2,673. As a result of Avadel Specialty Pharmaceuticals, LLC bankruptcy filing on February 6, 2019, the company concluded that it no longer controls the operations of this subsidiary and accordingly deconsolidated this subsidiary.
Diluted net loss per share was $0.35 for the three months ended March 31, 2019, compared to diluted net loss per share of $0.32 in the same period last year.
Cash and marketable securities decreased $20,064 to $79,851 at March 31, 2019, from $99,915 at December 31, 2018. This decrease was largely driven from $21,206 use of cash in operations.

Critical Accounting Estimates 
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. To prepare these financial statements, management must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosures of contingent assets and liabilities. Actual results could be significantly different from these estimates. 
Our significant accounting policies are described in Note 1 of the audited consolidated financial statements included in our Annual Report Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”). The SEC suggests companies provide additional disclosure on those accounting policies considered most critical. The SEC considers an accounting policy to be critical if it is important to our financial condition and results of operations and requires significant judgments and estimates on the part of management in its application. Our estimates are often based on complex judgments, probabilities and assumptions that management believes to be reasonable, but that are inherently uncertain and unpredictable. It is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. For a complete discussion of our critical accounting policies, see the “Critical Accounting Policies” section of the MD&A in our 2018 Form 10-K. Effective January 1, 2019, the Company implemented ASC 842, Leases. On January 1, 2019, the impact of adopting this new accounting standard required the Company to recognize $5,046 and $5,131 of assets and liabilities, respectively, related to the Company’s operating leases. Other than this new leasing standard, there were no other significant changes to our critical accounting policies during the three months ended March 31, 2019. See Note 9: Leases in the notes to the unaudited condensed consolidated financial statements for further information.

- 31 -



Results of Operations 
The following is a summary of our financial results (in thousands, except per share amounts) for the three months ended March 31, 2019 and 2018, respectively:
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Comparative Statements of Loss
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Product sales
 
$
16,437

 
$
33,161

 
$
(16,724
)
 
(50.4
)%
License revenue
 

 
132

 
(132
)
 
(100.0
)%
Total revenues
 
16,437

 
33,293

 
(16,856
)
 
(50.6
)%
Operating expenses:
 
 

 
 

 


 


Cost of products
 
3,266

 
6,592

 
(3,326
)
 
(50.5
)%
Research and development expenses
 
7,329

 
9,951

 
(2,622
)
 
(26.3
)%
Selling, general and administrative expenses
 
10,446

 
24,487

 
(14,041
)
 
(57.3
)%
Intangible asset amortization
 
201

 
1,767

 
(1,566
)
 
(88.6
)%
Changes in fair value of related party contingent consideration
 
2,134

 
2,968

 
(834
)
 
(28.1
)%
Restructuring costs
 
1,228

 
153

 
1,075

 
702.6
 %
Total operating expenses
 
24,604

 
45,918

 
(21,314
)
 
(46.4
)%
Operating loss
 
(8,167
)
 
(12,625
)
 
4,458

 
(35.3
)%
Loss on deconsolidation of subsidiary
 
(2,673
)
 

 
(2,673
)
 
n/a

Investment and other income, net
 
817

 
54

 
763

 
1,413.0
 %
Interest expense
 
(3,062
)
 
(1,597
)
 
(1,465
)
 
(91.7
)%
Other income - changes in fair value of related party payable
 
(307
)
 
(395
)
 
88

 
22.3
 %
Loss before income taxes
 
(13,392
)
 
(14,563
)
 
1,171

 
8.0
 %
Income tax benefit
 
(374
)
 
(2,327
)
 
1,953

 
83.9
 %
Net loss
 
$
(13,018
)
 
$
(12,236
)
 
$
(782
)
 
(6.4
)%
Net loss per share - diluted
 
$
(0.35
)
 
$
(0.32
)
 
$
(0.03
)
 
(9.4
)%
The revenues for each of the Company’s significant products for the three months ended March 31, 2019 and 2018 were as follows: 
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Revenues:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Bloxiverz
 
$
2,568

 
$
7,491

 
$
(4,923
)
 
(65.7
)%
Vazculep
 
9,473

 
12,961

 
(3,488
)
 
(26.9
)%
Akovaz
 
3,792

 
10,217

 
(6,425
)
 
(62.9
)%
Other
 
604

 
2,492

 
(1,888
)
 
(75.8
)%
Product sales
 
16,437

 
33,161

 
(16,724
)
 
(50.4
)%
License revenue
 

 
132

 
(132
)
 
(100.0
)%
Total revenues
 
$
16,437

 
$
33,293

 
$
(16,856
)
 
(50.6
)%
 
Total revenues were $16,437 for the three months ended March 31, 2019, compared to $33,293 for the same prior year period. Bloxiverz’s revenue declined $4,923 in the current quarter when compared to the same prior year period primarily due to lower unit volumes and net selling price driven largely by new competition which entered the market driving price and unit volumes lower. Vazculep’s revenue decreased $3,488 during the quarter when compared to the prior year period due primarily to lower net selling prices and lower volumes in the current period when compared to the same prior year period. Akovaz’s revenue declined $6,425 driven largely by lower unit volumes and net selling price due to new competition which entered the market driving price and unit volumes lower. Other revenues, which includes Noctiva and the pediatric products declined during the three months

- 32 -



ended March 31, 2019 compared to the same period in the prior year due to the primarily due to the bankruptcy of Specialty Pharma and related deconsolidation on February 6, 2019 and the February 2018 divestiture of the pediatric products.
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Cost of Products:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Cost of products
 
$
3,266

 
$
6,592

 
$
(3,326
)
 
(50.5
)%
Percentage of total revenues
 
19.9
%
 
19.8
%
 
 

 
 

 
Cost of products decreased $3,326 or 50.5% during the three months ended March 31, 2019 compared to the same prior year period driven by lower sold units. As a percentage of total revenue, cost of products sold was comparable to the prior year period.
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Research and Development Expenses:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Research and development expenses
 
$
7,329

 
$
9,951

 
$
(2,622
)
 
(26.3
)%
Percentage of total revenues
 
44.6
%
 
29.9
%
 
 

 
 

 
Research and development expenses decreased $2,622 or (26.3)% during the three months ended March 31, 2019 as compared to the same period in 2018. This decline was a result of $1.3 million of lower spending associated with the exit of Noctiva and $1.2 million of cost reductions at the Company’s Lyon, France R&D center. The Company continues to invest a substantial portion of R&D in its FT218 development program.
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Selling, General and Administrative Expenses:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Selling, general and administrative expenses
 
$
10,446

 
$
24,487

 
$
(14,041
)
 
(57.3
)%
Percentage of total revenues
 
63.6
%
 
73.5
%
 
 

 
 

 
Selling, general and administrative expenses decreased $14,041 or 57.3% during the three months ended March 31, 2019 as compared to the same prior year period. This decrease was primarily due to a decrease of $10,100 of sales and marketing costs related to the exit of Noctiva during the current quarter when compared to the same period of the prior year. The decrease is also related to $2,700 of costs during the three months ended March 31, 2018 related to our pediatrics products which were divested in February 2018.
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Intangibles Asset Amortization:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Intangible asset amortization
 
$
201

 
$
1,767

 
$
(1,566
)
 
(88.6
)%
Percentage of total revenues
 
1.2
%
 
5.3
%
 
 

 
 

 
Intangible asset amortization expense decreased $1,566 or 88.6% during the three months ended March 31, 2019 driven by the impairment of the intangible asset related to Noctiva at December 31, 2018.

- 33 -



 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Changes in Fair Value of Related Party Contingent Consideration:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Changes in fair value of related party contingent consideration
 
$
2,134

 
$
2,968

 
$
(834
)
 
(28.1
)%
Percentage of total revenues
 
13.0
%
 
8.9
%
 
 

 
 

 
We compute the fair value of the related party contingent consideration using several significant assumptions and when these assumptions change, due to underlying market conditions, the fair value of these liabilities change as well. Each of the underlying assumptions used to determine the fair values of these contingent liabilities can, and often do, change based on adjustments in current market conditions, competition and other factors. These changes can have a material impact on our unaudited condensed consolidated statements of loss and balance sheet.  

As a result of changes in the underlying assumptions used to determine the estimated fair values of our acquisition-related contingent consideration earn-out payments - Éclat, we recorded gains of $2,134 and $2,968 and lowered the fair value of the acquisition-related contingent consideration earn-out payments - Éclat for the three months ended March 31, 2019 and 2018, respectively. As noted in our critical accounting estimates included in the 2018 Form 10-K, there are numerous assumptions and estimates we use when determining the fair value of the acquisition-related earn-out payments - Éclat. These assumptions include estimates of pricing, market size, the market share the related products are forecast to achieve, the cost of goods related to such products and an appropriate discount rate to use when present valuing the related cash flows.

For the three months ended March 31, 2019, as a result of changes to these estimates when compared to the same estimates at December 31, 2018, we recorded an increase in the fair value of our contingent consideration liabilities due to changes in certain underlying market conditions of the acquisition-related contingent consideration earn-out payments - Éclat.

For the three months ended March 31, 2018, as a result of changes to these estimates when compared to the same estimates at December 31, 2017, we recorded an increase in the fair value of our contingent consideration liabilities, largely due to changes in certain underlying market conditions of the acquisition-related contingent consideration earn-out payments - Éclat.

 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Restructuring Costs
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Restructuring costs
 
$
1,228

 
$
153

 
$
1,075

 
702.6
%
Percentage of total revenues
 
7.5
%
 
0.5
%
 
 

 
 

 
Restructuring charges of $1,228 primarily comprising severance and legal costs were recognized during the three months ended March 31, 2019. These charges were primarily related to severance and legal costs. During the first quarter of 2019, the Company announced a plan to reduce its Corporate workforce at our U.S. and Ireland sites by more than 50%.  This reduction is an effort to align the Company’s cost structure with our ongoing and future planned projects. See Note 15: Restructuring Costs for further details.
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Investment and Other Income, net
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Investment and other income, net
 
$
817

 
$
54

 
$
763

 
1,413.0
%
Percentage of total revenues
 
5.0
%
 
0.2
%
 
 

 
 

Investment and other income, net increased for the three months ended March 31, 2019 when compared to the same period in the prior year driven by higher realized and unrealized gains on our marketable securities during the current period when compared to the prior period.

- 34 -



 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Interest Expense
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Interest expense
 
$
3,062

 
$
1,597

 
$
1,465

 
91.7
%
Percentage of total revenues
 
18.6
%
 
4.8
%
 
 

 
 

Interest expense increased $1,465 for the three months end March 31, 2019 when compared to the same period in the prior year as a result of a full quarter of imputed interest recorded in 2019 versus half of this amount in 2018 due to the 2023 Notes February 2018 issuance.
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Loss on Deconsolidation of Subsidiary
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Loss on deconsolidation of subsidiary
 
$
(2,673
)
 
$

 
$
(2,673
)
 
n/a
Percentage of total revenues
 
(16.3
)%
 
%
 
 

 
 

As a result of Avadel Specialty Pharmaceuticals, LLC bankruptcy filing on February 6, 2019, the Company concluded that it no longer controls its operations and accordingly deconsolidated this subsidiary. The Company recorded a loss on the deconsolidation as a result of removing the net assets and certain liabilities of this subsidiary from our unaudited condensed consolidated financial statements. See Note 3: Subsidiary Bankruptcy and Deconsolidation for more discussion.

 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Other Income - Changes in Fair Value of Related Party Payable
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Other income - changes in fair value of related party payable
 
$
(307
)
 
$
(395
)
 
$
88

 
22.3
%
Percentage of total revenues
 
(1.9
)%
 
(1.2
)%
 
 

 
 

 
We recorded income of $307 and $395 to reduce the fair value of these liabilities during the three months ended March 31, 2019 and 2018, respectively, due to the same reasons associated with the Éclat product sales forecasts as described in the section “Changes in Fair Value of Related Party Contingent Consideration” for these periods. As noted in our critical accounting estimates section included in the 2018 Form 10-K, there are a number of assumptions and estimates we use when determining the fair value of the related party payable payments. These estimates include pricing, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates often do change based on changes in current market conditions, competition and other factors.

 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Income Tax Benefit:
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Income tax benefit
 
$
(374
)
 
$
(2,327
)
 
$
1,953

 
83.9
%
Percentage of loss before income taxes
 
(2.8
)%
 
(16.0
)%
 
 

 
 

 

- 35 -



The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate for the three months ended March 31, 2019 and 2018, are as follows: 
 
 
Three Months Ended March 31,
 
 
2019
 
2018
 
 
 
 
 
Statutory tax rate  
 
12.5
 %
 
12.5
 %
International tax rates differential
 
5.0
 %
 
8.9
 %
Change in valuation allowance
 
(11.4
)%
 
(4.7
)%
Change in fair value of nondeductible contingent consideration
 
(3.1
)%
 
(3.8
)%
Nondeductible stock-based compensation
 
(0.4
)%
 
(1.1
)%
Unrecognized tax benefits
 
(0.9
)%
 
(1.5
)%
State and local income taxes, net of federal
 
 %
 
0.1
 %
Nondeductible interest expense
 
(1.2
)%
 
 %
Other
 
2.2
 %
 
5.6
 %
Effective income tax rate
 
2.7
 %
 
16.0
 %
 
 
 
 
 
Income tax benefit - at statutory tax rate
 
$
(1,673
)
 
$
(1,820
)
International tax rates differential
 
(668
)
 
(1,298
)
Change in valuation allowance
 
1,520

 
690

Change in fair value of nondeductible contingent consideration
 
413

 
551

Nondeductible stock-based compensation
 
51

 
160

Unrecognized tax benefits
 
124

 
220

State and local income taxes, net of federal
 
2

 
(19
)
Nondeductible interest expense
 
157

 

Other
 
(300
)
 
(811
)
Income tax benefit - at effective income tax rate
 
$
(374
)
 
$
(2,327
)
 
The income tax benefit for the three months ended March 31, 2019 was $374 compared to an income tax benefit of $2,327 for the three months ended March 31, 2018. The decrease in the income tax benefit for the three months ended March 31, 2019 is primarily the result of a decrease in the amount of loss generated in the United States, when compared to the same prior year period.
Liquidity and Capital Resources 
The Company’s cash flows from operating, investing and financing activities, as reflected in the unaudited condensed consolidated statements of cash flows, are summarized in the following table: 
 
 
 
 
 
 
Three Months Ended
 
 
Three Months Ended March 31,
 
Increase / (Decrease)
 
 
 
2019 vs. 2018
Net cash provided by (used in):
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
Operating activities
 
$
(21,206
)
 
$
(18,008
)
 
$
(3,198
)
 
(17.8
)%
Investing activities
 
21,390

 
(80,739
)
 
102,129

 
126.5
 %
Financing activities
 
92

 
122,915

 
(122,823
)
 
(99.9
)%
 
Operating Activities 
Net cash used in operating activities of $21,206 for the three months ended March 31, 2019 increased $3,198 compared to the same prior year period. This decrease in operating cash flow is primarily due to lower cash earnings (net income or loss adjusted for non-cash credits and charges) of $1,134 when compared to the same period last year. The decrease in operating cash flow was also due to higher cash used for accounts payable and other current liabilities of $5,622 when compared to the same period last

- 36 -



year, partially offset by lower cash payments for related party contingent consideration of $2,927 during the current period when compared to the prior period.
Investing Activities 
Cash provided by investing activities was $21,390 for the three months ended March 31, 2019, was related to net cash proceeds received from the excess of sales over purchases of marketable securities. Cash used in investing activities of $80,739 during the same prior year period was related to the use of cash to purchase marketable securities in excess of sales of marketable securities.
Financing Activities 
Cash provided by financing activities for the three months ended March 31, 2019 was $92, which decreased $122,823 for the same prior year period. During the three months ended March 31, 2018, $143,750 of cash was provided by financing activities through the issuance of the 2023 Notes. A portion of the proceeds from the offering of the 2023 Notes was used for share repurchases totaling $18,000 and to pay direct expenses associated with the issuance of the 2023 Notes of $5,391 during the first quarter of 2018.
Liquidity and Risk Management 
The adequacy of our cash resources depends on the outcome of certain business conditions including the cost of our FT218 clinical development plan, our cost structure, our hospital products revenue projections and other factors set forth in “Risk Factors” within Part I, Item 1A of the 2018 Form 10-K and within Part II, Item 1A of this quarterly report on Form 10-Q. To grow and invest in our business, we will need to commit substantial resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate our business. Our assumptions concerning the outcome of certain business conditions may prove to be wrong or other factors may adversely affect our business, and as a result we could exhaust or significantly decrease our available cash and marketable securities balances which could, among other things, force us to raise additional funds and/or force us to reduce our expenses, either of which could have a material adverse effect on our business. If available to us raising additional capital may be accomplished through one or more public or private debt or equity financings, collaborations or partnering arrangements. Any equity financing would be dilutive to our shareholders.
Borrowings
In February 2018, we issued the 2023 Notes. We received net proceeds of approximately $137,560 from the sale of the 2023 Notes, after deducting fees and expenses of $6,190.

Share Repurchase Programs
The Company fully completed its authorized share buyback program during the year ended December 31, 2018.

Other Matters 
Litigation  
The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At March 31, 2019 and December 31, 2018, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s unaudited condensed consolidated financial position, results of operations, cash flows or liquidity. 
Litigation Related to Noctiva

Note 3: Subsidiary Bankruptcy and Deconsolidation briefly describes the Chapter 11 bankruptcy case which our subsidiary Specialty Pharma commenced on February 6, 2019, and which on April 26, 2019 resulted in the bankruptcy court-approved sale of all of Specialty Pharma’s intangible assets and inventory to an unaffiliated third party. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. During the pendency of the bankruptcy case, all pending litigation against Specialty Pharma is automatically stayed and any new litigation against Specialty Pharma is precluded unless the bankruptcy court orders otherwise. Below are descriptions of a litigation to which Specialty Pharma is a party and a contract dispute involving Specialty Pharma, both of which matters are subject to the automatic stay during the bankruptcy case.
Ferring Litigation. Some of the patents covering the NoctivaTM product (the “Noctiva Patents”) are the subject of litigation initiated by Ferring Pharmaceuticals Inc. and two of its foreign affiliates, who manufacture a competing product known as Nocdurna. 

- 37 -



Nocdurna was approved by the FDA in June 2018 and commercially launched in the U.S. in November 2018.  In this litigation, Ferring seeks to invalidate and disputes the inventorship of the Noctiva Patents, seeks damages for various alleged breaches of contractual and common law duties, and seeks damages for alleged infringement by NoctivaTM of Ferring’s “Nocdurna” trademark.  Specialty Pharma and certain other parties including Serenity Pharmaceuticals, LLC (“Serenity”) (the licensor of the Noctiva Patents) have defended this litigation, and have made counterclaims against Ferring, including for infringement of the Noctiva Patents and a declaratory judgment of noninfringement with respect to Ferring’s “Nocdurna” trademark. The court dismissed Ferring’s inventorship claim and its claims for alleged breaches of contractual and common law duties, although these dismissals may be appealed by Ferring.  On February 15, 2019, Specialty Pharma and its co-defendants moved to stay the litigation pending completion of the bankruptcy proceeding of Specialty Pharma.

Contract Dispute. On January 21, 2019, Serenity gave notice to Specialty Pharma of an alleged breach of the parties’ Noctiva license agreement. Serenity alleges that Specialty Pharma breached its contractual obligation to devote commercially reasonable efforts to the commercialization of Noctiva and seeks unspecified damages. On January 27, 2019, Specialty Pharma notified Serenity of a claim for $1.7 million in damages as a result of Serenity’s breach of its contractual obligation to pay the costs of the Ferring Litigation. Serenity’s notice to Specialty Pharma invoked the dispute resolution provisions of the Noctiva license agreement, which culminate in arbitration, but neither party has yet initiated an arbitration proceeding or filed suit.

Material Commitments  
Due to the Chapter 11 bankruptcy case of Specialty Pharma, discussed in Note 3: Subsidiary Bankruptcy and Deconsolidation, the Company’s various commitments to purchase finished product from customers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of March 31, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:

Purchase Commitments:
 
Balance
 
 
 
2019
 
$
7,194

2020
 
1,320

2021
 
1,320

2022
 
1,320

2023
 
220

Thereafter
 

Total
 
$
11,374


Other than commitments disclosed in Note 15: Contingent Liabilities and Commitments to the Company’s audited consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in Note 10: Long-Term Debt and Note 13: Post-Retirement Benefit Plans, respectively, to the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 10: Long-Term Related Party Payable, to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this report.
Contractual Obligations 
Disclosures regarding contractual obligations are included in Part II, Item 7 of the Company’s 2018 Annual Report on Form 10-K and updated in Note 10: Long-Term Related Party Payable to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this Report.

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. 
Interest Rate Risk
The Company is subject to interest rate risk as a result of its portfolio of marketable securities. The primary objectives of our investment policy are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and competitive yield. Although our investments are subject to market risk, our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure from any single issue, issuer or certain types of investment. Our investment policy allows us to maintain a portfolio of cash equivalents and marketable securities

- 38 -



in a variety of instruments, including U.S. federal government and federal agency securities, European Government bonds, corporate bonds or commercial paper issued by U.S. or European corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, tax-exempt obligations of states, agencies, and municipalities in the U.S and Europe, and equities. 
ITEM 4.     CONTROLS AND PROCEDURES. 
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of March 31, 2019, the end of the period covered by this quarterly report on Form 10-Q.  The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.  Based on their evaluation, as of the end of the period covered by this Form 10-Q, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) were effective as of March 31, 2019
Changes in Internal Control over Financial Reporting 
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 or 15d-15 that occurred during the three months ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION 
ITEM 1.
LEGAL PROCEEDINGS. 
The information contained in Note 19: Commitments and Contingencies  to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this Report is incorporated by reference herein.
ITEM 1A.    RISK FACTORS. 
There have been no material changes in our risk factors from those previously disclosed in the Company’s 2018 Annual Report. 

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. 
The Company fully completed its authorized share buyback program during the year ended December 31, 2018.
 
ITEM 3.     DEFAULTS UPON SENIOR SECURITIES. 
None.
ITEM 4.    MINE SAFETY DISCLOSURES. 
Not applicable.
ITEM 5.    OTHER INFORMATION. 
None.

- 39 -



ITEM 6.    EXHIBITS. 
Exhibit No.
 
Description
 
 
 
31.1*
 
31.2*
 
32.1**
 
32.2**
 
101.INS*
 
XBRL Instance Document
101.SCH*
 
XBRL Taxonomy Extension Schema Document
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
______________________ 
*    Filed herewith. 
**          Furnished herewith. 

- 40 -



SIGNATURES 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 
 
AVADEL PHARMACEUTICALS PLC
 
(Registrant)
 
 
 
Date: May 8, 2019
By:
/s/ Michael F. Kanan
 
 
Michael F. Kanan
 
 
Senior Vice President and Chief Financial Officer
 
 
(Duly Authorized Officer and Principal Financial Officer)
 



- 41 -
EX-31.1 2 exhibit311q12019.htm EXHIBIT 31.1 Exhibit


 Exhibit 31.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Gregory J. Divis, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 8, 2019
/s/ Gregory J. Divis
 
Gregory J. Divis
 
Interim Chief Executive Officer



EX-31.2 3 exhibit312q12019.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Michael F. Kanan, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc:
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: May 8, 2019
/s/ Michael F. Kanan
 
Michael F. Kanan
 
Senior Vice President and Chief Financial Officer



EX-32.1 4 exhibit321q12019.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc (the “Company”) for the period ended March 31, 2019 (the “Report”), the undersigned hereby certifies in his capacity as Chief Executive Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
 
1.           the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2.           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 8, 2019
/s/ Gregory J. Divis
 
Gregory J. Divis
 
Interim Chief Executive Officer



EX-32.2 5 exhibit322q12019.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc (the “Company”) for the period ended March 31, 2019 (the “Report”), the undersigned hereby certifies in his capacity as Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
 
1.           the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2.           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: May 8, 2019
/s/ Michael F. Kanan
 
Michael F. Kanan
 
Senior Vice President and Chief Financial Officer



EX-101.INS 6 avdl-20190331.xml XBRL INSTANCE DOCUMENT 0001012477 2019-01-01 2019-03-31 0001012477 2019-05-06 0001012477 2018-01-01 2018-03-31 0001012477 us-gaap:LicenseMember 2019-01-01 2019-03-31 0001012477 us-gaap:LicenseMember 2018-01-01 2018-03-31 0001012477 us-gaap:ProductMember 2018-01-01 2018-03-31 0001012477 us-gaap:ProductMember 2019-01-01 2019-03-31 0001012477 2018-12-31 0001012477 2019-03-31 0001012477 2017-12-31 0001012477 us-gaap:CommonStockMember 2018-12-31 0001012477 us-gaap:TreasuryStockMember 2018-12-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001012477 us-gaap:RetainedEarningsMember 2018-12-31 0001012477 us-gaap:CommonStockMember 2019-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001012477 us-gaap:RetainedEarningsMember 2019-03-31 0001012477 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001012477 us-gaap:TreasuryStockMember 2019-03-31 0001012477 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001012477 us-gaap:RetainedEarningsMember 2018-03-31 0001012477 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001012477 us-gaap:TreasuryStockMember 2017-12-31 0001012477 us-gaap:RetainedEarningsMember 2017-12-31 0001012477 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001012477 us-gaap:CommonStockMember 2018-03-31 0001012477 us-gaap:TreasuryStockMember 2018-03-31 0001012477 us-gaap:CommonStockMember 2017-12-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001012477 2018-03-31 0001012477 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001012477 avdl:SpecialtyPharmaMember 2019-03-31 0001012477 avdl:SpecialityPharamaMember us-gaap:SubsequentEventMember 2019-04-26 2019-04-26 0001012477 avdl:DebtorinPossessionCreditandSecurityFacilityMember avdl:DIPCreditAgreementMember 2019-01-01 2019-03-31 0001012477 avdl:SpecialityPharamaMember avdl:DebtorinPossessionCreditandSecurityFacilityMember avdl:DIPCreditAgreementMember 2019-02-08 0001012477 us-gaap:SeniorNotesMember 2019-03-31 0001012477 avdl:FourPointFiftyPercentExchangeableSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:FixedIncomeSecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:FixedIncomeSecuritiesMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:FixedIncomeSecuritiesMember 2018-12-31 0001012477 us-gaap:MoneyMarketFundsMember 2018-12-31 0001012477 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:EquitySecuritiesMember 2018-12-31 0001012477 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:EquitySecuritiesMember 2018-01-01 2018-12-31 0001012477 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001012477 us-gaap:MoneyMarketFundsMember 2019-03-31 0001012477 us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001012477 us-gaap:EquitySecuritiesMember 2019-03-31 0001012477 us-gaap:FixedIncomeSecuritiesMember 2019-03-31 0001012477 us-gaap:EquitySecuritiesMember 2019-01-01 2019-03-31 0001012477 avdl:DebtSecuritiesExcludingMoneyMarketFundsAvailableForSaleMember 2019-03-31 0001012477 srt:MaximumMember 2019-01-01 2019-03-31 0001012477 srt:MinimumMember 2019-01-01 2019-03-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:VazculepMember 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:NoctivaMember 2019-03-31 0001012477 us-gaap:InProcessResearchAndDevelopmentMember avdl:VazculepMember 2018-01-01 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:NoctivaMember 2018-12-31 0001012477 us-gaap:InProcessResearchAndDevelopmentMember avdl:NoctivaMember 2018-01-01 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:VazculepMember 2019-03-31 0001012477 2018-01-01 2018-12-31 0001012477 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001012477 avdl:OperatingLeasesCommencedMember 2019-03-31 0001012477 srt:MaximumMember 2019-03-31 0001012477 srt:MinimumMember 2019-03-31 0001012477 avdl:EclatPharmaceuticalsMember 2012-03-01 2012-03-31 0001012477 avdl:BroadfinDebtFinancingMember 2013-12-01 2013-12-31 0001012477 avdl:DeerfieldCsfLlcMember srt:AffiliatedEntityMember 2013-02-01 2013-02-28 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-01-01 2019-03-31 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-01-01 2019-03-31 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-03-31 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2019-01-01 2019-03-31 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2018-12-31 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2019-03-31 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2018-12-31 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2018-12-31 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-03-31 0001012477 us-gaap:SeniorNotesMember 2018-12-31 0001012477 us-gaap:LoansPayableMember 2018-12-31 0001012477 avdl:FourPointFiftyPercentExchangeableSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-12-31 0001012477 us-gaap:LoansPayableMember 2019-03-31 0001012477 avdl:FourPointFiftyPercentExchangeableSeniorNotesDue2023Member 2018-12-31 0001012477 avdl:FourPointFiftyPercentExchangeableSeniorNotesDue2023Member 2019-03-31 0001012477 country:FR 2019-01-01 2019-03-31 0001012477 country:FR 2018-01-01 2018-03-31 0001012477 country:US 2019-01-01 2019-03-31 0001012477 country:IE 2018-01-01 2018-03-31 0001012477 country:IE 2019-01-01 2019-03-31 0001012477 country:US 2018-01-01 2018-03-31 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember us-gaap:ScenarioForecastMember 2021-01-01 2021-01-31 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2018-02-12 2018-02-12 0001012477 avdl:FSCMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2018-02-12 2018-02-12 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2018-02-12 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2019-03-31 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2018-12-31 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2019-01-01 2019-03-31 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2019-03-31 0001012477 us-gaap:ScenarioForecastMember 2019-01-01 2019-12-31 0001012477 us-gaap:AccruedLiabilitiesMember 2019-03-31 0001012477 us-gaap:EmployeeSeveranceMember avdl:LyonFranceWorkforceReductionMember 2017-03-31 0001012477 us-gaap:AccountsPayableMember 2019-03-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2019-01-01 2019-03-31 0001012477 us-gaap:EmployeeSeveranceMember avdl:CorporateWorkforceReductionMember 2017-03-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2017-12-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2018-03-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2019-03-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2018-12-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2018-01-01 2018-03-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-03-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-03-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0001012477 avdl:BloxiverzMember 2019-01-01 2019-03-31 0001012477 avdl:OtherProductsMember 2018-01-01 2018-03-31 0001012477 avdl:BloxiverzMember 2018-01-01 2018-03-31 0001012477 avdl:VazculepMember 2018-01-01 2018-03-31 0001012477 avdl:VazculepMember 2019-01-01 2019-03-31 0001012477 avdl:AkovazMember 2018-01-01 2018-03-31 0001012477 avdl:OtherProductsMember 2019-01-01 2019-03-31 0001012477 avdl:AkovazMember 2019-01-01 2019-03-31 0001012477 us-gaap:InventoriesMember 2019-03-31 0001012477 avdl:SpecialtyPharmaMember 2019-01-27 2019-01-27 xbrli:pure iso4217:USD avdl:segment xbrli:shares iso4217:USD xbrli:shares 2028000 1030000 3469000 0 1000000 1383000 1009000 1018000 6541000 6616000 17456000 7024000 10432000 10633000 0 10633000 2968000 2134000 307000 99000 208000 0 2600000 2200000 0.15 402000 0 5790000 3181000 -0.015 -0.009 0 157000 0.000 -0.012 395000 307000 534000 543000 5697000 5555000 220000 124000 494000 449000 4000 3000 213000 94000 134000 147000 5894000 5827000 49000 49000 407000 0.2 0.0175 0.00834 0.15 1024000 1003000 11374000 0 220000 1320000 7194000 1320000 1320000 283000 270000 7272000 7591000 1000000 0.50 0.50 153000 -170000 10300000 603000 2911000 2905000 6000 false --12-31 Q1 2019 2019-03-31 10-Q 0001012477 37355511 false Accelerated Filer AVADEL PHARMACEUTICALS PLC false AVDL 3503000 4150000 11330000 11772000 21695000 14689000 -23416000 -23203000 433756000 434199000 26699000 26699000 2167000 2167000 2134000 2134000 351000 351000 657000 1445000 1767000 201000 19374 19762 190300000 173622000 124851000 102437000 62141000 28449000 58772000 11449000 411000 7000 22000 316000 66000 635000 30000 30000 509000 43000 1180000 79000 13000 53000 79000 349000 9000 2000 0 7000 91359000 6411000 9400000 52733000 12714000 69935000 3442000 3673000 48438000 4249000 0 0 0 0 10267000 2775000 3651000 3841000 444000 0 0 444000 738000 688000 50000 0 90590000 52996000 6339000 9409000 12701000 6339000 9409000 52996000 12701000 70221000 48947000 3463000 3701000 4285000 11449000 3463000 3701000 48947000 4285000 2968000 2134000 0 0 2134000 98925000 72767000 28840000 1041000 2184000 25615000 27593000 976000 2048000 24569000 0 16564000 40911000 9325000 9630000 24347000 305000 0 -1750000 0.01 0.01 500000000 500000000 42720000 42762000 37313000 37355000 427000 427000 -12225000 -238000 249000 374000 -161000 -12805000 114000 115000 6592000 3266000 45918000 24604000 1352000 619000 143750000 143750000 -26699000 -26699000 0.0450 0.0450 263000 -28059000 -26614000 2700000 0 -407000 -2673000 23029000 23216000 1985000 369000 -20337000 9439000 9391000 28840000 27593000 19401000 18202000 -0.32 -0.35 -0.32 -0.35 179000 29000 0.160 0.027 0.125 0.125 -0.047 -0.114 0.089 0.050 -0.038 -0.031 -0.011 -0.004 0.056 0.022 0.001 0.000 0 9145000 9145000 9825000 9825000 10101000 10133000 0 23000 956000 331000 P15Y P3Y P5Y 815000 0 0 0 814000 85172000 73111000 12061000 12061000 0 12061000 1629000 0 1629000 1428000 0 1428000 18491000 18491000 18491000 18491000 0 0 6097000 6620000 5717000 5574000 6119000 6643000 66087000 66087000 0 -14563000 199000 -4927000 -9835000 285000 -10234000 -3443000 -13392000 -2327000 -374000 690000 1520000 -1298000 -668000 -1820000 -1673000 551000 413000 160000 51000 -811000 -300000 -19000 2000 90000 72000 921000 996000 6374000 752000 1891000 1021000 32000 -46000 -5854000 -4750000 -2851000 -222000 466000 -467000 518000 1818000 2285000 3228000 1629000 1428000 1597000 3062000 263000 3234000 3672000 4270000 3720000 4770000 4258000 500000 538000 4757000 1085000 54000 817000 301000 5548000 942000 693000 764000 1004000 1225000 920000 677000 187520000 183204000 190300000 173622000 38383000 31358000 3363000 2441000 115840000 115691000 117282000 117136000 106000 104000 58568000 115734000 117178000 1477000 1477000 1700000 90590000 70221000 -518000 -9000 122915000 92000 -80739000 21390000 -18008000 -21206000 -12236000 -12236000 -13018000 -13018000 2625000 28840000 27593000 1 -12625000 -8167000 345000 4871000 0 5131000 982000 3889000 310000 5802000 1000000 5046000 0.053 P5Y2M12D 5836000 1191000 695000 767000 1008000 1208000 967000 2798000 2497000 225000 1040000 36146000 36124000 59000 18000 249000 -161000 11000 11000 213000 213000 3526000 1927000 14002000 12577000 594000 149000 66000 146000 -395000 -307000 139000 -550000 238000 -374000 18000000 0 2167000 359000 638000 754000 825000 507000 7017000 3688000 164000 344000 3180000 275098000 13444000 41000 30000 0.01 0.01 50000000 50000000 0 0 0 0 0 0 8836000 6556000 2145000 2607000 143750000 0 47000 92000 194400000 34864000 250000 2911000 0 1911000 1749000 15263000 5391000 0 9951000 7329000 153000 170000 1398000 1228000 1000000 824000 879000 0 288000 356000 63000 644000 879000 419000 30000 -8000 -357989000 -371007000 33293000 10217000 7491000 2492000 12961000 132000 33161000 3792000 2568000 604000 9473000 0 16437000 16437000 24487000 10446000 3000000 2134000 351000 41463000 2117000 42066000 4424000 42720000 5407000 42763000 5407000 3350000 0 42000 1000 92000 92000 0 85580000 -64000 -23266000 -23202000 393478000 414000 -262685000 -22361000 87054000 -302000 -23255000 -22953000 427383000 420000 -274921000 -42573000 2780000 205000 -23416000 -23621000 433756000 427000 -357989000 -49998000 -9582000 579000 -23203000 -23782000 434199000 427000 -371007000 -49998000 44000 5407000 5407000 2307000 49998000 49998000 20212000 20212000 5315000 5315000 1378000 1100000 0 0 38559000 37354000 38559000 37354000 3971000 1726000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nature of Operations.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Avadel Pharmaceuticals plc&#160;(Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a branded specialty pharmaceutical company.&#160; Our primary focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.&#160; In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our &#8220;unapproved marketed drug&#8221; (UMD) program.&#160;&#160; The Company is headquartered in&#160;Dublin, Ireland&#160;with operations in&#160;St. Louis, Missouri&#160;and&#160;Lyon, France. For more information, please visit&#160;www.avadel.com.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump&#174; drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current marketed products include: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Akovaz&#174;</font><font> (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Bloxiverz&#174;</font><font> (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Vazculep&#174;</font><font> (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of our</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Akovaz</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bloxiverz</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vazculep</font><font style="font-family:inherit;font-size:10pt;"> products is used primarily in the hospital setting and was developed under our UMD program.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel&#8217;s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is the successor to Flamel Technologies S.A., a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;t&#233; anonyme</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Flamel&#8221;), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the &#8220;Merger&#8221;). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to &#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption &#8220; - The Reincorporation Merger.&#8221; of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 15, 2019. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation</font><font style="font-family:inherit;font-size:10pt;">), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, Since December 16, 2014, has been the owner of substantially all of Avadel&#8217;s intellectual property. Avadel France Holding SAS, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;t&#233; par actions simplifi&#233;e</font><font style="font-family:inherit;font-size:10pt;">, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&amp;D activities. A complete list of the Company&#8217;s subsidiaries can be found in Exhibit 21.1 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 15, 2019.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various other assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prepaid Expenses and Other Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valued-added tax recoverable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,607</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee from Armistice (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development tax credit receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation.</font><font style="font-family:inherit;font-size:10pt;"> The unaudited condensed consolidated balance sheet as of March 31, 2019, which is primarily derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company&#8217;s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2019, the Company&#8217;s indirect wholly owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (&#8220;Specialty Pharma&#8221;), filed a voluntary petition for reorganization under Chapter 11 of the United States (&#8220;U.S.&#8221;) Code (the &#8220;Bankruptcy Code&#8221;). in the U.S. District Bankruptcy Court for the District of Delaware (the &#8220;Bankruptcy Court&#8221;), Case No. 19-10248. Specialty Pharma is operating and managing its business as &#8220;debtors-in-possession&#8221; under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma&#8217;s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has investments in available-for-sale marketable securities which are recorded at fair market value. The change in the fair value of available-for-sale equity investments is recognized in our unaudited condensed consolidated statements of loss and the change in the fair value of all other available-for-sale investments is recorded as other comprehensive income (loss) in shareholders&#8217; (deficit) equity, net of income tax effects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables show the Company&#8217;s available-for-sale securities&#8217; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">509</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,947</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,249</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">635</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,733</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,714</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine realized gains or losses on the sale of marketable securities on a specific identification method. We reflect these gains and losses as a component of investment income in the accompanying unaudited condensed consolidated statements of loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized gross realized gains of&#160;</font><font style="font-family:inherit;font-size:10pt;">$94</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$213</font><font style="font-family:inherit;font-size:10pt;"> for the&#160;three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. These realized gains were offset by realized losses of </font><font style="font-family:inherit;font-size:10pt;">$147</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$134</font><font style="font-family:inherit;font-size:10pt;">&#160;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1-5 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">5-10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Greater than 10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has classified our investment in available-for-sale marketable securities as current assets in the unaudited condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Litigation</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> &#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At March 31, 2019 and December 31, 2018, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#8217;s unaudited condensed consolidated financial position, results of operations, cash flows or liquidity.&#160;</font><font style="font-family:inherit;font-size:10pt;"> &#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation Related to Noctiva</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation</font><font style="font-family:inherit;font-size:10pt;"> briefly describes the Chapter 11 bankruptcy case which our subsidiary Specialty Pharma commenced on February 6, 2019, and which on April 26, 2019 resulted in the bankruptcy court-approved sale of all of Specialty Pharma&#8217;s intangible assets and inventory to an unaffiliated third party. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. During the pendency of the bankruptcy case, all pending litigation against Specialty Pharma is automatically stayed and any new litigation against Specialty Pharma is precluded unless the bankruptcy court orders otherwise. Below are descriptions of a litigation to which Specialty Pharma is a party and a contract dispute involving Specialty Pharma, both of which matters are subject to the automatic stay during the bankruptcy case.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ferring Litigation.</font><font style="font-family:inherit;font-size:10pt;"> Some of the patents covering the Noctiva</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;product (the &#8220;Noctiva Patents&#8221;) are the subject of litigation initiated by Ferring Pharmaceuticals Inc. and two of its foreign affiliates, who manufacture a competing product known as Nocdurna.&#160; Nocdurna was approved by the FDA in June 2018 and commercially launched in the U.S. in November 2018.&#160; In this litigation, Ferring seeks to invalidate and disputes the inventorship of the Noctiva Patents, seeks damages for various alleged breaches of contractual and common law duties, and seeks damages for alleged infringement by Noctiva</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;of Ferring&#8217;s &#8220;Nocdurna&#8221; trademark.&#160; Specialty Pharma and certain other parties including Serenity Pharmaceuticals, LLC (&#8220;Serenity&#8221;) (the licensor of the Noctiva Patents) have defended this litigation, and have made counterclaims against Ferring, including&#160;for infringement of the Noctiva Patents and a declaratory judgment of noninfringement with respect to Ferring&#8217;s &#8220;Nocdurna&#8221; trademark. The court dismissed Ferring&#8217;s inventorship claim and its claims for alleged breaches of contractual and common law duties, although these dismissals may be appealed by Ferring.&#160; On February 15, 2019, Specialty Pharma and its co-defendants moved to stay the litigation pending completion of the bankruptcy proceeding of Specialty Pharma.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract Dispute.</font><font style="font-family:inherit;font-size:10pt;"> On January 21, 2019, Serenity gave notice to Specialty Pharma of an alleged breach of the parties&#8217; Noctiva license agreement. Serenity alleges that Specialty Pharma breached its contractual obligation to devote commercially reasonable efforts to the commercialization of Noctiva and seeks unspecified damages. On January 27, 2019, Specialty Pharma notified Serenity of a claim for $1.7 million in damages as a result of Serenity&#8217;s breach of its contractual obligation to pay the costs of the Ferring Litigation. Serenity&#8217;s notice to Specialty Pharma invoked the dispute resolution provisions of the Noctiva license agreement, which culminate in arbitration, but neither party has yet initiated an arbitration proceeding or filed suit.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Material Commitments</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the Chapter 11 bankruptcy case of Specialty Pharma, discussed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation, </font><font style="font-family:inherit;font-size:10pt;">the Company&#8217;s various commitments to purchase finished product from customers has changed from what was included in Part II, Item 8 of the Company&#8217;s 2018 Annual Report on Form 10-K. As of March 31, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Purchase Commitments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than commitments disclosed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 15: Contingent Liabilities and Commitments</font><font style="font-family:inherit;font-size:10pt;"> to the Company&#8217;s audited consolidated financial statements included in Part II, Item 8 of the Company&#8217;s 2018 Annual Report on Form 10-K, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 10: Long-Term Debt</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 13: Post-Retirement Benefit Plans</font><font style="font-family:inherit;font-size:10pt;">, respectively, to the Company&#8217;s consolidated financial statements included in Part II, Item 8 of the Company&#8217;s 2018 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 10: Long-Term Related Party Payable,</font><font style="font-family:inherit;font-size:10pt;"> to the Company&#8217;s unaudited condensed consolidated financial statements included in Part I, Item 1 of this report.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Loss&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the components of accumulated other comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of tax effects:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive Loss:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustment:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,621</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrealized gain (loss) on marketable securities, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at March 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss at March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,255</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect on the Company&#8217;s unaudited condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the Chapter 11 bankruptcy case of Specialty Pharma, discussed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation, </font><font style="font-family:inherit;font-size:10pt;">the Company&#8217;s various commitments to purchase finished product from customers has changed from what was included in Part II, Item 8 of the Company&#8217;s 2018 Annual Report on Form 10-K. As of March 31, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Purchase Commitments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Debt</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-Term debt is summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Principal amount of 4.50% exchangeable senior notes due 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: debt discount and issuance costs, net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net carrying amount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,178</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component of exchangeable notes, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Divestiture of the Pediatric Assets</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 12, 2018, the Company, together with its subsidiaries&#160;Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC (&#8220;FSC Therapeutics&#8221;), and Avadel US Holdings, Inc. (&#8220;Holdings&#8221;), as the &#8220;Sellers,&#8221;&#160;entered into an asset purchase agreement (the &#8220;Purchase Agreement&#8221;) with Cerecor, Inc. (&#8220;Cerecor&#8221;). The transaction closed on February 16, 2018 wherein Cerecor purchased from the Sellers four pediatric commercial stage assets &#8211; Karbinal&#8482; ER, Cefaclor, Flexichamber&#8482; and AcipHex&#174;&#160;Sprinkle&#8482;, together with certain associated business assets &#8211; which were held by FSC.&#160; The Company acquired FSC in February 2016 from Deerfield and certain of its affiliates. Pursuant to the Purchase Agreement, Cerecor assumed the Company&#8217;s&#160; remaining payment obligations to Deerfield under the Membership Interest Purchase Agreement, dated as of February 5, 2016, between Holdings, Flamel Technologies SA (the predecessor of the Company) and Deerfield and certain of its affiliates, which payment obligations consist of the following (collectively, the &#8220;Assumed Obligations&#8221;): (i) a quarterly payment of </font><font style="font-family:inherit;font-size:10pt;">$263</font><font style="font-family:inherit;font-size:10pt;"> beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of </font><font style="font-family:inherit;font-size:10pt;">$2,625</font><font style="font-family:inherit;font-size:10pt;">; (ii) a payment in January 2021 of </font><font style="font-family:inherit;font-size:10pt;">$15,263</font><font style="font-family:inherit;font-size:10pt;">; and (iii) a quarterly royalty payment of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> on net sales of the FSC products through February 5, 2026 (&#8220;FSC Product Royalties&#8221;), in an aggregate amount of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$10,300</font><font style="font-family:inherit;font-size:10pt;">.&#160; Cerecor also assumed certain contracts and other obligations related to the acquired assets, and in that connection Holdings agreed to pay Cerecor certain make-whole payments associated with obligations Cerecor is assuming related to a certain supply contract related to Karbinal&#8482; ER. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the divestiture, the Company also entered into the following arrangements:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License and Development Agreement</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, in connection with the closing under the Purchase Agreement, Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (&#8220;Avadel Ireland&#8221;) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the &#8220;License and Development Agreement&#8221;) pursuant to which, among other things:</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland&#8217;s LiquiTime&#8482; technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime&#8482; products in excess of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon regulatory approval and commercial launch of any LiquiTime&#8482; products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digit range.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deerfield Guarantee</font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing under the Purchase Agreement, the Company and Holdings provided their guarantee (the &#8220;Deerfield Guarantee&#8221;) in favor of Deerfield. Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the Assumed Obligations under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of </font><font style="font-family:inherit;font-size:10pt;">$263</font><font style="font-family:inherit;font-size:10pt;"> beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of </font><font style="font-family:inherit;font-size:10pt;">$2,625</font><font style="font-family:inherit;font-size:10pt;">; (ii) a payment in January 2021 of </font><font style="font-family:inherit;font-size:10pt;">$15,263</font><font style="font-family:inherit;font-size:10pt;">; and (iii) a quarterly royalty payment of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> on net sales of the FSC products through February 6, 2026 (&#8220;FSC Product Royalties&#8221;), in an aggregate amount of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$10,300</font><font style="font-family:inherit;font-size:10pt;">. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the &#8220;Minimum Royalties&#8221;). Given the Company&#8217;s explicit guarantee to Deerfield, the Company recorded the guarantee in accordance with ASC 460. A valuation was performed, which was based largely on an analysis of the potential timing of each possible cash outflow described above and the likelihood of Cerecor&#8217;s default on such payments assuming an S&amp;P credit rating of CCC+. The result of this valuation identified a guarantee liability of </font><font style="font-family:inherit;font-size:10pt;">$6,643</font><font style="font-family:inherit;font-size:10pt;">. This liability is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of this liability was </font><font style="font-family:inherit;font-size:10pt;">$6,119</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Armistice Guarantee</font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing under the Purchase Agreement, Armistice Capital Master Fund, Ltd., the majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties. A valuation of the guarantee asset was performed in accordance with ASC 460 and a guarantee asset of </font><font style="font-family:inherit;font-size:10pt;">$6,620</font><font style="font-family:inherit;font-size:10pt;"> was recorded. This asset is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield noted above. At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of this asset was </font><font style="font-family:inherit;font-size:10pt;">$6,097</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the Avadel guarantee to Deerfield and the guarantee received by Avadel from Armistice largely offset and when combined are not material.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on management&#8217;s review of ASU 2014-08,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</font><font style="font-family:inherit;font-size:10pt;">, the disposition of our pediatric assets and related liabilities did not qualify for discontinued operations reporting. Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC, prior to its February 16, 2018 disposition date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net impact of this transaction was not material to the unaudited condensed consolidated statements of loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the diluted number of shares outstanding during each period. Except where the result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the exercise of outstanding equity compensation awards, ordinary shares expected to be issued under our employee stock purchase plan (&#8220;ESPP&#8221;) and the exercise of contingent consideration warrants, all which have been exercised or have expired during the first quarter of 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a choice to settle the conversion obligation under the 2023 Notes in cash, shares or any combination of the two. We utilize the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result is anti-dilutive. This method assumes the conversion of the 2023 Notes into shares of our ordinary shares and reflects the elimination of the interest expense related to the 2023 Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The dilutive effect of the warrants, stock options, RSU&#8217;s and ordinary shares expected to be issued under or ESPP has been calculated using the treasury stock method. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Loss Per Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average shares:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,559</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of dilutive securities&#8212;employee and director equity awards outstanding and 2023 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,354</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per share - diluted </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potential common shares of&#160;</font><font style="font-family:inherit;font-size:10pt;">19,762</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">19,374</font><font style="font-family:inherit;font-size:10pt;">&#160;were excluded from the calculation of weighted average shares for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, because their effect was considered to be </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">anti</font><font style="font-family:inherit;font-size:10pt;">-dilutive. For the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in this period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: &#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221;&#160;defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques: &#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income approach, which is based on the present value of a future stream of net cash flows. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: &#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices for identical assets or liabilities in active markets. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that reflect estimates and assumptions. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 6</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,463</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Related party payable (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A review of fair value hierarchy classifications is conducted on a quarterly basis.&#160; Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, there were no transfers in and out of&#160;Level&#160;1, 2, or 3. During the&#160;three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, we did not recognize any other-than-temporary impairment loss.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate the fair value of our </font><font style="font-family:inherit;font-size:10pt;">$143,750</font><font style="font-family:inherit;font-size:10pt;">&#160;aggregate principal amount of&#160;4.50%&#160;exchangeable senior notes due 2023 (the &#8220;2023 Notes&#8221;), a Level 2 input, based on interest rates that would be currently available to the Company for issuance of similar types of debt instruments with similar terms and remaining maturities or recent trading prices obtained from brokers. The estimated fair value of the 2023 Notes at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$58,568</font><font style="font-family:inherit;font-size:10pt;"> compared to a book value of </font><font style="font-family:inherit;font-size:10pt;">$117,136</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the Company&#8217;s other debt is reflected in the balance sheet at carrying value. The fair value of these loans impracticable to estimate as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">11</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:normal;">Long-Term Debt</font><font style="font-family:inherit;font-size:10pt;"> for additional information regarding our debt obligations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s amortizable and unamortizable intangible assets at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Goodwill and Intangible Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Carrying</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Carrying</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortizable intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquired developed technology - Noctiva</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66,087</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquired developed technology - Vazculep</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total amortizable intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unamortizable intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total unamortizable intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded amortization expense related to amortizable intangible assets of </font><font style="font-family:inherit;font-size:10pt;">$201</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,767</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter 2018, certain conditions came to light, largely the lack of a meaningful increase in Noctiva prescriptions despite the substantial investment of resources, which indicated that the carrying value of the asset, may not be fully recoverable. As such, the Company performed an impairment test based on a comparison of the pretax discounted cash flows expected to be generated by the asset, which is a Level 3 fair value estimate, to the recorded value of the asset and concluded that the associated cash flows did not support any of the carrying value of the intangible asset and the Company recorded a full impairment charge of $66,087 at December 31, 2018 related to the acquired developed technology associated with Noctiva. The February 6, 2019 Chapter 11 bankruptcy filing of Specialty Pharma, the subsidiary which markets, sells and distributes Noctiva, confirmed management&#8217;s conclusion on the impairment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortizable intangible assets are amortized over their estimated useful lives, which generally range from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">fifteen</font><font style="font-family:inherit;font-size:10pt;"> years. Estimated amortization of intangible assets for the next </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years is as follows:&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Amortization Expense: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxe</font><font style="font-family:inherit;font-size:10pt;">s</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of loss before income taxes are as follows:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss Before Income Taxes:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ireland</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,835</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">France</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,563</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The items accounting for the difference between the income tax provision computed at the statutory rate and the Company&#8217;s effective tax rate are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income Tax Rate Reconciliation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Statutory tax rate </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit - at statutory tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,673</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,820</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit - at effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax benefit for the three months ended March 31, 2019 was $374 compared to an income tax benefit of $2,327 for the three months ended March 31, 2018. The decrease in the income tax benefit for the three months ended March 31, 2019 is primarily the result of a decrease in the amount of loss generated in the United States, when compared to the same prior year period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal categories of inventories, net reserves of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,085</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$4,757</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Inventory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net reserves decreased by&#160;</font><font style="font-family:inherit;font-size:10pt;">$3,672</font><font style="font-family:inherit;font-size:10pt;">&#160;during the three months ended March 31, 2019 driven largely by the deconsolidation of Specialty Pharma.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1-5 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">5-10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Greater than 10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease costs, which is included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the period ended March 31 were as follows ($ in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease cost:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease costs </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sublease income </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Variable lease costs were immaterial for the three months ended March 31, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of the Company&#8217;s operating lease liabilities were as follows ($ in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Remaining nine months of 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">942</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Present value of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,871</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases&#8221; which supersedes ASC 840 &#8220;Leases&#8221; and creates a new topic, ASC 842 &#8220;Leases.&#8221; This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. On January 1, 2019, the Company adopted the ASU using the modified retrospective transition approach and elected the transition option to recognize the adjustment in the period of adoption rather than in the earliest period presented. As January 1, 2019, adoption of the new guidance resulted in the initial recognition of operating lease right-of-use assets of </font><font style="font-family:inherit;font-size:10pt;">$5,046</font><font style="font-family:inherit;font-size:10pt;"> and operating lease liabilities of </font><font style="font-family:inherit;font-size:10pt;">$5,131</font><font style="font-family:inherit;font-size:10pt;">. At March 31, 2019, the balances of the operating lease right-of-use asset and total operating lease liability are </font><font style="font-family:inherit;font-size:10pt;">$5,802</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,871</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$982</font><font style="font-family:inherit;font-size:10pt;"> of the operating lease liability is current.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases certain facilities for office and manufacturing purposes, comprising approximately 99% of the total lease population. All leased facilities are classified as operating leases with remaining lease terms between one and seven years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. For all of the Company&#8217;s leases, lease and non-lease components are accounted for as a single lease component, as all non-lease components are immaterial to break out separately. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease costs, which is included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the period ended March 31 were as follows ($ in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease cost:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease costs </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sublease income </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Variable lease costs were immaterial for the three months ended March 31, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2019, the Company reduced its operating lease liabilities by </font><font style="font-family:inherit;font-size:10pt;">$310</font><font style="font-family:inherit;font-size:10pt;"> for cash paid. In addition, new operating leases commenced resulting in the recognition of operating lease right-of-use assets and liabilities of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively, as the entire lease payment was paid on March 31, 2019. As of March 31, 2019, the Company is aware of one additional embedded lease that has not yet commenced and will not commence until the time of FDA approval of the product (if approved). Once FDA approval is given and the start date is determined, annual production suite fees of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;"> would commence&#160;and at that time, and an operating lease right-of-use asset and corresponding operating lease liability will be recorded. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2019, our operating leases have a weighted-average remaining lease term of </font><font style="font-family:inherit;font-size:10pt;">5.2 years</font><font style="font-family:inherit;font-size:10pt;"> and a weighted-average discount rate of </font><font style="font-family:inherit;font-size:10pt;">5.3%</font><font style="font-family:inherit;font-size:10pt;">. Nearly all of Avadel&#8217;s lease contracts do not provide a readily determinable implicit rate. For these contracts, Avadel&#8217;s estimated incremental borrowing rate is based on information available at the inception of the lease.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of the Company&#8217;s operating lease liabilities were as follows ($ in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Remaining nine months of 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">942</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Present value of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,871</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Newly Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Guidance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#8221; which supersedes ASC 840 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#8221; and creates a new topic, ASC 842 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">.&#8221; This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. In July 2018, the FASB issued&#160;ASU&#160;2018-11 &#8220;Targeted Improvements&#8221;, amending certain aspects of the new leasing standard. The amendment allows an additional optional transition method whereby an entity records a cumulative effect adjustment to opening retained earnings in the year of adoption without restating prior periods, which the Company has elected. The impact of this new guidance is further discussed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Leases</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820):&#160;Disclosure Framework&#8212; Changes to the Disclosure Requirement for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">&#8221; which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.</font><font style="font-family:inherit;font-size:10pt;">&#8221;&#160;This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Newly Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Guidance</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#8221; which supersedes ASC 840 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#8221; and creates a new topic, ASC 842 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">.&#8221; This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. In July 2018, the FASB issued&#160;ASU&#160;2018-11 &#8220;Targeted Improvements&#8221;, amending certain aspects of the new leasing standard. The amendment allows an additional optional transition method whereby an entity records a cumulative effect adjustment to opening retained earnings in the year of adoption without restating prior periods, which the Company has elected. The impact of this new guidance is further discussed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Leases</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820):&#160;Disclosure Framework&#8212; Changes to the Disclosure Requirement for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">&#8221; which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.</font><font style="font-family:inherit;font-size:10pt;">&#8221;&#160;This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Assets and Liabilities&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various other assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prepaid Expenses and Other Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valued-added tax recoverable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,607</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee from Armistice (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development tax credit receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Non-Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax assets, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Long-term deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee from Armistice (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Right of use assets at contract manufacturing organizations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued Expenses </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued social charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued restructuring (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 15</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,616</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,541</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract research organization charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract manufacturing organization costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,030</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract sales organization and marketing costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Non-Current Liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for retirement indemnity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer allowances </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">619</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee to Deerfield (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,574</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,717</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,002</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Non-Current Liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for retirement indemnity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer allowances </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">619</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee to Deerfield (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,574</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,717</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,002</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Related Party Payable&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term related party payable and related activity are reported at fair value and consist of the following at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Activity during the Three Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Changes in Fair Value of Related Party Payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-Term Related Party Payable: </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance, March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition-related contingent consideration:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earn-out payments - &#201;clat Pharmaceuticals (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financing-related:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Deerfield (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,184</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(344</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Broadfin (c)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total related party payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,688</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total long-term related party payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,202</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) In March 2012, the Company acquired all of the membership interests of &#201;clat from Breaking Stick Holdings, L.L.C. (&#8220;Breaking Stick&#8221;, formerly &#201;clat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company&#8217;s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of any gross profit generated by certain &#201;clat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,600</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain &#201;clat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,200</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">0.834%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain &#201;clat products until December 31, 2024.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of each related party payable listed in (a), (b) and (c) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified &#201;clat products using an appropriate risk-adjusted discount rate of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management&#8217;s revision of key assumptions, will be recorded in the unaudited condensed consolidated statements of loss in the line items entitled &#8220;Changes in fair value of related party contingent consideration&#8221; for items noted in (b) above and in &#8220;Other expense - changes in fair value of related party payable&#8221; for items (b) and (c) above. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1: Summary of Significant Accounting Policies </font><font style="font-family:inherit;font-size:10pt;">under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company&#8217;s 2018 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has chosen to make a fair value election pursuant to ASC 825, &#8220;Financial Instruments&#8221; for its royalty agreements detailed in items (b) and (c) above. These financing-related liabilities are recorded at fair market value on the unaudited condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of &#8220;Other expense &#8211; change in fair value of related party payable&#8221; on the unaudited condensed consolidated statements of loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-month periods ended&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Party Payable Rollforward:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,017</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,167</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Disposition of the pediatric assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiary Bankruptcy and Deconsolidation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bankruptcy Filing and Deconsolidation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of Specialty Pharma&#8217;s bankruptcy filing on February 6, 2019, Avadel has ceded authority for managing the business to the Bankruptcy Court, and Avadel management cannot carry on Specialty Pharma&#8217;s activities in the ordinary course of business without Bankruptcy Court approval. Avadel manages the day-to-day operations of Specialty Pharma, but does not have discretion to make significant capital or operating budgetary changes or decisions and purchase or sell significant assets, as Specialty Pharma&#8217;s material decisions are subject to review by the Bankruptcy Court. For these reasons, we have concluded that Avadel has lost control of Specialty Pharma, and no longer has significant influence over Specialty Pharma during the pendency of the bankruptcy. Therefore, we deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy in February 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to deconsolidate Specialty Pharma, the carrying values of the assets and certain liabilities of Specialty Pharma were removed from our unaudited condensed consolidated balance sheet as of February 5, 2019, and we recorded our investment in Specialty Pharma at its estimated fair value of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">. As the estimated fair value of our investment in Specialty Pharma was lower than its net book value immediately prior to the deconsolidation, we recorded a non-cash charge of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$2,673</font><font style="font-family:inherit;font-size:10pt;">&#160;associated with the deconsolidation of Specialty Pharma. Subsequent to the deconsolidation of Specialty Pharma, we are accounting for our investment in Specialty Pharma using the cost method of accounting because Avadel does not exercise significant influence over the operations of Specialty Pharma due to the Chapter 11 filing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2019, Specialty Pharma sold its intangible assets and remaining inventory to an unaffiliated third party in exchange for aggregate cash proceeds of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$250</font><font style="font-family:inherit;font-size:10pt;">, pursuant to an order approving such sale which was issued by the Bankruptcy Court on April 15, 2019. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DIP Financing &#8211; Related Party Relationship</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the bankruptcy filing, Specialty Pharma entered into a Debtor in Possession Credit and Security Agreement with Avadel US Holdings (&#8220;DIP Credit Agreement&#8221;) dated as of February 8, 2019, in an aggregate amount of up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$2,700</font><font style="font-family:inherit;font-size:10pt;">, of which the funds are to be used by Specialty Pharma solely to fund operations through February 6, 2020. As of March 31, 2019, the Company had funded&#160;</font><font style="font-family:inherit;font-size:10pt;">$407</font><font style="font-family:inherit;font-size:10pt;">&#160;under the DIP Credit Agreement. As the Company has assessed that it is unlikely that Specialty Pharma will pay back the loan to Avadel, the </font><font style="font-family:inherit;font-size:10pt;">$407</font><font style="font-family:inherit;font-size:10pt;"> has been recorded as part of the loss on deconsolidation of subsidiary within the unaudited condensed consolidated statements of loss. At March 31, 2019 the fair value of the remaining commitment under the DIP Credit Agreement is not material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Corporate Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2019, the Company announced a plan to reduce our Corporate workforce by more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;2019 Corporate Restructuring&#8221;). The reduction in workforce is primarily a result of the exit of Noctiva during the first quarter of 2019 (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Subsidiary Bankruptcy and Deconsoldiation</font><font style="font-family:inherit;font-size:10pt;">), as well as an effort to better align the Company&#8217;s remaining cost structure at our U.S. and Ireland locations with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of the fiscal year 2019, and to result in employee severance, benefits and other costs of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">, which are likely to be recognized through December 31, 2019. 2019 Corporate Restructuring charges of </font><font style="font-family:inherit;font-size:10pt;">$1,398</font><font style="font-family:inherit;font-size:10pt;"> were recognized during the three months ended March 31, 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company&#8217;s cost reduction plan obligations for the three months ended March 31, 2019:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Corporate Restructuring Obligations:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at March 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring liabilities of </font><font style="font-family:inherit;font-size:10pt;">$356</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$288</font><font style="font-family:inherit;font-size:10pt;"> are included in the unaudited condensed consolidated balance sheet in accrued expenses and accounts payable, respectively, at March 31, 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 French Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2017, the Company announced a plan to reduce our workforce at our Venniseux, France site by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;2017 French Restructuring&#8221;).&#160; This reduction was an effort to align the Company&#8217;s cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council for our French operations and received approval from the French&#160;Labor Commission (DIRECCTE) to implement the plan. The reduction was substantially complete at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">. The 2017 French Restructuring income of&#160;</font><font style="font-family:inherit;font-size:10pt;">$170</font><font style="font-family:inherit;font-size:10pt;"> and restructuring charges of </font><font style="font-family:inherit;font-size:10pt;">$153</font><font style="font-family:inherit;font-size:10pt;">&#160;were recognized during the&#160;three months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. The following table sets forth activities for the Company&#8217;s cost reduction plan obligations for the&#160;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 French Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at March 31, </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">824</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2017 French Restructuring accrual is included in the unaudited condensed consolidated balance sheet in accrued expenses at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue.</font><font style="font-family:inherit;font-size:10pt;"> Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (&#8220;R&amp;D&#8221;) achievements.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">&#8220;Revenue from Contracts with Customers&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer&#894; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price&#894; (iv) Allocate the transaction price to the performance obligations in the contract&#894; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#8217;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales and Services&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company&#8217;s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company&#8217;s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Revenue&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">For a complete discussion of the accounting for net product revenue and license revenues, see </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">: Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Product Sales and Services </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company implemented ASC 606,&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</font><font style="font-family:inherit;font-size:10pt;">&#8221;. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company&#8217;s product and the Company&#8217;s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company&#8217;s gross product sales are subject to a variety of price deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Reserves to reduce Gross Revenues to Net Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Product Returns</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Chargebacks, Discounts and Rebates </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Revenue from licensing arrangements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of the Company&#8217;s licensing agreements may contain multiple performance obligations, including certain R&amp;D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees&#894; development, regulatory and commercial milestone payments. Each of these payments results in license revenues. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">License of Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Disaggregation of revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company&#8217;s revenues by product, see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Company Operations by Product</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Contract Balances</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A receivable is recognized in the period the Company sells its products and when the Company&#8217;s right to consideration is unconditional. See the unaudited condensed consolidated balance sheets for the balance of accounts receivable at</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">See below for contract liability discussion and balance related to a license agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">There were </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">no</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> material deferred contract costs at </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Transaction Price Allocated to the Remaining Performance Obligation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Product Sales and Services </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company implemented ASC 606,&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</font><font style="font-family:inherit;font-size:10pt;">&#8221;. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company&#8217;s product and the Company&#8217;s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company&#8217;s gross product sales are subject to a variety of price deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Reserves to reduce Gross Revenues to Net Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company&#8217;s estimates. If actual results in the future vary from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Product Returns</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Chargebacks, Discounts and Rebates </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Revenue from licensing arrangements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of the Company&#8217;s licensing agreements may contain multiple performance obligations, including certain R&amp;D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees&#894; development, regulatory and commercial milestone payments. Each of these payments results in license revenues. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">License of Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Disaggregation of revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company&#8217;s revenues by product, see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Company Operations by Product</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Contract Balances</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A receivable is recognized in the period the Company sells its products and when the Company&#8217;s right to consideration is unconditional. See the unaudited condensed consolidated balance sheets for the balance of accounts receivable at</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">See below for contract liability discussion and balance related to a license agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">There were </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">no</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> material deferred contract costs at </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Transaction Price Allocated to the Remaining Performance Obligation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued Expenses </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued social charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued restructuring (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 15</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,616</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,541</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract research organization charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract manufacturing organization costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,030</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract sales organization and marketing costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the components of accumulated other comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of tax effects:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive Loss:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustment:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,621</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrealized gain (loss) on marketable securities, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at March 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">579</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss at March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,203</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,255</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-Term debt is summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Principal amount of 4.50% exchangeable senior notes due 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: debt discount and issuance costs, net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net carrying amount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,178</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component of exchangeable notes, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Loss Per Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average shares:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,354</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,559</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of dilutive securities&#8212;employee and director equity awards outstanding and 2023 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,354</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per share - diluted </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The items accounting for the difference between the income tax provision computed at the statutory rate and the Company&#8217;s effective tax rate are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income Tax Rate Reconciliation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Statutory tax rate </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit - at statutory tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,673</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,820</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit - at effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 6</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,463</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,285</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Related party payable (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s amortizable and unamortizable intangible assets at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Goodwill and Intangible Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Carrying</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Carrying</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortizable intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquired developed technology - Noctiva</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66,087</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquired developed technology - Vazculep</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total amortizable intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unamortizable intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total unamortizable intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were ($ in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease Commitment:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of loss before income taxes are as follows:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss Before Income Taxes:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ireland</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,835</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">France</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,563</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal categories of inventories, net reserves of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,085</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$4,757</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Inventory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Non-Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax assets, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Long-term deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee from Armistice (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Right of use assets at contract manufacturing organizations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term related party payable and related activity are reported at fair value and consist of the following at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Activity during the Three Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Changes in Fair Value of Related Party Payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-Term Related Party Payable: </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance, March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition-related contingent consideration:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earn-out payments - &#201;clat Pharmaceuticals (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financing-related:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Deerfield (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,184</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(344</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Broadfin (c)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total related party payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,688</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,391</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total long-term related party payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,202</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) In March 2012, the Company acquired all of the membership interests of &#201;clat from Breaking Stick Holdings, L.L.C. (&#8220;Breaking Stick&#8221;, formerly &#201;clat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company&#8217;s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of any gross profit generated by certain &#201;clat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,600</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain &#201;clat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,200</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">0.834%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain &#201;clat products until December 31, 2024.</font></div></td></tr></table></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-month periods ended&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Party Payable Rollforward:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,017</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,167</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Disposition of the pediatric assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,441</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company&#8217;s cost reduction plan obligations for the three months ended March 31, 2019:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Corporate Restructuring Obligations:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at March 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company&#8217;s cost reduction plan obligations for the&#160;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 French Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at March 31, </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">824</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of total revenues by these products:&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues by Product:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Bloxiverz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vazculep</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,473</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Akovaz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">License revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,293</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization of intangible assets for the next </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years is as follows:&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Amortization Expense: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Company Revenue by Product&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that it operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company&#8217;s Chief Operating Decision Maker is the interim CEO. The interim CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company&#8217;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of total revenues by these products:&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues by Product:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Bloxiverz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vazculep</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,473</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Akovaz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">License revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,293</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nature of Operations.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Avadel Pharmaceuticals plc&#160;(Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a branded specialty pharmaceutical company.&#160; Our primary focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.&#160; In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our &#8220;unapproved marketed drug&#8221; (UMD) program.&#160;&#160; The Company is headquartered in&#160;Dublin, Ireland&#160;with operations in&#160;St. Louis, Missouri&#160;and&#160;Lyon, France. For more information, please visit&#160;www.avadel.com.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump&#174; drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current marketed products include: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Akovaz&#174;</font><font> (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Bloxiverz&#174;</font><font> (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Vazculep&#174;</font><font> (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of our</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Akovaz</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bloxiverz</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vazculep</font><font style="font-family:inherit;font-size:10pt;"> products is used primarily in the hospital setting and was developed under our UMD program.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel&#8217;s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is the successor to Flamel Technologies S.A., a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;t&#233; anonyme</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Flamel&#8221;), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the &#8220;Merger&#8221;). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to &#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption &#8220; - The Reincorporation Merger.&#8221; of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 15, 2019. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation</font><font style="font-family:inherit;font-size:10pt;">), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, Since December 16, 2014, has been the owner of substantially all of Avadel&#8217;s intellectual property. Avadel France Holding SAS, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">soci&#233;t&#233; par actions simplifi&#233;e</font><font style="font-family:inherit;font-size:10pt;">, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&amp;D activities. A complete list of the Company&#8217;s subsidiaries can be found in Exhibit 21.1 of the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 15, 2019.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation.</font><font style="font-family:inherit;font-size:10pt;"> The unaudited condensed consolidated balance sheet as of March 31, 2019, which is primarily derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company&#8217;s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2019, the Company&#8217;s indirect wholly owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (&#8220;Specialty Pharma&#8221;), filed a voluntary petition for reorganization under Chapter 11 of the United States (&#8220;U.S.&#8221;) Code (the &#8220;Bankruptcy Code&#8221;). in the U.S. District Bankruptcy Court for the District of Delaware (the &#8220;Bankruptcy Court&#8221;), Case No. 19-10248. Specialty Pharma is operating and managing its business as &#8220;debtors-in-possession&#8221; under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma&#8217;s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC Therapeutics and FSC Laboratories, Inc., (collectively &#8220;FSC&#8221;), prior to its February 16, 2018 disposition date. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">14</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:normal;">Divestiture of the Pediatric Assets</font><font style="font-family:inherit;font-size:10pt;">, for additional information. All intercompany accounts and transactions have been eliminated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue.</font><font style="font-family:inherit;font-size:10pt;"> Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (&#8220;R&amp;D&#8221;) achievements.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">&#8220;Revenue from Contracts with Customers&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer&#894; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price&#894; (iv) Allocate the transaction price to the performance obligations in the contract&#894; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#8217;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales and Services&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company&#8217;s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company&#8217;s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Revenue&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">For a complete discussion of the accounting for net product revenue and license revenues, see </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">: Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables show the Company&#8217;s available-for-sale securities&#8217; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;</font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">509</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,947</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,249</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">635</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,733</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,714</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></div> EX-101.SCH 7 avdl-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2120100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Commitments and Contingencies - (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Company Operations by Product link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Company Revenue by Product - Summary of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Company Revenue by Product (Tables) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Comprehensive Income (Loss) - Components (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Comprehensive Loss - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Divestiture of the Pediatric Assets link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Divestiture of the Pediatric Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Leases - Components of lease costs (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Leases - Maturities of operating lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Leases - Maturities of operating lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Long-Term Debt Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Long-Term Debt Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Long-Term Related Party Payable link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Long-Term Related Party Payable - Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Long-Term Related Party Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Long-Term Related Party Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Marketable Securities Marketable Securities - Schedule of Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Net Loss Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Newly Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Other Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Other Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Restructuring Costs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Restructuring Costs - Severance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Subsidiary Bankruptcy and Deconsolidation link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Subsidiary Bankruptcy and Deconsolidation (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY Statement link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 avdl-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 avdl-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 avdl-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 4.50% Exchangeable Senior Notes Due 2023 Four Point Fifty Percent Exchangeable Senior Notes Due 2023 [Member] Four Point Fifty Percent Exchangeable Senior Notes Due 2023 [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Loans Payable Loans Payable [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term debt Long-term Debt, Gross Less: debt discount and issuance costs, net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Net carrying amount of liability component Long-term Debt Other debt Other Long-term Debt Less: current maturities Long-term Debt, Current Maturities Long-term debt, less current portion Long-term Debt, Excluding Current Maturities Equity component of exchangeable notes, net of issuance costs Debt Instrument, Convertible, Carrying Amount of Equity Component Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Investments, Debt and Equity Securities [Abstract] Marketable securities, realized gain Marketable Securities, Realized Gain Marketable Securities, Realized Gain Marketable securities, realized loss Marketable Securities, Realized Loss Marketable Securities, Realized Loss Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Ordinary shares Common Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated deficit Retained Earnings [Member] Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Treasury Shares Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning balance Stockholders' Equity Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Vesting of restricted shares (in shares) Stock Issued During Period, Shares, Other Vesting of restricted shares Stock Issued During Period, Value, Other Employee share purchase plan share issuance (in shares) Stock Issued During Period, Shares, Employee Stock Ownership Plan Employee share purchase plan share issuance Stock Issued During Period, Value, Employee Stock Purchase Plan Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Exercise of warrants (in shares) Stock Issued During Period, Shares, Expiration Of Warrants Stock Issued During Period, Shares, Expiration Of Warrants Exercise of warrants Stock Issued During Period, Value, Expiration Of Warrants Stock Issued During Period, Value, Expiration Of Warrants Expiration of warrants Adjustments to Additional Paid in Capital, Other Equity component of 2023 Notes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Share repurchases (in shares) Treasury Stock, Shares, Acquired Share repurchases Treasury Stock, Value, Acquired, Cost Method Ending balance (in shares) Ending balance Reorganizations [Abstract] Subsidiary Bankruptcy and Deconsolidation Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block] Other Liabilities Disclosure [Abstract] Accrued Expenses Accrued Liabilities, Current [Abstract] Accrued compensation Workers' Compensation Liability, Current Accrued social charges Accrued Social Charges Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued social charges. Accrued restructuring (see Note 15) Restructuring Reserve, Current Customer allowances Accrued trade discounts and rebates Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued discounts and rebates Accrued contract research organization charges Accrued Contract Research Organization Charges Accrued Contract Research Organization Charges Accrued contract manufacturing organization costs Accrued Contract Manufacturing Organization Liabilities Accrued Contract Manufacturing Organization Liabilities Accrued contract sales organization and marketing costs Accrued Contract Research Organization Accrued Contract Research Organization Other Other Accrued Liabilities, Current Total Accrued Liabilities, Current Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance Employee Severance [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Corporate Workforce Reduction Corporate Workforce Reduction [Member] Corporate Workforce Reduction [Member] 2019 Corporate Restructuring Obligations Two Thousand Nineteen Corporate Restructuring Obligations [Member] Two Thousand Nineteen Corporate Restructuring Obligations [Member] Lyon France Workforce Reduction Lyon France Workforce Reduction [Member] Lyon France Workforce Reduction [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued Liabilities Accrued Liabilities [Member] Accounts Payable Accounts Payable [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Expected number of positions eliminated (as a percent) Restructuring And Related Costs, Expected Number Of Positions Eliminated, Percent Restructuring And Related Costs, Expected Number Of Positions Eliminated, Percent Severance Costs Severance Costs Restructuring costs Restructuring Charges Restructuring reserve Restructuring Reserve Other Assets and Liabilities Other Liabilities Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] Inventories Inventories [Member] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] 2019 Purchase Commitment, Maximum, Due in Next Twelve Months Purchase Commitment, Maximum, Due in Next Twelve Months 2020 Purchase Commitment, Maximum, Due in Second Year Purchase Commitment, Maximum, Due in Second Year 2021 Purchase Commitment, Maximum, Due in Third Year Purchase Commitment, Maximum, Due in Third Year 2022 Purchase Commitment, Maximum, Due in Fourth Year Purchase Commitment, Maximum, Due in Fourth Year 2023 Purchase Commitment, Maximum, Due in Fifth Year Purchase Commitment, Maximum, Due in Fifth Year Thereafter Purchase Commitment, Maximum, Due After Fifth Year Purchase Commitment, Maximum, Due After Fifth Year Total Purchase Commitment, Maximum Purchase Commitment, Maximum Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Estimated Amortization Expense: Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2019 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Five Statement of Financial Position [Abstract] Preferred shares, nominal value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred shares, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred shares, shares issued (in shares) Preferred Stock, Shares Issued Preferred shares, shares outstanding (in shares) Preferred Stock, Shares Outstanding Ordinary shares, nominal value (in usd per share) Common Stock, Par or Stated Value Per Share Ordinary shares, shares authorized (in shares) Common Stock, Shares Authorized Ordinary shares, shares issued (in shares) Common Stock, Shares, Issued Ordinary shares, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares held (in shares) Treasury Stock, Shares Leases [Abstract] Leases Lessee, Operating Leases [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Amortization of premiums on marketable securities Marketable Securities, Gain (Loss) Remeasurement of related party acquisition-related contingent consideration Acquisition Related Contingent Consideration Remeasurement Represents the remeasurement of acquisition related contingent considerations Remeasurement of related party financing-related contingent consideration Financing Related Contingent Consideration Remeasurement Represents the remeasurement of financing related contingent considerations Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts Change in deferred tax and income tax deferred charge Increase (Decrease) in Income Taxes Stock-based compensation expense Share-based Compensation Loss on deconsolidation of subsidiary Cash Divested from Deconsolidation Other adjustments Other Operating Activities, Cash Flow Statement Net changes in assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Research and development tax credit receivable Increase (Decrease) In Research and Development Tax Credit Receivable The increase (decrease) during the reporting period in research and development tax credit receivable. Accounts payable & other current liabilities Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Accrued income taxes Increase (Decrease) in Income Taxes Payable Earn-out payments for related party contingent consideration in excess of acquisition-date fair value Earn Out Payment In Excess Of Acquisition Date Fair Value Represents the Earn Out Payment In Excess Of Acquisition Date Fair Value Royalty payments for related party payable in excess of original fair value Payments for Royalties Other assets and liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-sale Purchases of marketable securities Payments to Acquire Marketable Securities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Earn-out payments for related party contingent consideration Earn Out Payment Represents the amount of acquisition earn out payment made. Proceeds from debt issuance Proceeds from Issuance of Long-term Debt Payments for debt issuance costs Repayments of Long-term Debt Share repurchases Payments for Repurchase of Common Stock Proceeds from exercise of warrants Proceeds from Warrant Exercises Other financing activities, net Proceeds from (Payments for) Other Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign currency exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net change in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at January 1, Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at March 31, Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Income taxes paid Income Taxes Paid Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Marketable securities Marketable Securities, Current Accounts receivable Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Goodwill Goodwill Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Research and development tax credit receivable Research and Development Tax Credit Receivable Non Current The non current portion of tax credit receivable on research and development as on the balance sheet date. Other non-current assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current portion of long-term debt Current portion of long-term related party payable Due to Related Parties, Current Current portion of operating lease liability Operating Lease, Liability, Current Accounts payable Accounts Payable, Current Deferred revenue Contract with Customer, Liability Accrued expenses Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term related party payable, less current portion Due to Related Parties, Noncurrent Long-term operating lease liability Operating Lease, Liability, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Shareholders’ (deficit) equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at March 31, 2019 and December 31, 2018, respectively Preferred Stock, Value, Issued Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,762 issued and 37,355 outstanding at March 31, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018 Common Stock, Value, Issued Treasury shares, at cost, 5,407 shares held at March 31, 2019 and December 31, 2018, respectively Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total shareholders’ (deficit) equity Total liabilities and shareholders’ (deficit) equity Liabilities and Equity Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Acquisition-related contingent consideration: Acquisition-related Costs [Member] Financing-related: Financing Related Costs [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Earn-out payments Earn Out Payments [Member] Royalty agreement - Deerfield Deerfield Royalty agreement [Member] Royalty agreement - Broadfin Broadfin Royalty agreement [Member] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Acquisition-related contingent consideration: Business Combination, Liabilities Arising from Contingencies, Amount Recognized [Roll Forward] Business Combination, Liabilities Arising from Contingencies, Amount Recognized [Roll Forward] Related party payable, beginning balance Business Combination, Liabilities Arising from Contingencies, Amount Recognized Payments to Related Parties Payments to Acquire Businesses, Gross Operating Expense Business Combination, Acquisition Related Costs Other Expense Business Combination Financing Related Costs This element represents financing-related costs incurred to effect a business combination which costs have been expensed during the period. Related party payable, ending balance Less: Current portion Long-term related party payable Other Comprehensive Income (Loss), Tax [Abstract] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Foreign currency translation (loss) gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Portion Attributable to Parent, Available-for-sale Securities Total other comprehensive income, net of tax Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Long-Term Debt Debt Disclosure [Text Block] Related Party Payable Rollforward: Business Combination, Changes in Related Party Payable [Roll Forward] Business Combination, Changes in Related Party Payable [Roll Forward] Payment of related party payable Fair value adjustments Liabilities, Fair Value Adjustment Expiration of warrants Payments for Repurchase of Warrants Disposition of the pediatric assets Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] FSC FSC [Member] FSC [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] 2016 MIPA 2016 MIPA [Member] 2016 MIPA [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Debt instrument, periodic payment, interest Debt Instrument, Periodic Payment, Interest Noncash or part noncash acquisition, debt assumed Noncash or Part Noncash Acquisition, Debt Assumed Repayments of assumed debt Repayments of Assumed Debt Percentage of royalty payable on net sales Percentage Of Royalty Payable On Net Sales The percentage of royalty that has to be paid by the company as per the royalty agreement. Royalty payable on net sales, maximum Royalty Payable on Net Sales, Maximum Royalty Payable on Net Sales, Maximum Research and development reimbursement, in excess of Research and Development Reimbursement, In Excess Of Research and Development Reimbursement, In Excess Of Guaranty liabilities Guaranty Liabilities Guaranty assets Guaranty Assets Earnings Per Share [Abstract] Schedule of Earnings Per Share Reconciliation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Newly Issued Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Other Non-Current Liabilities: Other Liabilities, Noncurrent [Abstract] Provision for retirement indemnity Provision For Retirement Indemnity Noncurrent The non current portion of provision for retirement indemnity as of the balance sheet date. Customer allowances Customer Refund Liability, Noncurrent Unrecognized tax benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Guarantee to Deerfield Other Total Segment Reporting [Abstract] Schedule of Segment Reporting Information, Revenue by Product Schedule of Segment Reporting Information, by Segment [Table Text Block] Number of operating segments (in segments) Number of Operating Segments Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Bloxiverz Bloxiverz [Member] Vazculep Vazculep [Member] Akovaz Akovaz [Member] Akovaz [Member] Other Other Products [Member] Product sales Product [Member] License revenue License [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Other comprehensive income (loss), tax Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Prepaid Expenses and Other Current Assets: Prepaid Expense and Other Assets, Current [Abstract] Valued-added tax recoverable Value Added Tax Receivable, Current Prepaid and other expenses Prepaid Expense, Current Guarantee from Armistice Guarantee, Current Guarantee, Current Income tax receivable Income Taxes Receivable, Current Research and development tax credit receivable Research And Development Tax Credit Receivable, Current Research And Development Tax Credit Receivable, Current Short-term deposit Short-term Investments Other Other Assets, Current Total Loss Contingencies [Table] Loss Contingencies [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Specialty Pharma Specialty Pharma [Member] Specialty Pharma [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Equity securities Equity Securities [Member] Money market funds Money Market Funds [Member] Corporate bonds Corporate Debt Securities [Member] Government securities - U.S. US Government Agencies Debt Securities [Member] Other fixed-income securities Fixed Income Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Adjusted Cost Equity Securities, FV-NI, Cost Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Fair Value Equity Securities, FV-NI Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Adjusted Cost Debt Securities, Available-for-sale, Amortized Cost Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair Value Debt Securities, Available-for-sale Components of lease costs Lease, Cost [Table Text Block] Maturities of operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Income Taxes [Table] Income Taxes [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Ireland IRELAND United States UNITED STATES France FRANCE Income Taxes [Line Items] Income Taxes [Line Items] Total income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Stockholders' Equity Note [Abstract] Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Schedule of Available-for-sale and Equity Securities Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] Schedule of Contractual Maturity Dates Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Inventory Disclosure [Abstract] Inventory reserves Inventory Valuation Reserves Increase in inventory reserves Inventory Adjustments Inventory: Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Gross Raw materials Inventory, Raw Materials, Gross Total Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Lease Arrangement [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Lease Arrangement [Domain] Lease Arrangement [Domain] [Domain] for Lease Arrangement [Axis] Operating Leases Commenced Operating Leases Commenced [Member] Operating Leases Commenced [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating lease liabilities Operating Lease, Liability Operating lease payments Operating Lease, Payments Lessee, operating lease, lease not yet commenced, operating lease expense Lessee, Operating Lease, Lease Not yet Commenced, Operating Lease Expense Lessee, Operating Lease, Lease Not yet Commenced, Operating Lease Expense Operating lease, weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Revenue from Contract with Customer [Abstract] Revenue Recognition Revenue from Contract with Customer [Text Block] Restructuring Costs Restructuring and Related Activities Disclosure [Text Block] Deferred contract costs Capitalized Contract Cost, Net Operating lease costs Operating Lease, Cost Sublease income (2) Sublease Income Total lease cost Lease, Cost Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value Disclosures [Abstract] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Speciality Pharama Speciality Pharama [Member] Speciality Pharama [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] DIP Credit Agreement DIP Credit Agreement [Member] DIP Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Debtor in Possession Credit and Security Facility Debtor in Possession Credit and Security Facility [Member] Debtor in Possession Credit and Security Facility [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Equity method investments, fair value Equity Method Investments, Fair Value Disclosure Gain (loss) on deconsolidation of subsidiary Deconsolidation, Gain (Loss), Amount Aggregate cash proceeds of intangible assets and remaining inventory Proceeds from Sale of Intangible Assets DIP financing, amount arranged Debtor-in-Possession Financing, Amount Arranged Payments for debtor in possession financing Payments For Debtor In Possession Financing Payments For Debtor In Possession Financing Schedule of Prepaid Expenses and Other Current Assets Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block] Tabular disclosure of the carrying amounts of prepaid expenses and other current assets. Schedule of Other Assets, Noncurrent Schedule of Other Assets, Noncurrent [Table Text Block] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule Of Long Term Liabilities Other Noncurrent Liabilities [Table Text Block] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease payments Operating Leases, Future Minimum Payments Due Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Inventories Inventory Disclosure [Text Block] Accounting Policies [Abstract] Nature of Operations Nature Of Business Policy [Policy Text Block] Disclosure of accounting policy for nature of business. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Newly Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Revenue Revenue from Contract with Customer [Policy Text Block] Income Statement [Abstract] Revenues: Revenues [Abstract] Operating expenses: Costs and Expenses [Abstract] Cost of products Cost of Goods and Services Sold Research and development expenses Research and Development Expense Selling, general and administrative expenses Selling, General and Administrative Expense Intangible asset amortization Amortization of Intangible Assets Changes in fair value of related party contingent consideration Total operating expenses Costs and Expenses Operating loss Operating Income (Loss) Investment and other income, net Investment Income, Net Interest expense Interest Expense, Debt Loss on deconsolidation of subsidiary Other income - changes in fair value of related party payable Other Nonoperating Income (Expense) Loss before income taxes Income tax benefit Income Tax Expense (Benefit) Net loss Net income (loss) per share - basic (in dollars per share) Earnings Per Share, Basic Net income (loss) per share - diluted (in dollars per share) Earnings Per Share, Diluted Weighted average number of shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average number of shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity securities Marketable securities Total assets Assets, Fair Value Disclosure Related party payable Due to Related Parties Total liabilities Nonfinancial Liabilities Fair Value Disclosure Long-term debt, fair value Long-term Debt, Fair Value Book value of long-term debt Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Emerging Growth Company Entity Emerging Growth Company Entity Smaller Reporting Company Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Debt Securities, Excluding Money Market Funds, Available For Sale Debt Securities, Excluding Money Market Funds, Available For Sale [Member] Debt Securities, Excluding Money Market Funds, Available For Sale [Member] Less than 1 Year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value 1-5 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value 5-10 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value Greater than 10 Years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value Fair Value Net Loss Per Share Earnings Per Share [Text Block] Finite-Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed technology Developed Technology Rights [Member] In Process Research and Development [Member] In Process Research and Development [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Noctiva Noctiva [Member] Noctiva [Member] Amortizable intangible assets: Finite-Lived Intangible Assets, Net [Abstract] Gross Value Finite-Lived Intangible Assets, Gross Accumulated Amortization Accumulated Amortization, Goodwill Represents the amount of accumulated amortization of goodwill. Impairment Impairment of Intangible Assets, Finite-lived Net Carrying Amount Finite-Lived Intangible Assets, Net Unamortizable intangible assets: Business Combination, Goodwill [Abstract] Gross Value Goodwill, Gross Accumulated Amortization Goodwill, Impaired, Accumulated Impairment Loss Net Carrying Amount Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Restructuring reserve, beginning balance Charges for employee severance, benefits and other Restructuring Charges Before Gain (Loss) Due to Curtailment Restructuring Charges Before Gain (Loss) Due to Curtailment Payments Payments for Restructuring Foreign currency impact Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring reserve, ending balance Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Long-Term Related Party Payable Related Party Transactions Disclosure [Text Block] Company Revenue by Product Segment Reporting Disclosure [Text Block] Other Non-Current Assets: Other Assets, Noncurrent [Abstract] Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Long-term deposits Long-term Investments Guarantee from Armistice Guarantee, Noncurrent Guarantee, Noncurrent Right of use assets at contract manufacturing organizations Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent Other Other Noncurrent Receivables The carrying amount of other noncurrent receivables. Total Divestiture of the Pediatric Assets Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Schedule of Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Remaining nine months of 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Eclat Pharmaceuticals Eclat Pharmaceuticals [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Deerfield FSC LLC Deerfield CSF LLC [Member] Broadfin Debt Financing Broadfin Debt Financing [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Percentage of earn-out payments Percentage Of Earn Out Payments Percentage Of Earn Out Payments Cash consideration received on royalty agreement Cash Consideration Received On Royalty Agreement The amount represents the cash consideration received by the company for entering into royalty agreement. Discounted cash flow risk adjusted discount rate Discounted Cash Flow Risk Adjusted Discount Rate This element represents the risk adjusted discount rate used for estimating fair value of cash flow. Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Fair Value Measurement Fair Value Disclosures [Text Block] Weighted average shares: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic shares (in shares) Effect of dilutive securities—options and warrants outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Diluted shares (in shares) Contractual Obligation, Fiscal Year Maturity Schedule Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent International tax rates differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in fair value of nondeductible contingent consideration Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Nondeductible stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Unrecognized tax benefits Effective Income Tax Rate Reconciliation Deferred Charge From IP Transfer Effective income tax rate reconciliation deferred charge from IP transfer. State and local income taxes, net of federal Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Nondeductible interest expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Percent Other Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Amount [Abstract] Effective Income Tax Rate Reconciliation, Amount [Abstract] Income tax benefit - at statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount International tax rates differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in fair value of nondeductible contingent consideration Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Nondeductible stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Unrecognized tax benefits Income Tax Reconciliation Nondeductible Expense Deferred Charge From IP Transfer Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible deferred charges from IP transfer costs. State and local income taxes, net of federal Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Nondeductible interest expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Income tax benefit - at effective income tax rate Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign currency translation adjustment: Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized gain (loss) on marketable securities, net Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Other Comprehensive Loss: Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Loss: AOCI Attributable to Parent, Net of Tax [Roll Forward] Net other comprehensive income (loss) Schedule of Debt Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Components of Income Before Income Tax Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] EX-101.PRE 11 avdl-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2019
May 06, 2019
Document And Entity Information [Abstract]    
Entity Registrant Name AVADEL PHARMACEUTICALS PLC  
Entity Central Index Key 0001012477  
Trading Symbol AVDL  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Mar. 31, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Emerging Growth Company false  
Entity Smaller Reporting Company false  
Entity Common Stock, Shares Outstanding   37,355,511
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenues:    
Total revenues $ 16,437 $ 33,293
Operating expenses:    
Cost of products 3,266 6,592
Research and development expenses 7,329 9,951
Selling, general and administrative expenses 10,446 24,487
Intangible asset amortization 201 1,767
Changes in fair value of related party contingent consideration 2,134 2,968
Restructuring costs 1,228 153
Total operating expenses 24,604 45,918
Operating loss (8,167) (12,625)
Investment and other income, net 817 54
Interest expense (3,062) (1,597)
Loss on deconsolidation of subsidiary (2,673) 0
Other income - changes in fair value of related party payable (307) (395)
Loss before income taxes (13,392) (14,563)
Income tax benefit (374) (2,327)
Net loss $ (13,018) $ (12,236)
Net income (loss) per share - basic (in dollars per share) $ (0.35) $ (0.32)
Net income (loss) per share - diluted (in dollars per share) $ (0.35) $ (0.32)
Weighted average number of shares outstanding - basic (in shares) 37,354 38,559
Weighted average number of shares outstanding - diluted (in shares) 37,354 38,559
Product sales    
Revenues:    
Total revenues $ 16,437 $ 33,161
License revenue    
Revenues:    
Total revenues $ 0 $ 132
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Other Comprehensive Income (Loss), Tax [Abstract]    
Net loss $ (13,018) $ (12,236)
Other comprehensive (loss) income, net of tax:    
Foreign currency translation (loss) gain (161) 249
Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively 374 (238)
Total other comprehensive income, net of tax 213 11
Total comprehensive loss $ (12,805) $ (12,225)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Statement of Comprehensive Income [Abstract]    
Other comprehensive income (loss), tax $ (18) $ (59)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 9,630 $ 9,325
Marketable securities 70,221 90,590
Accounts receivable 11,772 11,330
Inventories 4,258 4,770
Prepaid expenses and other current assets 6,556 8,836
Total current assets 102,437 124,851
Property and equipment, net 1,749 1,911
Operating lease right-of-use assets 5,802  
Goodwill 18,491 18,491
Intangible assets, net 1,428 1,629
Research and development tax credit receivable 7,591 7,272
Other non-current assets 36,124 36,146
Total assets 173,622 190,300
Current liabilities:    
Current portion of long-term debt 104 106
Current portion of long-term related party payable 9,391 9,439
Current portion of operating lease liability 982  
Accounts payable 4,150 3,503
Deferred revenue 115 114
Accrued expenses 14,689 21,695
Other current liabilities 1,927 3,526
Total current liabilities 31,358 38,383
Long-term debt, less current portion 117,178 115,734
Long-term related party payable, less current portion 18,202 19,401
Long-term operating lease liability 3,889  
Other non-current liabilities 12,577 14,002
Total liabilities 183,204 187,520
Shareholders’ (deficit) equity:    
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at March 31, 2019 and December 31, 2018, respectively 0 0
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,762 issued and 37,355 outstanding at March 31, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018 427 427
Treasury shares, at cost, 5,407 shares held at March 31, 2019 and December 31, 2018, respectively (49,998) (49,998)
Additional paid-in capital 434,199 433,756
Accumulated deficit (371,007) (357,989)
Accumulated other comprehensive loss (23,203) (23,416)
Total shareholders’ (deficit) equity (9,582) 2,780
Total liabilities and shareholders’ (deficit) equity $ 173,622 $ 190,300
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2019
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred shares, nominal value (in usd per share) $ 0.01 $ 0.01
Preferred shares, shares authorized (in shares) 50,000,000 50,000,000
Preferred shares, shares issued (in shares) 0 0
Preferred shares, shares outstanding (in shares) 0 0
Ordinary shares, nominal value (in usd per share) $ 0.01 $ 0.01
Ordinary shares, shares authorized (in shares) 500,000,000 500,000,000
Ordinary shares, shares issued (in shares) 42,762,000 42,720,000
Ordinary shares, shares outstanding (in shares) 37,355,000 37,313,000
Treasury stock, shares held (in shares) 5,407,000 5,407,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY Statement - USD ($)
shares in Thousands, $ in Thousands
Total
Ordinary shares
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive (loss) income
Treasury Shares
Beginning balance (in shares) at Dec. 31, 2017   41,463       2,117
Beginning balance at Dec. 31, 2017 $ 85,580 $ 414 $ 393,478 $ (262,685) $ (23,266) $ (22,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (12,236)     (12,236)    
Other comprehensive income 11       11  
Stock-based compensation expense 2,134   2,134      
Exercise of warrants (in shares)   603        
Exercise of warrants 2,911 $ 6 2,905      
Expiration of warrants 2,167   2,167      
Equity component of 2023 Notes 26,699   26,699      
Share repurchases (in shares)           2,307
Share repurchases (20,212)         $ (20,212)
Ending balance (in shares) at Mar. 31, 2018   42,066       4,424
Ending balance at Mar. 31, 2018 87,054 $ 420 427,383 (274,921) (23,255) $ (42,573)
Beginning balance (in shares) at Dec. 31, 2018   42,720       5,407
Beginning balance at Dec. 31, 2018 2,780 $ 427 433,756 (357,989) (23,416) $ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (13,018)     (13,018)    
Other comprehensive income 213       213  
Vesting of restricted shares (in shares)   1        
Vesting of restricted shares 0          
Employee share purchase plan share issuance (in shares)   42        
Employee share purchase plan share issuance 92   92      
Stock-based compensation expense 351   351      
Ending balance (in shares) at Mar. 31, 2019   42,763       5,407
Ending balance at Mar. 31, 2019 $ (9,582) $ 427 $ 434,199 $ (371,007) $ (23,203) $ (49,998)
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.19.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash flows from operating activities:    
Net loss $ (13,018) $ (12,236)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 369 1,985
Amortization of premiums on marketable securities 9 518
Remeasurement of related party acquisition-related contingent consideration 2,134 2,968
Remeasurement of related party financing-related contingent consideration 307 395
Amortization of debt discount and debt issuance costs 1,445 657
Change in deferred tax and income tax deferred charge (222) (2,851)
Stock-based compensation expense 351 2,134
Loss on deconsolidation of subsidiary 1,750 0
Other adjustments (550) 139
Net changes in assets and liabilities    
Accounts receivable (1,021) (1,891)
Inventories 467 (466)
Prepaid expenses and other current assets (3,228) (2,285)
Research and development tax credit receivable (449) (494)
Accounts payable & other current liabilities 752 6,374
Accrued expenses (4,750) (5,854)
Accrued income taxes (46) 32
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value (3,181) (5,790)
Royalty payments for related party payable in excess of original fair value (507) (825)
Other assets and liabilities (1,818) (518)
Net cash used in operating activities (21,206) (18,008)
Cash flows from investing activities:    
Purchases of property and equipment (30) (41)
Proceeds from sales of marketable securities 34,864 194,400
Purchases of marketable securities (13,444) (275,098)
Net cash provided by (used in) investing activities 21,390 (80,739)
Cash flows from financing activities:    
Earn-out payments for related party contingent consideration 0 (402)
Proceeds from debt issuance 0 143,750
Payments for debt issuance costs 0 (5,391)
Share repurchases 0 (18,000)
Proceeds from exercise of warrants 0 2,911
Other financing activities, net 92 47
Net cash provided by financing activities 92 122,915
Effect of foreign currency exchange rate changes on cash and cash equivalents 29 179
Net change in cash and cash equivalents 305 24,347
Cash and cash equivalents at January 1, 9,325 16,564
Cash and cash equivalents at March 31, 9,630 40,911
Supplemental disclosures of cash flow information:    
Interest paid 3,234 263
Income taxes paid $ 72 $ 90
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Nature of Operations.  Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company.  Our primary focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.   The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020.

Our current marketed products include:
Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “ - The Reincorporation Merger.” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, Since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities. A complete list of the Company’s subsidiaries can be found in Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

Basis of Presentation. The unaudited condensed consolidated balance sheet as of March 31, 2019, which is primarily derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.
The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. 
On February 6, 2019, the Company’s indirect wholly owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See Note 3: Subsidiary Bankruptcy and Deconsolidation.
Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC Therapeutics and FSC Laboratories, Inc., (collectively “FSC”), prior to its February 16, 2018 disposition date. See Note 14: Divestiture of the Pediatric Assets, for additional information. All intercompany accounts and transactions have been eliminated.
Revenue. Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements. 
Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Sales and Services 

The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis.

License Revenue 

The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.

For a complete discussion of the accounting for net product revenue and license revenues, see Note 4: Revenue Recognition.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.19.1
Newly Issued Accounting Pronouncements
3 Months Ended
Mar. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Newly Issued Accounting Pronouncements
Newly Issued Accounting Standards
Recently Adopted Accounting Guidance

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. In July 2018, the FASB issued ASU 2018-11 “Targeted Improvements”, amending certain aspects of the new leasing standard. The amendment allows an additional optional transition method whereby an entity records a cumulative effect adjustment to opening retained earnings in the year of adoption without restating prior periods, which the Company has elected. The impact of this new guidance is further discussed in Note 9: Leases.

Recent Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.19.1
Subsidiary Bankruptcy and Deconsolidation
3 Months Ended
Mar. 31, 2019
Reorganizations [Abstract]  
Subsidiary Bankruptcy and Deconsolidation
Subsidiary Bankruptcy and Deconsolidation

Bankruptcy Filing and Deconsolidation

As a result of Specialty Pharma’s bankruptcy filing on February 6, 2019, Avadel has ceded authority for managing the business to the Bankruptcy Court, and Avadel management cannot carry on Specialty Pharma’s activities in the ordinary course of business without Bankruptcy Court approval. Avadel manages the day-to-day operations of Specialty Pharma, but does not have discretion to make significant capital or operating budgetary changes or decisions and purchase or sell significant assets, as Specialty Pharma’s material decisions are subject to review by the Bankruptcy Court. For these reasons, we have concluded that Avadel has lost control of Specialty Pharma, and no longer has significant influence over Specialty Pharma during the pendency of the bankruptcy. Therefore, we deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy in February 2019.

In order to deconsolidate Specialty Pharma, the carrying values of the assets and certain liabilities of Specialty Pharma were removed from our unaudited condensed consolidated balance sheet as of February 5, 2019, and we recorded our investment in Specialty Pharma at its estimated fair value of $0. As the estimated fair value of our investment in Specialty Pharma was lower than its net book value immediately prior to the deconsolidation, we recorded a non-cash charge of approximately $2,673 associated with the deconsolidation of Specialty Pharma. Subsequent to the deconsolidation of Specialty Pharma, we are accounting for our investment in Specialty Pharma using the cost method of accounting because Avadel does not exercise significant influence over the operations of Specialty Pharma due to the Chapter 11 filing.

On April 26, 2019, Specialty Pharma sold its intangible assets and remaining inventory to an unaffiliated third party in exchange for aggregate cash proceeds of approximately $250, pursuant to an order approving such sale which was issued by the Bankruptcy Court on April 15, 2019. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business.

DIP Financing – Related Party Relationship

In connection with the bankruptcy filing, Specialty Pharma entered into a Debtor in Possession Credit and Security Agreement with Avadel US Holdings (“DIP Credit Agreement”) dated as of February 8, 2019, in an aggregate amount of up to $2,700, of which the funds are to be used by Specialty Pharma solely to fund operations through February 6, 2020. As of March 31, 2019, the Company had funded $407 under the DIP Credit Agreement. As the Company has assessed that it is unlikely that Specialty Pharma will pay back the loan to Avadel, the $407 has been recorded as part of the loss on deconsolidation of subsidiary within the unaudited condensed consolidated statements of loss. At March 31, 2019 the fair value of the remaining commitment under the DIP Credit Agreement is not material.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition
3 Months Ended
Mar. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Revenue Recognition

The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.

Product Sales and Services

Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Reserves to reduce Gross Revenues to Net Revenues

Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Product Returns

Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Chargebacks, Discounts and Rebates

Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.

Revenue from licensing arrangements

The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Disaggregation of revenue

The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product.

Contract Balances

The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.

A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional. See the unaudited condensed consolidated balance sheets for the balance of accounts receivable at March 31, 2019.

See below for contract liability discussion and balance related to a license agreement.

There were no material deferred contract costs at March 31, 2019.

Transaction Price Allocated to the Remaining Performance Obligation

For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.

For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product.

The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurement
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurement
Fair Value Measurement
The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:  

ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:  

Income approach, which is based on the present value of a future stream of net cash flows.
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:  
Level 1 - Quoted prices for identical assets or liabilities in active markets.
Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.
Level 3 - Unobservable inputs that reflect estimates and assumptions.
The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:
 
 
As of March 31, 2019
 
As of December 31, 2018
Fair Value Measurements:
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities (see Note 6)
 
 
 
 
 
 
 
 
 
 
 
 
Equity securities
 
$
9,825

 
$

 
$

 
$
9,145

 
$

 
$

Money market funds
 
48,947

 

 

 
52,996

 

 

Corporate bonds
 

 
3,463

 

 

 
6,339

 

Government securities - U.S.
 

 
4,285

 

 

 
12,701

 

Other fixed-income securities
 

 
3,701

 

 

 
9,409

 

Total assets
 
$
58,772

 
$
11,449

 
$

 
$
62,141

 
$
28,449

 
$

 
 
 
 
 
 
 
 
 
 
 
 
 
Related party payable (see Note 10)
 

 

 
27,593

 

 

 
28,840

Total liabilities
 
$

 
$

 
$
27,593

 
$

 
$

 
$
28,840


A review of fair value hierarchy classifications is conducted on a quarterly basis.  Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended March 31, 2019 and December 31, 2018, respectively, there were no transfers in and out of Level 1, 2, or 3. During the three month periods ended March 31, 2019 and 2018, respectively, we did not recognize any other-than-temporary impairment loss.
Some of the Company’s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.

Debt

We estimate the fair value of our $143,750 aggregate principal amount of 4.50% exchangeable senior notes due 2023 (the “2023 Notes”), a Level 2 input, based on interest rates that would be currently available to the Company for issuance of similar types of debt instruments with similar terms and remaining maturities or recent trading prices obtained from brokers. The estimated fair value of the 2023 Notes at March 31, 2019 is $58,568 compared to a book value of $117,136.

Additionally, the Company’s other debt is reflected in the balance sheet at carrying value. The fair value of these loans impracticable to estimate as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.

See Note 11: Long-Term Debt for additional information regarding our debt obligations.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities
3 Months Ended
Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
Marketable Securities 
The Company has investments in available-for-sale marketable securities which are recorded at fair market value. The change in the fair value of available-for-sale equity investments is recognized in our unaudited condensed consolidated statements of loss and the change in the fair value of all other available-for-sale investments is recorded as other comprehensive income (loss) in shareholders’ (deficit) equity, net of income tax effects.
The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of March 31, 2019 and December 31, 2018, respectively:
 
 
March 31, 2019
Marketable Securities:
 
Adjusted Cost
 
Unrealized Gains
 
Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Equity securities
 
$
10,133

 
$
23

 
$
(331
)
 
$
9,825

Money market funds
 
48,438

 
509

 

 
48,947

Corporate bonds
 
3,442

 
30

 
(9
)
 
3,463

Government securities - U.S.
 
4,249

 
43

 
(7
)
 
4,285

Other fixed-income securities
 
3,673

 
30

 
(2
)
 
3,701

Total
 
$
69,935

 
$
635

 
$
(349
)
 
$
70,221

 
 
December 31, 2018
Marketable Securities:
 
Adjusted Cost
 
Unrealized Gains
 
Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Equity securities
 
$
10,101

 
$

 
$
(956
)
 
$
9,145

Money market funds
 
52,733

 
316

 
(53
)
 
52,996

Corporate bonds
 
6,411

 
7

 
(79
)
 
6,339

Government securities - U.S.
 
12,714

 
66

 
(79
)
 
12,701

Other fixed-income securities
 
9,400

 
22

 
(13
)
 
9,409

Total
 
$
91,359


$
411


$
(1,180
)

$
90,590

 
We determine realized gains or losses on the sale of marketable securities on a specific identification method. We reflect these gains and losses as a component of investment income in the accompanying unaudited condensed consolidated statements of loss.
We recognized gross realized gains of $94 and $213 for the three months ended March 31, 2019, and 2018, respectively. These realized gains were offset by realized losses of $147 and $134 for the three months ended March 31, 2019, and 2018, respectively.
The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of March 31, 2019:
 
 
Maturities
Marketable Debt Securities:
 
Less than 1 Year
 
1-5 Years
 
5-10 Years
 
Greater than 10 Years
 
Total
 
 
 
 
 
 
 
 
 
 
 
Corporate bonds
 
$
688

 
$
2,775

 
$

 
$

 
$
3,463

Government securities - U.S.
 

 
3,841

 

 
444

 
4,285

Other fixed-income securities
 
50

 
3,651

 

 

 
3,701

Total
 
$
738

 
$
10,267

 
$

 
$
444

 
$
11,449


The Company has classified our investment in available-for-sale marketable securities as current assets in the unaudited condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories
3 Months Ended
Mar. 31, 2019
Inventory Disclosure [Abstract]  
Inventories
Inventories 
The principal categories of inventories, net reserves of $1,085 and $4,757 at March 31, 2019 and December 31, 2018, respectively, are comprised of the following:
Inventory:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Finished goods
 
$
3,720

 
$
4,270

Raw materials
 
538

 
500

Total  
 
$
4,258

 
$
4,770



Total net reserves decreased by $3,672 during the three months ended March 31, 2019 driven largely by the deconsolidation of Specialty Pharma.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets
3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Goodwill and Intangible Assets 
The Company’s amortizable and unamortizable intangible assets at March 31, 2019 and December 31, 2018 are as follows: 
 
 
March 31, 2019
 
December 31, 2018
Goodwill and Intangible Assets:
 
Gross
Value
 
Accumulated
Amortization
 
Net Carrying
Amount
 
Gross
Value
 
Accumulated
Amortization
 
Impairment
 
Net Carrying
Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amortizable intangible assets:
 
 

 
 

 
 

 
 

 
 

 
 
 
 

Acquired developed technology - Noctiva
 
$

 
$

 
$

 
$
73,111

 
$
(7,024
)
 
$
(66,087
)
 
$

Acquired developed technology - Vazculep
 
12,061

 
(10,633
)
 
1,428

 
12,061

 
(10,432
)
 

 
1,629

Total amortizable intangible assets
 
$
12,061

 
$
(10,633
)
 
$
1,428

 
$
85,172

 
$
(17,456
)
 
$
(66,087
)
 
$
1,629

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unamortizable intangible assets:
 
 

 
 

 
 

 
 

 
 

 
 
 
 

Goodwill
 
$
18,491

 
$

 
$
18,491

 
$
18,491

 
$

 
$

 
$
18,491

Total unamortizable intangible assets
 
$
18,491


$


$
18,491


$
18,491


$


$

 
$
18,491

 
The Company recorded amortization expense related to amortizable intangible assets of $201 and $1,767 for the three months ended March 31, 2019 and 2018, respectively.
During the fourth quarter 2018, certain conditions came to light, largely the lack of a meaningful increase in Noctiva prescriptions despite the substantial investment of resources, which indicated that the carrying value of the asset, may not be fully recoverable. As such, the Company performed an impairment test based on a comparison of the pretax discounted cash flows expected to be generated by the asset, which is a Level 3 fair value estimate, to the recorded value of the asset and concluded that the associated cash flows did not support any of the carrying value of the intangible asset and the Company recorded a full impairment charge of $66,087 at December 31, 2018 related to the acquired developed technology associated with Noctiva. The February 6, 2019 Chapter 11 bankruptcy filing of Specialty Pharma, the subsidiary which markets, sells and distributes Noctiva, confirmed management’s conclusion on the impairment.
Amortizable intangible assets are amortized over their estimated useful lives, which generally range from three to fifteen years. Estimated amortization of intangible assets for the next five years is as follows: 
Estimated Amortization Expense:
 
Amount
 
 
 
2019
 
$
815

2020
 
814

2021
 

2022
 

2023
 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.19.1
Leases
3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
Leases
Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. On January 1, 2019, the Company adopted the ASU using the modified retrospective transition approach and elected the transition option to recognize the adjustment in the period of adoption rather than in the earliest period presented. As January 1, 2019, adoption of the new guidance resulted in the initial recognition of operating lease right-of-use assets of $5,046 and operating lease liabilities of $5,131. At March 31, 2019, the balances of the operating lease right-of-use asset and total operating lease liability are $5,802 and $4,871, respectively, of which $982 of the operating lease liability is current.

The Company leases certain facilities for office and manufacturing purposes, comprising approximately 99% of the total lease population. All leased facilities are classified as operating leases with remaining lease terms between one and seven years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. For all of the Company’s leases, lease and non-lease components are accounted for as a single lease component, as all non-lease components are immaterial to break out separately.

The components of lease costs, which is included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the period ended March 31 were as follows ($ in thousands):
Lease cost:
 
2019
 
 
 
Operating lease costs (1)
 
$
345

Sublease income (2)
 
44

Total lease cost
 
$
301


(1) Variable lease costs were immaterial for the three months ended March 31, 2019.
(2) Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020.

During the three months ended March 31, 2019, the Company reduced its operating lease liabilities by $310 for cash paid. In addition, new operating leases commenced resulting in the recognition of operating lease right-of-use assets and liabilities of $1,000 and $0, respectively, as the entire lease payment was paid on March 31, 2019. As of March 31, 2019, the Company is aware of one additional embedded lease that has not yet commenced and will not commence until the time of FDA approval of the product (if approved). Once FDA approval is given and the start date is determined, annual production suite fees of approximately $3,000 to $4,000 would commence and at that time, and an operating lease right-of-use asset and corresponding operating lease liability will be recorded.

As of March 31, 2019, our operating leases have a weighted-average remaining lease term of 5.2 years and a weighted-average discount rate of 5.3%. Nearly all of Avadel’s lease contracts do not provide a readily determinable implicit rate. For these contracts, Avadel’s estimated incremental borrowing rate is based on information available at the inception of the lease.

Maturities of the Company’s operating lease liabilities were as follows ($ in thousands):
Maturities:
 
Operating Leases
 
 
 
Remaining nine months of 2019
 
$
920

2020
 
1,225

2021
 
1,004

2022
 
764

2023
 
693

Thereafter
 
942

Total lease payments
 
5,548

Less: interest
 
677

Present value of lease liabilities
 
$
4,871

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Related Party Payable
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Long-Term Related Party Payable
Long-Term Related Party Payable 
Long-term related party payable and related activity are reported at fair value and consist of the following at March 31, 2019 and December 31, 2018:
 
 
 
Activity during the Three Months Ended
March 31, 2019
 
 
 
 
 
 
 
Changes in Fair Value of Related Party Payable
 
 
Long-Term Related Party Payable:
Balance,
December 31, 2018
 
Payments to
Related Parties
 
Operating Expense
 
Other
Expense
 
Balance, March 31, 2019
 
 
 
 
 
 
 
 
 
 
Acquisition-related contingent consideration:
 

 
 

 
 

 
 

 
 

Earn-out payments - Éclat Pharmaceuticals (a)
$
25,615

 
$
(3,180
)
 
$
2,134

 
$

 
$
24,569

Financing-related:
 

 
 

 
 

 
 

 

Royalty agreement - Deerfield (b)
2,184

 
(344
)
 

 
208

 
2,048

Royalty agreement - Broadfin (c)
1,041

 
(164
)
 

 
99

 
976

Total related party payable
28,840

 
$
(3,688
)
 
$
2,134

 
$
307

 
27,593

Less: Current portion
(9,439
)
 
 

 
 

 
 

 
(9,391
)
Total long-term related party payable
$
19,401

 
 

 
 

 
 

 
$
18,202


(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.
(b)
As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.
(c)
As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.
At March 31, 2019, the fair value of each related party payable listed in (a), (b) and (c) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat products using an appropriate risk-adjusted discount rate of 15%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the unaudited condensed consolidated statements of loss in the line items entitled “Changes in fair value of related party contingent consideration” for items noted in (b) above and in “Other expense - changes in fair value of related party payable” for items (b) and (c) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities. 
The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (b) and (c) above. These financing-related liabilities are recorded at fair market value on the unaudited condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the unaudited condensed consolidated statements of loss.
The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the three-month periods ended March 31, 2019 and 2018, respectively:
Related Party Payable Rollforward:
 
Balance
 
 
 
Balance, December 31, 2017
 
$
98,925

Payments of related party payable
 
(7,017
)
Fair value adjustments (1)
 
3,363

Expiration of warrants
 
(2,167
)
Disposition of the pediatric assets
 
(20,337
)
Balance, March 31, 2018
 
$
72,767

 
 
 
Balance, December 31, 2018
 
$
28,840

Payments of related party payable
 
(3,688
)
Fair value adjustments (1)
 
2,441

Balance, March 31, 2019
 
$
27,593

(1) Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Debt
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Long-Term Debt
Long-Term Debt
Long-Term debt is summarized as follows:
 
 
March 31, 2019
 
December 31, 2018
Principal amount of 4.50% exchangeable senior notes due 2023
 
$
143,750

 
$
143,750

Less: debt discount and issuance costs, net
 
(26,614
)
 
(28,059
)
Net carrying amount of liability component
 
117,136

 
115,691

Other debt
 
146

 
149

     Subtotal
 
117,282

 
115,840

Less: current maturities
 
(104
)
 
(106
)
     Long-term debt
 
$
117,178

 
$
115,734

 
 
 
 
 
Equity component:
 
 
 
 
Equity component of exchangeable notes, net of issuance costs
 
$
(26,699
)
 
$
(26,699
)
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes
3 Months Ended
Mar. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The components of loss before income taxes are as follows: 
 
 
Three Months Ended March 31,
Loss Before Income Taxes:
 
2019
 
2018
 
 
 
 
 
Ireland
 
$
(10,234
)
 
$
(4,927
)
United States
 
(3,443
)
 
(9,835
)
France
 
285

 
199

Total loss before income taxes
 
$
(13,392
)
 
$
(14,563
)
 
The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:
 
 
Three Months Ended March 31,
Income Tax Rate Reconciliation:
 
2019
 
2018
 
 
 
 
 
Statutory tax rate  
 
12.5
 %

12.5
 %
International tax rates differential
 
5.0
 %

8.9
 %
Change in valuation allowance
 
(11.4
)%

(4.7
)%
Change in fair value of nondeductible contingent consideration
 
(3.1
)%

(3.8
)%
Nondeductible stock-based compensation
 
(0.4
)%

(1.1
)%
Unrecognized tax benefits
 
(0.9
)%

(1.5
)%
State and local income taxes, net of federal
 
 %

0.1
 %
Nondeductible interest expense
 
(1.2
)%
 
 %
Other
 
2.2
 %

5.6
 %
Effective income tax rate
 
2.7
 %

16.0
 %
 
 
 
 
 
Income tax benefit - at statutory tax rate
 
$
(1,673
)
 
$
(1,820
)
International tax rates differential
 
(668
)
 
(1,298
)
Change in valuation allowance
 
1,520

 
690

Change in fair value of nondeductible contingent consideration
 
413

 
551

Nondeductible stock-based compensation
 
51

 
160

Unrecognized tax benefits
 
124

 
220

State and local income taxes, net of federal
 
2

 
(19
)
Nondeductible interest expense
 
157

 

Other
 
(300
)
 
(811
)
Income tax benefit - at effective income tax rate
 
$
(374
)
 
$
(2,327
)
 
The income tax benefit for the three months ended March 31, 2019 was $374 compared to an income tax benefit of $2,327 for the three months ended March 31, 2018. The decrease in the income tax benefit for the three months ended March 31, 2019 is primarily the result of a decrease in the amount of loss generated in the United States, when compared to the same prior year period.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Other Assets and Liabilities
3 Months Ended
Mar. 31, 2019
Other Liabilities Disclosure [Abstract]  
Other Assets and Liabilities
Other Assets and Liabilities 
Various other assets and liabilities are summarized as follows:
Prepaid Expenses and Other Current Assets:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Valued-added tax recoverable
 
$
1,100

 
$
1,378

Prepaid and other expenses
 
2,607

 
2,145

Guarantee from Armistice (see Note 14)
 
543

 
534

Income tax receivable
 
996

 
921

Research and development tax credit receivable
 
270

 
283

Short-term deposit
 

 
3,350

Other
 
1,040

 
225

Total  
 
$
6,556

 
$
8,836

 
Other Non-Current Assets:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Deferred tax assets, net
 
$
23,216

 
$
23,029

Long-term deposits
 
1,477

 
1,477

Guarantee from Armistice (see Note 14)
 
5,555

 
5,697

Right of use assets at contract manufacturing organizations
 
5,827

 
5,894

Other
 
49

 
49

Total  
 
$
36,124

 
$
36,146

 
Accrued Expenses
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Accrued compensation
 
$
1,726

 
$
3,971

Accrued social charges
 
1,018

 
1,009

Accrued restructuring (see Note 15)
 
419

 
879

Customer allowances
 
6,616

 
6,541

Accrued contract research organization charges
 
1,383

 
1,000

Accrued contract manufacturing organization costs
 
1,030

 
2,028

Accrued contract sales organization and marketing costs
 

 
3,469

Other
 
2,497

 
2,798

Total  
 
$
14,689

 
$
21,695

 
Other Non-Current Liabilities:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Provision for retirement indemnity
 
$
1,003

 
$
1,024

Customer allowances
 
619

 
1,352

Unrecognized tax benefits
 
5,315

 
5,315

Guarantee to Deerfield (see Note 14)
 
5,574

 
5,717

Other
 
66

 
594

Total  
 
$
12,577

 
$
14,002

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Divestiture of the Pediatric Assets
3 Months Ended
Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Divestiture of the Pediatric Assets
Divestiture of the Pediatric Assets

On February 12, 2018, the Company, together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” entered into an asset purchase agreement (the “Purchase Agreement”) with Cerecor, Inc. (“Cerecor”). The transaction closed on February 16, 2018 wherein Cerecor purchased from the Sellers four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets – which were held by FSC.  The Company acquired FSC in February 2016 from Deerfield and certain of its affiliates. Pursuant to the Purchase Agreement, Cerecor assumed the Company’s  remaining payment obligations to Deerfield under the Membership Interest Purchase Agreement, dated as of February 5, 2016, between Holdings, Flamel Technologies SA (the predecessor of the Company) and Deerfield and certain of its affiliates, which payment obligations consist of the following (collectively, the “Assumed Obligations”): (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 5, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300.  Cerecor also assumed certain contracts and other obligations related to the acquired assets, and in that connection Holdings agreed to pay Cerecor certain make-whole payments associated with obligations Cerecor is assuming related to a certain supply contract related to Karbinal™ ER.

In conjunction with the divestiture, the Company also entered into the following arrangements:

License and Development Agreement

Also, in connection with the closing under the Purchase Agreement, Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (“Avadel Ireland”) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the “License and Development Agreement”) pursuant to which, among other things:

Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland’s LiquiTime™ technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;

Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime™ products in excess of $1,000 in the aggregate;

Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees; and
Upon regulatory approval and commercial launch of any LiquiTime™ products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digit range. 

Deerfield Guarantee

In connection with the closing under the Purchase Agreement, the Company and Holdings provided their guarantee (the “Deerfield Guarantee”) in favor of Deerfield. Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the Assumed Obligations under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 6, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the “Minimum Royalties”). Given the Company’s explicit guarantee to Deerfield, the Company recorded the guarantee in accordance with ASC 460. A valuation was performed, which was based largely on an analysis of the potential timing of each possible cash outflow described above and the likelihood of Cerecor’s default on such payments assuming an S&P credit rating of CCC+. The result of this valuation identified a guarantee liability of $6,643. This liability is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield. At March 31, 2019, the carrying value of this liability was $6,119.

Armistice Guarantee

In connection with the closing under the Purchase Agreement, Armistice Capital Master Fund, Ltd., the majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties. A valuation of the guarantee asset was performed in accordance with ASC 460 and a guarantee asset of $6,620 was recorded. This asset is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield noted above. At March 31, 2019, the carrying value of this asset was $6,097.

The fair values of the Avadel guarantee to Deerfield and the guarantee received by Avadel from Armistice largely offset and when combined are not material.

Based on management’s review of ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, the disposition of our pediatric assets and related liabilities did not qualify for discontinued operations reporting. Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC, prior to its February 16, 2018 disposition date.

The net impact of this transaction was not material to the unaudited condensed consolidated statements of loss.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Costs
3 Months Ended
Mar. 31, 2019
Restructuring and Related Activities [Abstract]  
Restructuring Costs
Restructuring Costs
2019 Corporate Restructuring
During the first quarter of 2019, the Company announced a plan to reduce our Corporate workforce by more than 50% (“2019 Corporate Restructuring”). The reduction in workforce is primarily a result of the exit of Noctiva during the first quarter of 2019 (see Note 3: Subsidiary Bankruptcy and Deconsoldiation), as well as an effort to better align the Company’s remaining cost structure at our U.S. and Ireland locations with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of the fiscal year 2019, and to result in employee severance, benefits and other costs of up to approximately $3,000, which are likely to be recognized through December 31, 2019. 2019 Corporate Restructuring charges of $1,398 were recognized during the three months ended March 31, 2019.
The following table sets forth activities for the Company’s cost reduction plan obligations for the three months ended March 31, 2019:
2019 Corporate Restructuring Obligations:
 
2019
 
 
 
Balance of restructuring accrual at January 1,
 
$

Charges for employee severance, benefits and other costs
 
1,398

Payments
 
(754
)
Balance of restructuring accrual at March 31,
 
$
644


Restructuring liabilities of $356 and $288 are included in the unaudited condensed consolidated balance sheet in accrued expenses and accounts payable, respectively, at March 31, 2019.
2017 French Restructuring
During the first quarter of 2017, the Company announced a plan to reduce our workforce at our Venniseux, France site by approximately 50% (“2017 French Restructuring”).  This reduction was an effort to align the Company’s cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council for our French operations and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction was substantially complete at March 31, 2019. The 2017 French Restructuring income of $170 and restructuring charges of $153 were recognized during the three months ended March 31, 2019 and 2018, respectively. The following table sets forth activities for the Company’s cost reduction plan obligations for the three months ended March 31, 2019 and 2018:
2017 French Restructuring Obligation:
 
2019
 
2018
 
 
 
 
 
Balance of restructuring accrual at January 1,
 
$
879

 
$
1,000

Charges for employee severance, benefits and other
 
(170
)
 
153

Payments
 
(638
)
 
(359
)
Foreign currency impact
 
(8
)
 
30

Balance of restructuring accrual at March 31,
 
$
63

 
$
824


The 2017 French Restructuring accrual is included in the unaudited condensed consolidated balance sheet in accrued expenses at March 31, 2019 and 2018.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Net Loss Per Share
Net Loss Per Share 
Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the diluted number of shares outstanding during each period. Except where the result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the exercise of outstanding equity compensation awards, ordinary shares expected to be issued under our employee stock purchase plan (“ESPP”) and the exercise of contingent consideration warrants, all which have been exercised or have expired during the first quarter of 2018.

We have a choice to settle the conversion obligation under the 2023 Notes in cash, shares or any combination of the two. We utilize the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result is anti-dilutive. This method assumes the conversion of the 2023 Notes into shares of our ordinary shares and reflects the elimination of the interest expense related to the 2023 Notes.

The dilutive effect of the warrants, stock options, RSU’s and ordinary shares expected to be issued under or ESPP has been calculated using the treasury stock method.
A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows: 
 
 
Three Months Ended March 31,
Net Loss Per Share:
 
2019
 
2018
 
 
 
 
 
Net loss
 
$
(13,018
)
 
$
(12,236
)
 
 
 
 
 
Weighted average shares:
 
 

 
 

Basic shares
 
37,354

 
38,559

Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes
 

 

Diluted shares
 
37,354

 
38,559

 
 
 
 
 
Net loss per share - basic
 
$
(0.35
)

$
(0.32
)
Net loss per share - diluted  
 
$
(0.35
)

$
(0.32
)
 
Potential common shares of 19,762 and 19,374 were excluded from the calculation of weighted average shares for the three months ended March 31, 2019 and 2018, respectively, because their effect was considered to be anti-dilutive. For the three months ended March 31, 2019 and 2018, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in this period.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Comprehensive Loss
3 Months Ended
Mar. 31, 2019
Stockholders' Equity Note [Abstract]  
Comprehensive Loss
Comprehensive Loss 
The following table shows the components of accumulated other comprehensive loss for the three months ended March 31, 2019 and 2018, respectively, net of tax effects: 
 
 
Three Months Ended March 31,
Accumulated Other Comprehensive Loss:
 
2019
 
2018
 
 
 
 
 
Foreign currency translation adjustment:
 
 

 
 

Beginning balance
 
$
(23,621
)
 
$
(23,202
)
Net other comprehensive (loss) income
 
(161
)
 
249

Balance at March 31,
 
$
(23,782
)
 
$
(22,953
)
 
 
 
 
 
Unrealized gain (loss) on marketable securities, net
 
 

 
 

Beginning balance
 
$
205

 
$
(64
)
Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively
 
374

 
(238
)
Balance at March 31,
 
$
579

 
$
(302
)
Accumulated other comprehensive loss at March 31,
 
$
(23,203
)
 
$
(23,255
)
 
The effect on the Company’s unaudited condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Company Operations by Product
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Company Revenue by Product
Company Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the interim CEO. The interim CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended March 31,
Revenues by Product:
 
2019
 
2018
 
 
 
 
 
Bloxiverz
 
$
2,568

 
$
7,491

Vazculep
 
9,473

 
12,961

Akovaz
 
3,792

 
10,217

Other
 
604

 
2,492

Total product sales
 
16,437

 
33,161

License revenue
 

 
132

Total revenues
 
$
16,437

 
$
33,293

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies 
Litigation  
The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At March 31, 2019 and December 31, 2018, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s unaudited condensed consolidated financial position, results of operations, cash flows or liquidity.   

Litigation Related to Noctiva

Note 3: Subsidiary Bankruptcy and Deconsolidation briefly describes the Chapter 11 bankruptcy case which our subsidiary Specialty Pharma commenced on February 6, 2019, and which on April 26, 2019 resulted in the bankruptcy court-approved sale of all of Specialty Pharma’s intangible assets and inventory to an unaffiliated third party. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. During the pendency of the bankruptcy case, all pending litigation against Specialty Pharma is automatically stayed and any new litigation against Specialty Pharma is precluded unless the bankruptcy court orders otherwise. Below are descriptions of a litigation to which Specialty Pharma is a party and a contract dispute involving Specialty Pharma, both of which matters are subject to the automatic stay during the bankruptcy case.

Ferring Litigation. Some of the patents covering the NoctivaTM product (the “Noctiva Patents”) are the subject of litigation initiated by Ferring Pharmaceuticals Inc. and two of its foreign affiliates, who manufacture a competing product known as Nocdurna.  Nocdurna was approved by the FDA in June 2018 and commercially launched in the U.S. in November 2018.  In this litigation, Ferring seeks to invalidate and disputes the inventorship of the Noctiva Patents, seeks damages for various alleged breaches of contractual and common law duties, and seeks damages for alleged infringement by NoctivaTM of Ferring’s “Nocdurna” trademark.  Specialty Pharma and certain other parties including Serenity Pharmaceuticals, LLC (“Serenity”) (the licensor of the Noctiva Patents) have defended this litigation, and have made counterclaims against Ferring, including for infringement of the Noctiva Patents and a declaratory judgment of noninfringement with respect to Ferring’s “Nocdurna” trademark. The court dismissed Ferring’s inventorship claim and its claims for alleged breaches of contractual and common law duties, although these dismissals may be appealed by Ferring.  On February 15, 2019, Specialty Pharma and its co-defendants moved to stay the litigation pending completion of the bankruptcy proceeding of Specialty Pharma.

Contract Dispute. On January 21, 2019, Serenity gave notice to Specialty Pharma of an alleged breach of the parties’ Noctiva license agreement. Serenity alleges that Specialty Pharma breached its contractual obligation to devote commercially reasonable efforts to the commercialization of Noctiva and seeks unspecified damages. On January 27, 2019, Specialty Pharma notified Serenity of a claim for $1.7 million in damages as a result of Serenity’s breach of its contractual obligation to pay the costs of the Ferring Litigation. Serenity’s notice to Specialty Pharma invoked the dispute resolution provisions of the Noctiva license agreement, which culminate in arbitration, but neither party has yet initiated an arbitration proceeding or filed suit.

Material Commitments
Due to the Chapter 11 bankruptcy case of Specialty Pharma, discussed in Note 3: Subsidiary Bankruptcy and Deconsolidation, the Company’s various commitments to purchase finished product from customers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of March 31, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:

Purchase Commitments:
 
Balance
 
 
 
2019
 
$
7,194

2020
 
1,320

2021
 
1,320

2022
 
1,320

2023
 
220

Thereafter
 

Total
 
$
11,374



Other than commitments disclosed in Note 15: Contingent Liabilities and Commitments to the Company’s audited consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in Note 10: Long-Term Debt and Note 13: Post-Retirement Benefit Plans, respectively, to the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 10: Long-Term Related Party Payable, to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this report.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Nature of Operations
Nature of Operations.  Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company.  Our primary focus is on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.   The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted an NDA in March 2019 on UMD #4, which, if approved, could contribute revenues to Avadel starting in 2020.

Our current marketed products include:
Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “ - The Reincorporation Merger.” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, Since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities. A complete list of the Company’s subsidiaries can be found in Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.
Basis of Presentation
Basis of Presentation. The unaudited condensed consolidated balance sheet as of March 31, 2019, which is primarily derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.
The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. 
On February 6, 2019, the Company’s indirect wholly owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See Note 3: Subsidiary Bankruptcy and Deconsolidation.
Newly Issued Accounting Pronouncements
Newly Issued Accounting Standards
Recently Adopted Accounting Guidance

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. In July 2018, the FASB issued ASU 2018-11 “Targeted Improvements”, amending certain aspects of the new leasing standard. The amendment allows an additional optional transition method whereby an entity records a cumulative effect adjustment to opening retained earnings in the year of adoption without restating prior periods, which the Company has elected. The impact of this new guidance is further discussed in Note 9: Leases.

Recent Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.

Revenue
Revenue. Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements. 
Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Sales and Services 

The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis.

License Revenue 

The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.

For a complete discussion of the accounting for net product revenue and license revenues, see Note 4: Revenue Recognition.
Revenue Recognition

The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.

Product Sales and Services

Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Reserves to reduce Gross Revenues to Net Revenues

Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Product Returns

Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Chargebacks, Discounts and Rebates

Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.

Revenue from licensing arrangements

The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Disaggregation of revenue

The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product.

Contract Balances

The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.

A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional. See the unaudited condensed consolidated balance sheets for the balance of accounts receivable at March 31, 2019.

See below for contract liability discussion and balance related to a license agreement.

There were no material deferred contract costs at March 31, 2019.

Transaction Price Allocated to the Remaining Performance Obligation

For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.

For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product.

The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurement (Tables)
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:
 
 
As of March 31, 2019
 
As of December 31, 2018
Fair Value Measurements:
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities (see Note 6)
 
 
 
 
 
 
 
 
 
 
 
 
Equity securities
 
$
9,825

 
$

 
$

 
$
9,145

 
$

 
$

Money market funds
 
48,947

 

 

 
52,996

 

 

Corporate bonds
 

 
3,463

 

 

 
6,339

 

Government securities - U.S.
 

 
4,285

 

 

 
12,701

 

Other fixed-income securities
 

 
3,701

 

 

 
9,409

 

Total assets
 
$
58,772

 
$
11,449

 
$

 
$
62,141

 
$
28,449

 
$

 
 
 
 
 
 
 
 
 
 
 
 
 
Related party payable (see Note 10)
 

 

 
27,593

 

 

 
28,840

Total liabilities
 
$

 
$

 
$
27,593

 
$

 
$

 
$
28,840

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-sale and Equity Securities
The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of March 31, 2019 and December 31, 2018, respectively:
 
 
March 31, 2019
Marketable Securities:
 
Adjusted Cost
 
Unrealized Gains
 
Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Equity securities
 
$
10,133

 
$
23

 
$
(331
)
 
$
9,825

Money market funds
 
48,438

 
509

 

 
48,947

Corporate bonds
 
3,442

 
30

 
(9
)
 
3,463

Government securities - U.S.
 
4,249

 
43

 
(7
)
 
4,285

Other fixed-income securities
 
3,673

 
30

 
(2
)
 
3,701

Total
 
$
69,935

 
$
635

 
$
(349
)
 
$
70,221

 
 
December 31, 2018
Marketable Securities:
 
Adjusted Cost
 
Unrealized Gains
 
Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Equity securities
 
$
10,101

 
$

 
$
(956
)
 
$
9,145

Money market funds
 
52,733

 
316

 
(53
)
 
52,996

Corporate bonds
 
6,411

 
7

 
(79
)
 
6,339

Government securities - U.S.
 
12,714

 
66

 
(79
)
 
12,701

Other fixed-income securities
 
9,400

 
22

 
(13
)
 
9,409

Total
 
$
91,359


$
411


$
(1,180
)

$
90,590

 
Schedule of Contractual Maturity Dates
The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of March 31, 2019:
 
 
Maturities
Marketable Debt Securities:
 
Less than 1 Year
 
1-5 Years
 
5-10 Years
 
Greater than 10 Years
 
Total
 
 
 
 
 
 
 
 
 
 
 
Corporate bonds
 
$
688

 
$
2,775

 
$

 
$

 
$
3,463

Government securities - U.S.
 

 
3,841

 

 
444

 
4,285

Other fixed-income securities
 
50

 
3,651

 

 

 
3,701

Total
 
$
738

 
$
10,267

 
$

 
$
444

 
$
11,449

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories (Tables)
3 Months Ended
Mar. 31, 2019
Inventory Disclosure [Abstract]  
Schedule of Inventory
The principal categories of inventories, net reserves of $1,085 and $4,757 at March 31, 2019 and December 31, 2018, respectively, are comprised of the following:
Inventory:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Finished goods
 
$
3,720

 
$
4,270

Raw materials
 
538

 
500

Total  
 
$
4,258

 
$
4,770

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The Company’s amortizable and unamortizable intangible assets at March 31, 2019 and December 31, 2018 are as follows: 
 
 
March 31, 2019
 
December 31, 2018
Goodwill and Intangible Assets:
 
Gross
Value
 
Accumulated
Amortization
 
Net Carrying
Amount
 
Gross
Value
 
Accumulated
Amortization
 
Impairment
 
Net Carrying
Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amortizable intangible assets:
 
 

 
 

 
 

 
 

 
 

 
 
 
 

Acquired developed technology - Noctiva
 
$

 
$

 
$

 
$
73,111

 
$
(7,024
)
 
$
(66,087
)
 
$

Acquired developed technology - Vazculep
 
12,061

 
(10,633
)
 
1,428

 
12,061

 
(10,432
)
 

 
1,629

Total amortizable intangible assets
 
$
12,061

 
$
(10,633
)
 
$
1,428

 
$
85,172

 
$
(17,456
)
 
$
(66,087
)
 
$
1,629

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unamortizable intangible assets:
 
 

 
 

 
 

 
 

 
 

 
 
 
 

Goodwill
 
$
18,491

 
$

 
$
18,491

 
$
18,491

 
$

 
$

 
$
18,491

Total unamortizable intangible assets
 
$
18,491


$


$
18,491


$
18,491


$


$

 
$
18,491

 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization of intangible assets for the next five years is as follows: 
Estimated Amortization Expense:
 
Amount
 
 
 
2019
 
$
815

2020
 
814

2021
 

2022
 

2023
 

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Leases (Tables)
3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
Components of lease costs
The components of lease costs, which is included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the period ended March 31 were as follows ($ in thousands):
Lease cost:
 
2019
 
 
 
Operating lease costs (1)
 
$
345

Sublease income (2)
 
44

Total lease cost
 
$
301


(1) Variable lease costs were immaterial for the three months ended March 31, 2019.
(2) Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020.
Maturities of operating lease liabilities
Maturities of the Company’s operating lease liabilities were as follows ($ in thousands):
Maturities:
 
Operating Leases
 
 
 
Remaining nine months of 2019
 
$
920

2020
 
1,225

2021
 
1,004

2022
 
764

2023
 
693

Thereafter
 
942

Total lease payments
 
5,548

Less: interest
 
677

Present value of lease liabilities
 
$
4,871

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were ($ in thousands):
Lease Commitment:
 
Operating Leases
 
 
 
2019
 
$
1,191

2020
 
1,208

2021
 
1,008

2022
 
767

2023
 
695

Thereafter
 
967

Total minimum lease payments
 
$
5,836

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Related Party Payable (Tables)
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Related Party Transactions
Long-term related party payable and related activity are reported at fair value and consist of the following at March 31, 2019 and December 31, 2018:
 
 
 
Activity during the Three Months Ended
March 31, 2019
 
 
 
 
 
 
 
Changes in Fair Value of Related Party Payable
 
 
Long-Term Related Party Payable:
Balance,
December 31, 2018
 
Payments to
Related Parties
 
Operating Expense
 
Other
Expense
 
Balance, March 31, 2019
 
 
 
 
 
 
 
 
 
 
Acquisition-related contingent consideration:
 

 
 

 
 

 
 

 
 

Earn-out payments - Éclat Pharmaceuticals (a)
$
25,615

 
$
(3,180
)
 
$
2,134

 
$

 
$
24,569

Financing-related:
 

 
 

 
 

 
 

 

Royalty agreement - Deerfield (b)
2,184

 
(344
)
 

 
208

 
2,048

Royalty agreement - Broadfin (c)
1,041

 
(164
)
 

 
99

 
976

Total related party payable
28,840

 
$
(3,688
)
 
$
2,134

 
$
307

 
27,593

Less: Current portion
(9,439
)
 
 

 
 

 
 

 
(9,391
)
Total long-term related party payable
$
19,401

 
 

 
 

 
 

 
$
18,202


(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.
(b)
As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.
(c)
As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.
The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the three-month periods ended March 31, 2019 and 2018, respectively:
Related Party Payable Rollforward:
 
Balance
 
 
 
Balance, December 31, 2017
 
$
98,925

Payments of related party payable
 
(7,017
)
Fair value adjustments (1)
 
3,363

Expiration of warrants
 
(2,167
)
Disposition of the pediatric assets
 
(20,337
)
Balance, March 31, 2018
 
$
72,767

 
 
 
Balance, December 31, 2018
 
$
28,840

Payments of related party payable
 
(3,688
)
Fair value adjustments (1)
 
2,441

Balance, March 31, 2019
 
$
27,593

(1) Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Debt (Tables)
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Debt
Long-Term debt is summarized as follows:
 
 
March 31, 2019
 
December 31, 2018
Principal amount of 4.50% exchangeable senior notes due 2023
 
$
143,750

 
$
143,750

Less: debt discount and issuance costs, net
 
(26,614
)
 
(28,059
)
Net carrying amount of liability component
 
117,136

 
115,691

Other debt
 
146

 
149

     Subtotal
 
117,282

 
115,840

Less: current maturities
 
(104
)
 
(106
)
     Long-term debt
 
$
117,178

 
$
115,734

 
 
 
 
 
Equity component:
 
 
 
 
Equity component of exchangeable notes, net of issuance costs
 
$
(26,699
)
 
$
(26,699
)
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Before Income Tax
The components of loss before income taxes are as follows: 
 
 
Three Months Ended March 31,
Loss Before Income Taxes:
 
2019
 
2018
 
 
 
 
 
Ireland
 
$
(10,234
)
 
$
(4,927
)
United States
 
(3,443
)
 
(9,835
)
France
 
285

 
199

Total loss before income taxes
 
$
(13,392
)
 
$
(14,563
)
Schedule of Effective Income Tax Rate Reconciliation
The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:
 
 
Three Months Ended March 31,
Income Tax Rate Reconciliation:
 
2019
 
2018
 
 
 
 
 
Statutory tax rate  
 
12.5
 %

12.5
 %
International tax rates differential
 
5.0
 %

8.9
 %
Change in valuation allowance
 
(11.4
)%

(4.7
)%
Change in fair value of nondeductible contingent consideration
 
(3.1
)%

(3.8
)%
Nondeductible stock-based compensation
 
(0.4
)%

(1.1
)%
Unrecognized tax benefits
 
(0.9
)%

(1.5
)%
State and local income taxes, net of federal
 
 %

0.1
 %
Nondeductible interest expense
 
(1.2
)%
 
 %
Other
 
2.2
 %

5.6
 %
Effective income tax rate
 
2.7
 %

16.0
 %
 
 
 
 
 
Income tax benefit - at statutory tax rate
 
$
(1,673
)
 
$
(1,820
)
International tax rates differential
 
(668
)
 
(1,298
)
Change in valuation allowance
 
1,520

 
690

Change in fair value of nondeductible contingent consideration
 
413

 
551

Nondeductible stock-based compensation
 
51

 
160

Unrecognized tax benefits
 
124

 
220

State and local income taxes, net of federal
 
2

 
(19
)
Nondeductible interest expense
 
157

 

Other
 
(300
)
 
(811
)
Income tax benefit - at effective income tax rate
 
$
(374
)
 
$
(2,327
)
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Other Assets and Liabilities (Tables)
3 Months Ended
Mar. 31, 2019
Other Liabilities Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Various other assets and liabilities are summarized as follows:
Prepaid Expenses and Other Current Assets:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Valued-added tax recoverable
 
$
1,100

 
$
1,378

Prepaid and other expenses
 
2,607

 
2,145

Guarantee from Armistice (see Note 14)
 
543

 
534

Income tax receivable
 
996

 
921

Research and development tax credit receivable
 
270

 
283

Short-term deposit
 

 
3,350

Other
 
1,040

 
225

Total  
 
$
6,556

 
$
8,836

Schedule of Other Assets, Noncurrent
Other Non-Current Assets:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Deferred tax assets, net
 
$
23,216

 
$
23,029

Long-term deposits
 
1,477

 
1,477

Guarantee from Armistice (see Note 14)
 
5,555

 
5,697

Right of use assets at contract manufacturing organizations
 
5,827

 
5,894

Other
 
49

 
49

Total  
 
$
36,124

 
$
36,146

Schedule of Accrued Liabilities
Accrued Expenses
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Accrued compensation
 
$
1,726

 
$
3,971

Accrued social charges
 
1,018

 
1,009

Accrued restructuring (see Note 15)
 
419

 
879

Customer allowances
 
6,616

 
6,541

Accrued contract research organization charges
 
1,383

 
1,000

Accrued contract manufacturing organization costs
 
1,030

 
2,028

Accrued contract sales organization and marketing costs
 

 
3,469

Other
 
2,497

 
2,798

Total  
 
$
14,689

 
$
21,695

Schedule Of Long Term Liabilities
Other Non-Current Liabilities:
 
March 31, 2019
 
December 31, 2018
 
 
 
 
 
Provision for retirement indemnity
 
$
1,003

 
$
1,024

Customer allowances
 
619

 
1,352

Unrecognized tax benefits
 
5,315

 
5,315

Guarantee to Deerfield (see Note 14)
 
5,574

 
5,717

Other
 
66

 
594

Total  
 
$
12,577

 
$
14,002

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Costs (Tables)
3 Months Ended
Mar. 31, 2019
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Related Costs
The following table sets forth activities for the Company’s cost reduction plan obligations for the three months ended March 31, 2019:
2019 Corporate Restructuring Obligations:
 
2019
 
 
 
Balance of restructuring accrual at January 1,
 
$

Charges for employee severance, benefits and other costs
 
1,398

Payments
 
(754
)
Balance of restructuring accrual at March 31,
 
$
644

The following table sets forth activities for the Company’s cost reduction plan obligations for the three months ended March 31, 2019 and 2018:
2017 French Restructuring Obligation:
 
2019
 
2018
 
 
 
 
 
Balance of restructuring accrual at January 1,
 
$
879

 
$
1,000

Charges for employee severance, benefits and other
 
(170
)
 
153

Payments
 
(638
)
 
(359
)
Foreign currency impact
 
(8
)
 
30

Balance of restructuring accrual at March 31,
 
$
63

 
$
824

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share Reconciliation
A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows: 
 
 
Three Months Ended March 31,
Net Loss Per Share:
 
2019
 
2018
 
 
 
 
 
Net loss
 
$
(13,018
)
 
$
(12,236
)
 
 
 
 
 
Weighted average shares:
 
 

 
 

Basic shares
 
37,354

 
38,559

Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes
 

 

Diluted shares
 
37,354

 
38,559

 
 
 
 
 
Net loss per share - basic
 
$
(0.35
)

$
(0.32
)
Net loss per share - diluted  
 
$
(0.35
)

$
(0.32
)
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Comprehensive Income (Loss) (Tables)
3 Months Ended
Mar. 31, 2019
Stockholders' Equity Note [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table shows the components of accumulated other comprehensive loss for the three months ended March 31, 2019 and 2018, respectively, net of tax effects: 
 
 
Three Months Ended March 31,
Accumulated Other Comprehensive Loss:
 
2019
 
2018
 
 
 
 
 
Foreign currency translation adjustment:
 
 

 
 

Beginning balance
 
$
(23,621
)
 
$
(23,202
)
Net other comprehensive (loss) income
 
(161
)
 
249

Balance at March 31,
 
$
(23,782
)
 
$
(22,953
)
 
 
 
 
 
Unrealized gain (loss) on marketable securities, net
 
 

 
 

Beginning balance
 
$
205

 
$
(64
)
Net other comprehensive income (loss), net of ($18) and ($59) tax, respectively
 
374

 
(238
)
Balance at March 31,
 
$
579

 
$
(302
)
Accumulated other comprehensive loss at March 31,
 
$
(23,203
)
 
$
(23,255
)
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.19.1
Company Revenue by Product (Tables)
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, Revenue by Product
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended March 31,
Revenues by Product:
 
2019
 
2018
 
 
 
 
 
Bloxiverz
 
$
2,568

 
$
7,491

Vazculep
 
9,473

 
12,961

Akovaz
 
3,792

 
10,217

Other
 
604

 
2,492

Total product sales
 
16,437

 
33,161

License revenue
 

 
132

Total revenues
 
$
16,437

 
$
33,293

XML 53 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - (Tables)
3 Months Ended
Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Contractual Obligation, Fiscal Year Maturity Schedule
Due to the Chapter 11 bankruptcy case of Specialty Pharma, discussed in Note 3: Subsidiary Bankruptcy and Deconsolidation, the Company’s various commitments to purchase finished product from customers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of March 31, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:

Purchase Commitments:
 
Balance
 
 
 
2019
 
$
7,194

2020
 
1,320

2021
 
1,320

2022
 
1,320

2023
 
220

Thereafter
 

Total
 
$
11,374

XML 54 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)
$ in Thousands
3 Months Ended
Apr. 26, 2019
Mar. 31, 2019
Mar. 31, 2018
Feb. 08, 2019
Business Acquisition, Contingent Consideration [Line Items]        
Gain (loss) on deconsolidation of subsidiary   $ (2,673) $ 0  
DIP Credit Agreement | Debtor in Possession Credit and Security Facility        
Business Acquisition, Contingent Consideration [Line Items]        
Gain (loss) on deconsolidation of subsidiary   (407)    
Payments for debtor in possession financing   407    
Specialty Pharma        
Business Acquisition, Contingent Consideration [Line Items]        
Equity method investments, fair value   $ 0    
Speciality Pharama | Subsequent Event        
Business Acquisition, Contingent Consideration [Line Items]        
Aggregate cash proceeds of intangible assets and remaining inventory $ 250      
Speciality Pharama | DIP Credit Agreement | Debtor in Possession Credit and Security Facility        
Business Acquisition, Contingent Consideration [Line Items]        
DIP financing, amount arranged       $ 2,700
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue Recognition - Narrative (Details) - USD ($)
Mar. 31, 2019
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]    
Deferred contract costs $ 0  
Deferred revenue $ 115,000 $ 114,000
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities $ 70,221 $ 90,590
Book value of long-term debt 117,282 115,840
Senior Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Book value of long-term debt $ 117,136 $ 115,691
4.50% Exchangeable Senior Notes Due 2023    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt instrument, interest rate, stated percentage 4.50% 4.50%
4.50% Exchangeable Senior Notes Due 2023 | Senior Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt $ 143,750 $ 143,750
Long-term debt, fair value 58,568  
Equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 9,825 9,145
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 48,947 52,996
Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 3,463 6,339
Government securities - U.S.    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 4,285 12,701
Other fixed-income securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 3,701 9,409
Fair Value Measurements, Recurring | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 58,772 62,141
Fair Value Measurements, Recurring | Level 1 | Equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 9,825 9,145
Fair Value Measurements, Recurring | Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 48,947 52,996
Fair Value Measurements, Recurring | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets 11,449 28,449
Fair Value Measurements, Recurring | Level 2 | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 3,463 6,339
Fair Value Measurements, Recurring | Level 2 | Government securities - U.S.    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 4,285 12,701
Fair Value Measurements, Recurring | Level 2 | Other fixed-income securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities 3,701 9,409
Fair Value Measurements, Recurring | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Related party payable 27,593 28,840
Total liabilities $ 27,593 $ 28,840
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]    
Marketable securities, realized gain $ 94 $ 213
Marketable securities, realized loss $ (147) $ (134)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities - Summary of Marketable Securities (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Adjusted Cost $ 69,935 $ 91,359
Unrealized Gains 635 411
Unrealized Losses (349) (1,180)
Fair Value 70,221 90,590
Equity securities    
Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]    
Adjusted Cost 10,133 10,101
Unrealized Gains 23 0
Unrealized Losses (331) (956)
Fair Value 9,825 9,145
Money market funds    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Adjusted Cost 48,438 52,733
Unrealized Gains 509 316
Unrealized Losses 0 (53)
Fair Value 48,947 52,996
Corporate bonds    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Adjusted Cost 3,442 6,411
Unrealized Gains 30 7
Unrealized Losses (9) (79)
Fair Value 3,463 6,339
Government securities - U.S.    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Adjusted Cost 4,249 12,714
Unrealized Gains 43 66
Unrealized Losses (7) (79)
Fair Value 4,285 12,701
Other fixed-income securities    
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]    
Adjusted Cost 3,673 9,400
Unrealized Gains 30 22
Unrealized Losses (2) (13)
Fair Value $ 3,701 $ 9,409
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities Marketable Securities - Schedule of Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]    
Fair Value $ 70,221 $ 90,590
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Less than 1 Year 688  
1-5 Years 2,775  
5-10 Years 0  
Greater than 10 Years 0  
Fair Value 3,463 6,339
Government securities - U.S.    
Debt Securities, Available-for-sale [Line Items]    
Less than 1 Year 0  
1-5 Years 3,841  
5-10 Years 0  
Greater than 10 Years 444  
Fair Value 4,285 12,701
Other fixed-income securities    
Debt Securities, Available-for-sale [Line Items]    
Less than 1 Year 50  
1-5 Years 3,651  
5-10 Years 0  
Greater than 10 Years 0  
Fair Value 3,701 $ 9,409
Debt Securities, Excluding Money Market Funds, Available For Sale    
Debt Securities, Available-for-sale [Line Items]    
Less than 1 Year 738  
1-5 Years 10,267  
5-10 Years 0  
Greater than 10 Years 444  
Fair Value $ 11,449  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.19.1
Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Inventory Disclosure [Abstract]    
Inventory reserves $ 1,085 $ 4,757
Increase in inventory reserves 3,672  
Inventory:    
Finished goods 3,720 4,270
Raw materials 538 500
Total $ 4,258 $ 4,770
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Mar. 31, 2019
Amortizable intangible assets:    
Gross Value $ 85,172,000 $ 12,061,000
Accumulated Amortization (17,456,000) (10,633,000)
Impairment (66,087,000)  
Net Carrying Amount 1,629,000 1,428,000
Unamortizable intangible assets:    
Gross Value 18,491,000 18,491,000
Accumulated Amortization 0 0
Net Carrying Amount 18,491,000 18,491,000
Developed technology | Noctiva    
Amortizable intangible assets:    
Gross Value 73,111,000 0
Accumulated Amortization (7,024,000) 0
Net Carrying Amount 0 0
Developed technology | Vazculep    
Amortizable intangible assets:    
Gross Value 12,061,000 12,061,000
Accumulated Amortization (10,432,000) (10,633,000)
Net Carrying Amount 1,629,000 $ 1,428,000
In Process Research and Development [Member] | Noctiva    
Amortizable intangible assets:    
Impairment (66,087,000)  
In Process Research and Development [Member] | Vazculep    
Amortizable intangible assets:    
Impairment $ 0  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible asset amortization $ 201 $ 1,767
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.19.1
Goodwill and Intangible Assets - Estimated Future Amortization (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 5 years
Estimated Amortization Expense:  
2019 $ 815
2020 814
2021 0
2022 0
2023 $ 0
Minimum  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 3 years
Maximum  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful life (in years) 15 years
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Narrative (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Jan. 01, 2019
Lessee, Lease, Description [Line Items]    
Operating lease right-of-use assets $ 5,802,000  
Operating lease liabilities 4,871,000  
Current portion of operating lease liability 982,000  
Operating lease payments $ 310,000  
Operating lease, weighted average remaining lease term (in years) 5 years 2 months 12 days  
Operating lease, weighted average discount rate, percent 5.30%  
Minimum    
Lessee, Lease, Description [Line Items]    
Lessee, operating lease, lease not yet commenced, operating lease expense $ 3,000  
Maximum    
Lessee, Lease, Description [Line Items]    
Lessee, operating lease, lease not yet commenced, operating lease expense 4,000  
Operating Leases Commenced    
Lessee, Lease, Description [Line Items]    
Operating lease right-of-use assets 1,000,000  
Operating lease liabilities $ 0  
Accounting Standards Update 2016-02    
Lessee, Lease, Description [Line Items]    
Operating lease right-of-use assets   $ 5,046,000
Operating lease liabilities   $ 5,131,000
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Components of lease costs (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
Leases [Abstract]  
Operating lease costs $ 345
Sublease income (2) 44
Total lease cost $ 301
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Maturities of operating lease liabilities (Details)
$ in Thousands
Mar. 31, 2019
USD ($)
Leases [Abstract]  
Remaining nine months of 2019 $ 920
2020 1,225
2021 1,004
2022 764
2023 693
Thereafter 942
Total lease payments 5,548
Less: interest 677
Operating lease liabilities $ 4,871
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.19.1
Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 1,191
2020 1,208
2021 1,008
2022 767
2023 695
Thereafter 967
Total minimum lease payments $ 5,836
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Related Party Payable - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended
Dec. 31, 2013
Feb. 28, 2013
Mar. 31, 2012
Mar. 31, 2019
Minimum        
Line of Credit Facility [Line Items]        
Discounted cash flow risk adjusted discount rate       15.00%
Broadfin Debt Financing        
Line of Credit Facility [Line Items]        
Cash consideration received on royalty agreement $ 2,200      
Percentage of royalty payable on net sales 0.834%      
Affiliated Entity | Deerfield FSC LLC        
Line of Credit Facility [Line Items]        
Cash consideration received on royalty agreement   $ 2,600    
Percentage of royalty payable on net sales   1.75%    
Eclat Pharmaceuticals        
Line of Credit Facility [Line Items]        
Percentage of earn-out payments     20.00%  
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Related Party Payable - Activity (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Acquisition-related contingent consideration:      
Related party payable, beginning balance $ 28,840 $ 98,925  
Payments to Related Parties (3,688) (7,017)  
Operating Expense 2,134 2,968  
Other Expense 307    
Related party payable, ending balance 27,593 $ 72,767  
Less: Current portion (9,391)   $ (9,439)
Long-term related party payable 18,202   $ 19,401
Acquisition-related contingent consideration: | Earn-out payments      
Acquisition-related contingent consideration:      
Related party payable, beginning balance 25,615    
Payments to Related Parties (3,180)    
Operating Expense 2,134    
Other Expense 0    
Related party payable, ending balance 24,569    
Financing-related: | Royalty agreement - Deerfield      
Acquisition-related contingent consideration:      
Related party payable, beginning balance 2,184    
Payments to Related Parties (344)    
Operating Expense 0    
Other Expense 208    
Related party payable, ending balance 2,048    
Financing-related: | Royalty agreement - Broadfin      
Acquisition-related contingent consideration:      
Related party payable, beginning balance 1,041    
Payments to Related Parties (164)    
Operating Expense 0    
Other Expense 99    
Related party payable, ending balance $ 976    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Related Party Payable Rollforward:    
Related party payable, beginning balance $ 28,840 $ 98,925
Payment of related party payable (3,688) (7,017)
Fair value adjustments 2,441 3,363
Expiration of warrants   (2,167)
Disposition of the pediatric assets   20,337
Related party payable, ending balance $ 27,593 $ 72,767
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Debt Schedule of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Net carrying amount of liability component $ 117,282 $ 115,840
Other debt 66 594
Less: current maturities (104) (106)
Long-term debt, less current portion 117,178 115,734
Senior Notes    
Debt Instrument [Line Items]    
Less: debt discount and issuance costs, net (26,614) (28,059)
Net carrying amount of liability component 117,136 115,691
Equity component of exchangeable notes, net of issuance costs (26,699) (26,699)
Loans Payable    
Debt Instrument [Line Items]    
Other debt $ 146 $ 149
4.50% Exchangeable Senior Notes Due 2023    
Debt Instrument [Line Items]    
Debt instrument, interest rate, stated percentage 4.50% 4.50%
4.50% Exchangeable Senior Notes Due 2023 | Senior Notes    
Debt Instrument [Line Items]    
Long-term debt $ 143,750 $ 143,750
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Income Tax Disclosure [Abstract]    
Income tax benefit $ (374) $ (2,327)
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Income Taxes [Line Items]    
Total income before income taxes $ (13,392) $ (14,563)
Ireland    
Income Taxes [Line Items]    
Total income before income taxes (10,234) (4,927)
United States    
Income Taxes [Line Items]    
Total income before income taxes (3,443) (9,835)
France    
Income Taxes [Line Items]    
Total income before income taxes $ 285 $ 199
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes - Reconciliation of Tax Rate (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Percent [Abstract]    
Statutory tax rate 12.50% 12.50%
International tax rates differential 5.00% 8.90%
Change in valuation allowance (11.40%) (4.70%)
Change in fair value of nondeductible contingent consideration (3.10%) (3.80%)
Nondeductible stock-based compensation (0.40%) (1.10%)
Unrecognized tax benefits (0.90%) (1.50%)
State and local income taxes, net of federal 0.00% 0.10%
Nondeductible interest expense (1.20%) 0.00%
Other 2.20% 5.60%
Effective income tax rate 2.70% 16.00%
Effective Income Tax Rate Reconciliation, Amount [Abstract]    
Income tax benefit - at statutory tax rate $ (1,673) $ (1,820)
International tax rates differential (668) (1,298)
Change in valuation allowance 1,520 690
Change in fair value of nondeductible contingent consideration 413 551
Nondeductible stock-based compensation 51 160
Unrecognized tax benefits 124 220
State and local income taxes, net of federal 2 (19)
Nondeductible interest expense 157 0
Other (300) (811)
Income tax benefit - at effective income tax rate $ (374) $ (2,327)
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.19.1
Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Prepaid Expenses and Other Current Assets:    
Valued-added tax recoverable $ 1,100 $ 1,378
Prepaid and other expenses 2,607 2,145
Guarantee from Armistice 543 534
Income tax receivable 996 921
Research and development tax credit receivable 270 283
Short-term deposit 0 3,350
Other 1,040 225
Total $ 6,556 $ 8,836
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.19.1
Other Assets and Liabilities - Other Non-Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Other Non-Current Assets:    
Deferred tax assets $ 23,216 $ 23,029
Long-term deposits 1,477 1,477
Guarantee from Armistice 5,555 5,697
Right of use assets at contract manufacturing organizations 5,827 5,894
Other 49 49
Total $ 36,124 $ 36,146
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.19.1
Other Assets and Liabilities - Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Accrued Expenses    
Accrued compensation $ 1,726 $ 3,971
Accrued social charges 1,018 1,009
Accrued restructuring (see Note 15) 419 879
Customer allowances 6,616 6,541
Accrued contract research organization charges 1,383 1,000
Accrued contract manufacturing organization costs 1,030 2,028
Accrued contract sales organization and marketing costs 0 3,469
Other 2,497 2,798
Total $ 14,689 $ 21,695
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.19.1
Other Assets and Liabilities - Other Non-Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Other Non-Current Liabilities:    
Provision for retirement indemnity $ 1,003 $ 1,024
Customer allowances 619 1,352
Unrecognized tax benefits 5,315 5,315
Guarantee to Deerfield 5,574 5,717
Other 66 594
Total $ 12,577 $ 14,002
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.19.1
Divestiture of the Pediatric Assets - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended
Feb. 12, 2018
Jan. 31, 2021
Mar. 31, 2019
Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Guaranty liabilities     $ 5,574 $ 5,717
2016 MIPA | Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Debt instrument, periodic payment, interest $ 263      
Noncash or part noncash acquisition, debt assumed 2,625      
Research and development reimbursement, in excess of 1,000      
Guaranty liabilities 6,643   6,119  
Guaranty assets $ 6,620   $ 6,097  
FSC | 2016 MIPA | Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Percentage of royalty payable on net sales 15.00%      
Royalty payable on net sales, maximum $ 10,300      
Scenario, Forecast | 2016 MIPA | Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Repayments of assumed debt   $ 15,263    
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Costs - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Restructuring Cost and Reserve [Line Items]            
Restructuring costs $ 1,228 $ 153        
Scenario, Forecast            
Restructuring Cost and Reserve [Line Items]            
Severance Costs     $ 3,000      
Accrued Liabilities            
Restructuring Cost and Reserve [Line Items]            
Restructuring reserve 356          
Accounts Payable            
Restructuring Cost and Reserve [Line Items]            
Restructuring reserve 288          
2019 Corporate Restructuring Obligations            
Restructuring Cost and Reserve [Line Items]            
Restructuring costs 1,398          
Restructuring reserve 644     $ 0    
Lyon France Workforce Reduction            
Restructuring Cost and Reserve [Line Items]            
Restructuring costs 170          
Restructuring reserve $ 63 $ 824   $ 879 $ 1,000  
Employee Severance | Corporate Workforce Reduction            
Restructuring Cost and Reserve [Line Items]            
Expected number of positions eliminated (as a percent)           50.00%
Employee Severance | Lyon France Workforce Reduction            
Restructuring Cost and Reserve [Line Items]            
Expected number of positions eliminated (as a percent)           50.00%
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring Costs - Severance Obligation (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Restructuring Reserve [Roll Forward]    
Restructuring costs $ 1,228 $ 153
2019 Corporate Restructuring Obligations    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 0  
Restructuring costs 1,398  
Payments (754)  
Restructuring reserve, ending balance 644  
Lyon France Workforce Reduction    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 879 1,000
Charges for employee severance, benefits and other (170) 153
Restructuring costs 170  
Payments (638) (359)
Foreign currency impact (8) 30
Restructuring reserve, ending balance $ 63 $ 824
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Earnings Per Share [Abstract]    
Net loss $ (13,018) $ (12,236)
Weighted average shares:    
Basic shares (in shares) 37,354 38,559
Effect of dilutive securities—options and warrants outstanding (in shares) 0 0
Diluted shares (in shares) 37,354 38,559
Net income (loss) per share - basic (in dollars per share) $ (0.35) $ (0.32)
Net income (loss) per share - diluted (in dollars per share) $ (0.35) $ (0.32)
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share - Narrative (Details) - shares
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Earnings Per Share [Abstract]    
Antidilutive securities excluded from computation of earnings per share, amount (in shares) 19,762 19,374
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.19.1
Comprehensive Income (Loss) - Components (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Accumulated Other Comprehensive Loss:    
Beginning balance $ 2,780 $ 85,580
Net other comprehensive income (loss) (12,805) (12,225)
Ending balance (9,582) 87,054
Foreign currency translation adjustment:    
Accumulated Other Comprehensive Loss:    
Beginning balance (23,621) (23,202)
Net other comprehensive income (loss) (161) 249
Ending balance (23,782) (22,953)
Unrealized gain (loss) on marketable securities, net    
Accumulated Other Comprehensive Loss:    
Beginning balance 205 (64)
Net other comprehensive income (loss) 374 (238)
Ending balance 579 (302)
Accumulated Other Comprehensive Loss:    
Accumulated Other Comprehensive Loss:    
Beginning balance (23,416) (23,266)
Ending balance $ (23,203) $ (23,255)
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.19.1
Comprehensive Loss - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Stockholders' Equity Note [Abstract]    
Other comprehensive income (loss), tax $ (18) $ (59)
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.19.1
Company Revenue by Product - Summary of Revenue (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
segment
Mar. 31, 2018
USD ($)
Segment Reporting [Abstract]    
Number of operating segments (in segments) | segment 1  
Segment Reporting Information [Line Items]    
Total revenues $ 16,437 $ 33,293
Bloxiverz    
Segment Reporting Information [Line Items]    
Total revenues 2,568 7,491
Vazculep    
Segment Reporting Information [Line Items]    
Total revenues 9,473 12,961
Akovaz    
Segment Reporting Information [Line Items]    
Total revenues 3,792 10,217
Other    
Segment Reporting Information [Line Items]    
Total revenues 604 2,492
Product sales    
Segment Reporting Information [Line Items]    
Total revenues 16,437 33,161
License revenue    
Segment Reporting Information [Line Items]    
Total revenues $ 0 $ 132
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Narrative (Details)
$ in Millions
Jan. 27, 2019
USD ($)
Specialty Pharma  
Loss Contingencies [Line Items]  
Loss contingency, damages sought, value $ 1.7
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Purchase Commitments (Details) - Inventories
$ in Thousands
Mar. 31, 2019
USD ($)
Long-term Purchase Commitment [Line Items]  
2019 $ 7,194
2020 1,320
2021 1,320
2022 1,320
2023 220
Thereafter 0
Total $ 11,374
EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 153 317 1 false 63 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.avadel.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) Statements 2 false false R3.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 3 false false R4.htm 1002501 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 1003501 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? (DEFICIT) EQUITY Statement Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersDeficitEquityStatement UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? (DEFICIT) EQUITY Statement Statements 7 false false R8.htm 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.avadel.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Newly Issued Accounting Pronouncements Sheet http://www.avadel.com/role/NewlyIssuedAccountingPronouncements Newly Issued Accounting Pronouncements Notes 10 false false R11.htm 2103100 - Disclosure - Subsidiary Bankruptcy and Deconsolidation Sheet http://www.avadel.com/role/SubsidiaryBankruptcyAndDeconsolidation Subsidiary Bankruptcy and Deconsolidation Notes 11 false false R12.htm 2104100 - Disclosure - Revenue Recognition Sheet http://www.avadel.com/role/RevenueRecognition Revenue Recognition Notes 12 false false R13.htm 2105100 - Disclosure - Fair Value Measurement Sheet http://www.avadel.com/role/FairValueMeasurement Fair Value Measurement Notes 13 false false R14.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.avadel.com/role/MarketableSecurities Marketable Securities Notes 14 false false R15.htm 2108100 - Disclosure - Inventories Sheet http://www.avadel.com/role/Inventories Inventories Notes 15 false false R16.htm 2109100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 2110100 - Disclosure - Leases Sheet http://www.avadel.com/role/Leases Leases Notes 17 false false R18.htm 2111100 - Disclosure - Long-Term Related Party Payable Sheet http://www.avadel.com/role/LongTermRelatedPartyPayable Long-Term Related Party Payable Notes 18 false false R19.htm 2112100 - Disclosure - Long-Term Debt Sheet http://www.avadel.com/role/LongTermDebt Long-Term Debt Notes 19 false false R20.htm 2113100 - Disclosure - Income Taxes Sheet http://www.avadel.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2114100 - Disclosure - Other Assets and Liabilities Sheet http://www.avadel.com/role/OtherAssetsAndLiabilities Other Assets and Liabilities Notes 21 false false R22.htm 2115100 - Disclosure - Divestiture of the Pediatric Assets Sheet http://www.avadel.com/role/DivestitureOfPediatricAssets Divestiture of the Pediatric Assets Notes 22 false false R23.htm 2116100 - Disclosure - Restructuring Costs Sheet http://www.avadel.com/role/RestructuringCosts Restructuring Costs Notes 23 false false R24.htm 2117100 - Disclosure - Net Loss Per Share Sheet http://www.avadel.com/role/NetLossPerShare Net Loss Per Share Notes 24 false false R25.htm 2118100 - Disclosure - Comprehensive Loss Sheet http://www.avadel.com/role/ComprehensiveLoss Comprehensive Loss Notes 25 false false R26.htm 2119100 - Disclosure - Company Operations by Product Sheet http://www.avadel.com/role/CompanyOperationsByProduct Company Operations by Product Notes 26 false false R27.htm 2120100 - Disclosure - Commitments and Contingencies Sheet http://www.avadel.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 27 false false R28.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.avadel.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.avadel.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 2305301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.avadel.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.avadel.com/role/FairValueMeasurement 29 false false R30.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.avadel.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.avadel.com/role/MarketableSecurities 30 false false R31.htm 2308301 - Disclosure - Inventories (Tables) Sheet http://www.avadel.com/role/InventoriesTables Inventories (Tables) Tables http://www.avadel.com/role/Inventories 31 false false R32.htm 2309301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.avadel.com/role/GoodwillAndIntangibleAssets 32 false false R33.htm 2310301 - Disclosure - Leases (Tables) Sheet http://www.avadel.com/role/LeasesTables Leases (Tables) Tables http://www.avadel.com/role/Leases 33 false false R34.htm 2311301 - Disclosure - Long-Term Related Party Payable (Tables) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableTables Long-Term Related Party Payable (Tables) Tables http://www.avadel.com/role/LongTermRelatedPartyPayable 34 false false R35.htm 2312301 - Disclosure - Long-Term Debt (Tables) Sheet http://www.avadel.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.avadel.com/role/LongTermDebt 35 false false R36.htm 2313301 - Disclosure - Income Taxes (Tables) Sheet http://www.avadel.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.avadel.com/role/IncomeTaxes 36 false false R37.htm 2314301 - Disclosure - Other Assets and Liabilities (Tables) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesTables Other Assets and Liabilities (Tables) Tables http://www.avadel.com/role/OtherAssetsAndLiabilities 37 false false R38.htm 2316301 - Disclosure - Restructuring Costs (Tables) Sheet http://www.avadel.com/role/RestructuringCostsTables Restructuring Costs (Tables) Tables http://www.avadel.com/role/RestructuringCosts 38 false false R39.htm 2317301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.avadel.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.avadel.com/role/NetLossPerShare 39 false false R40.htm 2318301 - Disclosure - Comprehensive Income (Loss) (Tables) Sheet http://www.avadel.com/role/ComprehensiveIncomeLossTables Comprehensive Income (Loss) (Tables) Tables 40 false false R41.htm 2319301 - Disclosure - Company Revenue by Product (Tables) Sheet http://www.avadel.com/role/CompanyRevenueByProductTables Company Revenue by Product (Tables) Tables 41 false false R42.htm 2320301 - Disclosure - Commitments and Contingencies - (Tables) Sheet http://www.avadel.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies - (Tables) Tables http://www.avadel.com/role/CommitmentsAndContingencies 42 false false R43.htm 2403401 - Disclosure - Subsidiary Bankruptcy and Deconsolidation (Details) Sheet http://www.avadel.com/role/SubsidiaryBankruptcyAndDeconsolidationDetails Subsidiary Bankruptcy and Deconsolidation (Details) Details http://www.avadel.com/role/SubsidiaryBankruptcyAndDeconsolidation 43 false false R44.htm 2404401 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.avadel.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 44 false false R45.htm 2405402 - Disclosure - Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) Sheet http://www.avadel.com/role/FairValueMeasurementFairValueMeasurementMeasuredOnRecurringBasisDetails Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) Details 45 false false R46.htm 2407402 - Disclosure - Marketable Securities - Narrative (Details) Sheet http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails Marketable Securities - Narrative (Details) Details 46 false false R47.htm 2407403 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) Sheet http://www.avadel.com/role/MarketableSecuritiesSummaryOfMarketableSecuritiesDetails Marketable Securities - Summary of Marketable Securities (Details) Details 47 false false R48.htm 2407404 - Disclosure - Marketable Securities Marketable Securities - Schedule of Maturities (Details) Sheet http://www.avadel.com/role/MarketableSecuritiesMarketableSecuritiesScheduleOfMaturitiesDetails Marketable Securities Marketable Securities - Schedule of Maturities (Details) Details 48 false false R49.htm 2408402 - Disclosure - Inventories (Details) Sheet http://www.avadel.com/role/InventoriesDetails Inventories (Details) Details http://www.avadel.com/role/InventoriesTables 49 false false R50.htm 2409402 - Disclosure - Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsGrossValueAndNetCarryingAmountDetails Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) Details 50 false false R51.htm 2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 51 false false R52.htm 2409404 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization (Details) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationDetails Goodwill and Intangible Assets - Estimated Future Amortization (Details) Details 52 false false R53.htm 2410402 - Disclosure - Leases - Narrative (Details) Sheet http://www.avadel.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 53 false false R54.htm 2410403 - Disclosure - Leases - Components of lease costs (Details) Sheet http://www.avadel.com/role/LeasesComponentsOfLeaseCostsDetails Leases - Components of lease costs (Details) Details 54 false false R55.htm 2410404 - Disclosure - Leases - Maturities of operating lease liabilities (Details) Sheet http://www.avadel.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails Leases - Maturities of operating lease liabilities (Details) Details 55 false false R56.htm 2410405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Sheet http://www.avadel.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Details 56 false false R57.htm 2411402 - Disclosure - Long-Term Related Party Payable - Narrative (Details) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableNarrativeDetails Long-Term Related Party Payable - Narrative (Details) Details 57 false false R58.htm 2411403 - Disclosure - Long-Term Related Party Payable - Activity (Details) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableActivityDetails Long-Term Related Party Payable - Activity (Details) Details 58 false false R59.htm 2411404 - Disclosure - Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableLongTermRelatedPartyPayablePayableBalanceDetails Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) Details 59 false false R60.htm 2412402 - Disclosure - Long-Term Debt Schedule of Debt (Details) Sheet http://www.avadel.com/role/LongTermDebtScheduleOfDebtDetails Long-Term Debt Schedule of Debt (Details) Details 60 false false R61.htm 2413402 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.avadel.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 61 false false R62.htm 2413403 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details) Sheet http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails Income Taxes - Income (Loss) Before Income Taxes (Details) Details 62 false false R63.htm 2413404 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details) Sheet http://www.avadel.com/role/IncomeTaxesReconciliationOfTaxRateDetails Income Taxes - Reconciliation of Tax Rate (Details) Details 63 false false R64.htm 2414402 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetails Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) Details 64 false false R65.htm 2414403 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesOtherNonCurrentAssetsDetails Other Assets and Liabilities - Other Non-Current Assets (Details) Details 65 false false R66.htm 2414404 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesAccruedExpensesDetails Other Assets and Liabilities - Accrued Expenses (Details) Details 66 false false R67.htm 2414405 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesOtherNonCurrentLiabilitiesDetails Other Assets and Liabilities - Other Non-Current Liabilities (Details) Details 67 false false R68.htm 2415401 - Disclosure - Divestiture of the Pediatric Assets - Narrative (Details) Sheet http://www.avadel.com/role/DivestitureOfPediatricAssetsNarrativeDetails Divestiture of the Pediatric Assets - Narrative (Details) Details 68 false false R69.htm 2416402 - Disclosure - Restructuring Costs - Narrative (Details) Sheet http://www.avadel.com/role/RestructuringCostsNarrativeDetails Restructuring Costs - Narrative (Details) Details 69 false false R70.htm 2416403 - Disclosure - Restructuring Costs - Severance Obligation (Details) Sheet http://www.avadel.com/role/RestructuringCostsSeveranceObligationDetails Restructuring Costs - Severance Obligation (Details) Details 70 false false R71.htm 2417402 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) Sheet http://www.avadel.com/role/NetLossPerShareReconciliationOfBasicAndDilutedCalculationDetails Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) Details 71 false false R72.htm 2417403 - Disclosure - Net Loss Per Share - Narrative (Details) Sheet http://www.avadel.com/role/NetLossPerShareNarrativeDetails Net Loss Per Share - Narrative (Details) Details 72 false false R73.htm 2418402 - Disclosure - Comprehensive Income (Loss) - Components (Details) Sheet http://www.avadel.com/role/ComprehensiveIncomeLossComponentsDetails Comprehensive Income (Loss) - Components (Details) Details http://www.avadel.com/role/ComprehensiveIncomeLossTables 73 false false R74.htm 2418403 - Disclosure - Comprehensive Loss - Narrative (Details) Sheet http://www.avadel.com/role/ComprehensiveLossNarrativeDetails Comprehensive Loss - Narrative (Details) Details 74 false false R75.htm 2419402 - Disclosure - Company Revenue by Product - Summary of Revenue (Details) Sheet http://www.avadel.com/role/CompanyRevenueByProductSummaryOfRevenueDetails Company Revenue by Product - Summary of Revenue (Details) Details 75 false false R76.htm 2420402 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.avadel.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 76 false false R77.htm 2420403 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) Sheet http://www.avadel.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails Commitments and Contingencies - Purchase Commitments (Details) Details 77 false false All Reports Book All Reports avdl-20190331.xml avdl-20190331.xsd avdl-20190331_cal.xml avdl-20190331_def.xml avdl-20190331_lab.xml avdl-20190331_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 94 0001012477-19-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001012477-19-000005-xbrl.zip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�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end